

CUMULATIVE  
SUPPLEMENT 12  
JAN'97-DEC'97


# APPROVED DRUG PRODUCTS

WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS

17<sup>TH</sup> EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE  
FOOD AND DRUG ADMINISTRATION  
CENTER FOR DRUG EVALUATION AND RESEARCH  
OFFICE OF INFORMATION TECHNOLOGY  
DIVISION OF DATA MANAGEMENT AND SERVICES



**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**17TH EDITION**

**Cumulative Supplement 12**

**DECEMBER 1997**

**CONTENTS**

	<b>PAGE</b>
1.0 INTRODUCTION .....	iii
1.1 How to Use the Cumulative Supplement .....	iii
1.2 Court Order Affecting Uruguay Round Agreements Act-Extended Patents .....	iv
1.3 Applicant Name Changes .....	v
1.4 Acyclovir 200 mg Tablet-Reference Listed Drug .....	vi
1.5 Follitropin Alfa and Beta .....	vii
1.6 Availability of the Publication and Updating Procedures .....	vii
1.7 Report of Counts for the Prescription Drug Product List.....	viii
2.0 DRUG PRODUCT LISTS.....	
2.1 Prescription Drug Product List.....	1
2.2 OTC Drug Product List .....	85
2.3 Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List.....	89
2.4 Orphan Product Designations and Approvals List .....	90
2.5 Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	102
<b>PATENT AND EXCLUSIVITY INFORMATION ADDENDUM</b>	
A. Patent and Exclusivity Terms.....	103
B. Patent and Exclusivity Lists.....	107



**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**17TH EDITION**

**CUMULATIVE SUPPLEMENT 12  
DECEMBER 1997**

**1.0 INTRODUCTION**

**1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT**

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 17th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (\*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition. However, the overstruck data in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements (hard copy).

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 17th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 18th Edition.

## 1.2 COURT ORDER AFFECTING URUGUAY ROUND AGREEMENTS ACT-EXTENDED PATENTS

As a result of the April 4, 1996, decision of the United States Court of Appeals for the Federal Circuit in Merck, et al. v. Kessler, patent expiration dates for certain patents subject to patent term extensions under the Uruguay Round Agreements Act and to the patent term extension provisions at 35 U.S.C. § 156 may be changed. FDA has published a notice in the March 14, 1997, *Federal Register* advising NDA and NADA applicants that patent expiration dates changed by the Merck decision must be submitted within 60 days. Because there may be changes in listed patents as a result of the Merck decision, users of this publication should consult the most recent

supplement, and are encouraged to confirm that patent information upon which they intend to rely is current. (See the *Patent and Exclusivity Addendum* to the *Approved Drug Products with Therapeutic Equivalence Evaluations*, 17th Edition that explains the background information on this court decision).

### **1.3 APPLICANT NAME CHANGES**

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne PLSN [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

#### **APPLICANT NAME CHANGES**

##### **FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)**

CIBA GEIGY CORP  
(CIBA GEIGY)

CIBA GEIGY CORP PHARMACEUTICALS DIV  
(CIBA GEIGY)

CIBA PHARMACEUTICAL CO  
DIV CIBA GEIGY CORP  
(CIBA)

CIBA SELF MEDICATION INC  
DIV CIBA GEIGY CORP  
(CIBA)

CIBA VISION CORP  
(CIBA)

##### **NEW APPLICANT NAME (NEW ABBREVIATED NAME)**

NOVARTIS PHARMACEUTICALS CORP  
(NOVARTIS)

NOVARTIS PHARMACEUTICALS CORP  
(NOVARTIS)

NOVARTIS PHARMACEUTICALS CORP  
(NOVARTIS)

NOVARTIS CONSUMER HEALTH INC  
(NOVARTIS)

CIBA VISION CORPORATION A  
NOVARTIS COMPANY  
(CIBA)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME  
(FORMER ABBREVIATED NAME)

CIBA VISION OPHTHALMICS  
DIV CIBA VISION CORP  
(CIBA)

FERRING LABORATORIES INC  
(FERRING)

GEIGY PHARMACEUTICALS  
DIV CIBA GEIGY CORP  
(GEIGY)

LEMMON CO SUB TAG PHARMACEUTICAL INC  
(LEMMON)

REXAR PHARMACAL  
(REXAR)

RICHWOOD PHARMACEUTICAL CO INC  
(RICHWOOD PHARM)

SANDOZ CONSUMER HEALTH  
CARE GROUP DIV SANDOZ PHARMACEUTICALS  
(SANDOZ)

SANDOZ PHARMACEUTICALS  
CORP DIV SANDOZ INC  
(SANDOZ)

SANDOZ RESEARCH INSTITUTE INC  
(SANDOZ)

SANOFI WINTHROP INC  
(SANOFI WINTHROP)

SURVIVAL TECHNOLOGY INC  
(SURVIVAL TECH)

NEW APPLICANT NAME  
(NEW ABBREVIATED NAME)

CIBA VISION CORPORATION A  
NOVARTIS COMPANY  
(CIBA)

FERRING PHARMACEUTICALS INC  
(FERRING)

NOVARTIS PHARMACEUTICALS CORP  
(NOVARTIS)

BIOCRAFT LABORATORIES INC  
(BIOCRAFT)

**THEN CHANGED TO**  
TEVA PHARMACEUTICALS USA  
(TEVA)

SHIRE RICHWOOD INC  
(SHIRE RICHWOOD)

SHIRE RICHWOOD INC  
(SHIRE RICHWOOD)

NOVARTIS CONSUMER HEALTH INC  
(NOVARTIS)

NOVARTIS PHARMACEUTICALS CORP  
(NOVARTIS)

NOVARTIS PHARMACEUTICALS CORP  
(NOVARTIS)

SANOFI PHARMACEUTICAL INC  
(SANOFI)

MERIDIAN MEDICAL TECHNOLOGIES INC  
(MERIDIAN MEDCL TECHN)

**1.4 ACYCLOVIR 200MG TABLET-REFERENCE LISTED DRUG**

Novopharm's single source acyclovir tablets have been declared to be a reference listed drug for the 200 mg tablet in addition to the acylcovir (Zovirax) 800 mg tablet of the innovator. A generic firm wishing to submit

an ANDA for a duplicate of the 200 mg acyclovir tablet will be eligible for a waiver of the *in vivo* determination of bioequivalence (1) if their product is proportionally similar in its active and inactive ingredients to their own 800 mg acyclovir tablet and (2) by doing an acceptable comparative dissolution test (dissolution profile) against Novopharm's 200 mg acyclovir reference listed drug.

Before a waiver of the *in vivo* determination of bioequivalence can be granted for the 200 mg acyclovir tablet, the generic firm must have completed an acceptable fasting and fed study comparing their acyclovir 800 mg tablet against the Zovirax 800 mg tablet.

For further information on the study designs, you should contact the Division of Bioequivalence, Office of Generic Drugs.

#### **1.5 FOLLITROPIN ALFA AND BETA**

Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

#### **1.6 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES**

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

The following *Approved Drug Products with Therapeutic Equivalence Evaluations* files are now available on Internet and are updated each October and April: Prescription Drug Product List; OTC Drug Products; Discontinued Drug Products; Prescription and OTC Drug Product Patent and Exclusivity Data; and Appendices. The update in October will include drug products that have been approved through August and the update in April will include drug products that have been approved through December.

These files may be accessed on the Internet's World Wide Web. FDA's Internet site replaced the Agency's electronic bulletin board. To access the CDER Home Page, use this Uniform Resource Locator (URL): <http://www.fda.gov/cder>. You do not need an Internet connection to reach the FDA Home Page; you can use the free dial-up connection (800) 222-0185 for text based, non-graphical use only. For further assistance, please call (301) 443-4908.

## **1.7 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST**

### **DESCRIPTION OF REPORT**

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1996) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### **DEFINITIONS**

#### **Drug Product**

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### **New Molecular Entity**

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 1996*</u>	<u>JUN 1997</u>	<u>SEP 1997</u>	<u>DEC 1997</u>
DRUG PRODUCTS LISTED	9392	9533	9501	9624
SINGLE SOURCE	2383 (25.4%)	2388 (25.0%)	2420 (25.5%)	2462 (25.6%)
MULTISOURCE	6905 (73.5%)	7031 (73.8%)	6970 (73.8%)	7052 (73.3%)
THERAPEUTICALLY EQUIVALENT	6463 (68.8%)	6626 (69.5%)	6587 (69.3%)	6673 (69.3%)
NOT THERAPEUTICALLY EQUIVALENT	442 (4.7%)	405 (4.3%)	383 (4.0%)	379 (4.0%)
EXCEPTIONS <sup>1</sup>	104 (1.1%)	114 (1.2%)	111 (1.2%)	110 (1.1%)
NEW MOLECULAR ENTITIES APPROVED	--	8	14	14
NUMBER OF APPLICANTS	650	682	701	511

<sup>1</sup>Amino acid-containing products of varying composition (see Introduction, page xx of the List).

\*Exceptions were originally included in the total count of the Multisource Drug Products. Beginning with December 1996, exceptions were no longer included in the Multisource Drug Products total count, but included in the total count of the Drug Products Listed.



PRESCRIPTION DRUG PRODUCT LIST  
17TH EDITION  
RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'97 - DEC'97

1

ACARBOSE

TABLET; ORAL  
PRECOSE  
**BAYER** 25MG  
@ 25MG

N20482 004  
MAY 29, 1997  
N20482 004  
MAY 29, 1997

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL  
**BUSET**  
**AB MALLINCKRODT** 650MG;50MG  
**AB BUTALBITAL AND ACETAMINOPHEN**  
**GRAHAM DM** 650MG;50MG  
**AB CONTEN**  
**GRAHAM DM** 650MG;50MG  
**TENCON**  
**AB MALLINCKRODT** 650MG;50MG

N88991 001  
JUN 28, 1985  
N88991 001  
JUN 28, 1985  
N89405 001  
MAY 15, 1990  
N89405 001  
MAY 15, 1990

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL  
**BUTALBITAL, ACETAMINOPHEN, CAFFEINE**  
**AB GRAHAM DM** 325MG;50MG;40MG  
@ 325MG;50MG;40MG  
**FEMCET**  
**AB MALLINCKRODT** 325MG;50MG;40MG

N88741 001  
JUL 18, 1985  
N88765 001  
MAR 27, 1985  
N89023 001  
JUN 19, 1985  
N89067 001  
APR 19, 1985  
N89102 001  
JUN 19, 1985  
N88743 001  
JUL 18, 1985  
N88765 001  
MAR 27, 1985  
N89067 001  
APR 19, 1985  
N89102 001  
JUN 19, 1985  
N88743 001  
JUL 18, 1985  
N88765 001  
MAR 27, 1985  
N89067 001  
APR 19, 1985  
N89102 001  
JUN 19, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL  
**TRIAD**  
**AB MALLINCKRODT** 325MG;50MG;40MG  
N89023 001  
JUN 19, 1985

TABLET; ORAL  
**REPAN**  
**AB GRAHAM DM** 325MG;50MG;40MG  
N87804 001  
JAN 24, 1985  
**AB MALLINCKRODT** 325MG;50MG;40MG  
N87804 001  
JAN 24, 1985

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL  
**ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE**  
**AA MIKART** 356.4MG;30MG;16MG  
N40109 001  
AUG 26, 1997  
**DHC PLUS**  
**AA + PURDUE FREDERICK** 356.4MG;30MG;16MG  
N88584 001  
MAR 04, 1986

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL  
**ACETAMINOPHEN AND CODEINE PHOSPHATE**  
**AA DURAMED** 300MG;15MG  
N40223 001  
NOV 18, 1997  
**AA** 300MG;30MG  
N40223 002  
NOV 18, 1997  
**AA** 300MG;60MG  
N40223 003  
NOV 18, 1997

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL  
**ACETAMINOPHEN AND HYDROCODONE BITARTRATE**  
**AA \* GRAHAM DM** 500MG;5MG  
N87336 001  
JUL 08, 1985  
**AA** 500MG;5MG  
N88956 001  
JUL 19, 1985  
**HYDROCET**  
**AA GRAHAM DM** 500MG;5MG  
N89006 001  
AUG 09, 1985

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL  
**HYDROCET**  
**AA** MALLINCKRODT **500MG;5MG**

**LORCET-HD**  
**AA** + MALLINCKRODT **500MG;5MG**

**ZYDONE**  
**AA** MALLINCKRODT **500MG;5MG**

## TABLET; ORAL

**ACETAMINOPHEN AND HYDROCODONE BITARTRATE**  
**AA** GRAZIAN DM **500MG;5MG**

**HYDROCODONE BITARTRATE AND ACETAMINOPHEN**  
@ BARR **500MG;5MG**

**EON** **500MG;5MG**

**750MG;7.5MG**

**HALSEY** **500MG;5MG**

**650MG;7.5MG**

**650MG;10MG**

**750MG;7.5MG**

**PEACHTREE** **500MG;10MG**

**VINTAGE PHARMS** **500MG;2.5MG**

**650MG;7.5MG**

**WATSON LABS** **500MG;10MG**

**HYDROCODONE BITARTRATE/N/ ACETAMINOPHEN**

**BARR** **500MG;5MG**

**LORTAB**  
**AA** \* GRAZIAN DM **500MG;10MG**

**MALLINCKRODT** **500MG;5MG**

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL  
**LORTAB**  
**AA** + UCB

**N89006 001**  
AUG 09, 1985

**N87336 001**  
JUL 08, 1982

**N88956 001**  
JUL 19, 1985

**500MG;10MG**

**325MG;5MG**

**NORCO**  
+ WATSON LABS **325MG;10MG**

**N40100 001**  
JAN 26, 1996

**N40099 001**  
JUN 25, 1997

**N40148 001**  
FEB 14, 1997

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL  
**OXYCODONE AND ACETAMINOPHEN**

**AA** ROYCE LABS **500MG;5MG**

**N40234 001**  
OCT 30, 1997

TABLET; ORAL  
**OXYCODONE AND ACETAMINOPHEN**

**AA** ROYCE LABS **325MG;5MG**

**N40171 001**  
OCT 30, 1997

**PERCOSET**  
**AA** \* DUPONT MERCK **325MG;5MG**

**AA** + ENDO PHARMS **325MG;5MG**

**N85106 002**  
N85106 002

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL  
**PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN**

**AB** VINTAGE PHARMS **650MG;100MG**

**N74843 001**  
FEB 12, 1997

ACETAZOLAMIDE

TABLET; ORAL  
**ACETAZOLAMIDE**

**AB** TARO **125MG**

**N40195 001**  
MAY 28, 1997

**AB** **250MG**

**N40195 002**  
MAY 28, 1997

## RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'97 - DEC'97

3

ACETAZOLAMIDE SODIUMINJECTABLE; INJECTION  
ACETAZOLAMIDE SODIUM

<u>AP</u>	ABBOTT	<u>EQ 500MG BASE/VIAL</u>	N40108 001
<u>AB</u>	SANOFI WINTHROP	<u>EQ 500MG BASE/VIAL</u>	N40108 001 OCT 30, 1995

ACETIC ACID, GLACIAL; DESONIDESOLUTION/DROPS; AURICULAR (OTIC)  
TRIDESILON  
© BAYER 2%:0.05%

N17914 001

SOLUTION/DROPS; OTIC  
TRIDESILON  
BAYER 2%:0.05%

N17914 001

ACYCLOVIRCAPSULE; ORAL  
ACYCLOVIR

<u>AB</u>	AESGEN	<u>200MG</u>	N74833 001
<u>AB</u>	APOTHECON	<u>200MG</u>	N74889 001
<u>AB</u>	COPLEY PHARM	<u>200MG</u>	OCT 31, 1997
<u>AB</u>	ESI LEDERLE	<u>200MG</u>	N74914 001
<u>AB</u>	LEK PHARM	<u>200MG</u>	NOV 26, 1997
<u>AB</u>	TEMPION	<u>200MG</u>	N74872 001
<u>AB</u>	MYLAN	<u>200MG</u>	APR 22, 1997
<u>AB</u>	NOVOPHARM	<u>200MG</u>	N74578 001
<u>AB</u>	PUREPAC PHARM	<u>200MG</u>	APR 22, 1997
<u>AB</u>	ROXANE	<u>200MG</u>	N74906 001
<u>AB</u>	TEVA	<u>200MG</u>	AUG 26, 1997
<u>AB</u>	ZENITH GOLDLINE	<u>200MG</u>	N74570 002

ACYCLOVIRCAPSULE; ORAL  
ZOVIRAXAB + GLAXO WELLCOME 200MG N18828 001 JAN 25, 1985SUSPENSION; ORAL  
ACYCLOVIRAB ALPHARMA 200MG/5ML N74738 001 APR 28, 1997AB + GLAXO WELLCOME 200MG/5ML N19909 001 DEC 22, 1989TABLET; ORAL  
ACYCLOVIRAB AESGEN 400MG N74946 001 NOV 19, 1997AB 800MG N74946 002 NOV 19, 1997AB APOTHECON 400MG N74891 001 OCT 31, 1997AB 800MG N74891 002 OCT 31, 1997AB ESI LEDERLE 400MG N74834 001 APR 24, 1997AB 800MG N74834 002 APR 24, 1997AB LEK PHARM 400MG N74658 001 APR 22, 1997AB 800MG N74658 002 APR 22, 1997AB NOVOPHARM 400MG N74556 002 APR 22, 1997AB 800MG N74556 003 APR 22, 1997AB + 200MG N74556 001 APR 22, 1997AB PUREPAC PHARM 400MG N74870 001 JUN 05, 1997AB 800MG N74870 002 JUN 05, 1997AB ZENITH GOLDLINE 400MG N74836 001 APR 22, 1997AB 800MG N74836 002 APR 22, 1997AB ZOVIRAX GLAXO WELLCOME 400MG N20089 001 APR 30, 1991



## RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'97 - DEC'97

5

ALLOPURINOLTABLET; ORAL  
LOPURIN

> ADD >	AB	BASF	100MG	N71586 001
> ADD >	AB		300MG	N71587 001
> ADD >	AB		100MG	APR 02, 1987
> DLT >	AB	KNOLLI PHARM	100MG	N71586 001
> DLT >	AB		300MG	APR 02, 1987
> DLT >	AB		300MG	N71587 001
> DLT >	AB			APR 02, 1987

ALPRAZOLAMTABLET; ORAL  
ALPRAZOLAM

AB	ROYCE LABS	0.25MG	N74479 001
AB		0.5MG	JAN 21, 1997
AB		1MG	N74479 002
			JAN 21, 1997
			N74479 003
			JAN 21, 1997

ALPROSTADILINJECTABLE; INJECTION  
CAVERJECT

AP	PHARMACIA AND UPJOHN	0.005MG/VIAL	N20379 003
AP		0.01MG/VIAL	JUN 27, 1996
AP		0.02MG/VIAL	N20379 001
AP		0.04MG/VIAL	JUL 06, 1995
AP		0.005MG/ML	N20379 002
		0.01MG/ML	JUL 06, 1995
+		0.02MG/ML	N20379 004
+		0.005MG/VIAL	MAY 19, 1997
		0.01MG/VIAL	N20755 001
		0.02MG/VIAL	OCT 31, 1997
		0.005MG/ML	N20755 002
		0.01MG/ML	OCT 01, 1997
		0.02MG/ML	N20755 003
		0.005MG/VIAL	OCT 01, 1997
AP	SCHWARZ PHARMA	0.005MG/VIAL	N20649 001
AP		0.01MG/VIAL	JUN 12, 1997

ALPROSTADILINJECTABLE; INJECTION  
EDEX

AP	SCHWARZ PHARMA	0.02MG/VIAL	N20649 003
AP	+	0.04MG/VIAL	JUN 12, 1997

N20649 004	N20649 004
JUN 12, 1997	JUN 12, 1997

AMANTADINE HYDROCHLORIDECAPSULE; ORAL  
SYNTHETIC

AB	SOLVAY	100MG	N71000 001
@		100MG	SEP 04, 1986

N71000 001	N71000 001
SEP 04, 1986	SEP 04, 1986

## TABLET; ORAL

SYMMETREL		100MG	N18101 001
@ DUPONT MERCK		100MG	N18101 001
@ ENDO PHARMS		100MG	N18101 001

N18101 001	N18101 001
N18101 001	N18101 001

AMIKACIN SULFATEINJECTABLE; INJECTION  
AMIKACIN SULFATE

AP	ABBOTT	EQ 250MG BASE/ML	N64098 001
AP		EQ 250MG BASE/ML	JUN 26, 1995
AP	ELKINS GLENN	EQ 50MG BASE/ML	N64099 001
AP		EQ 50MG BASE/ML	JUN 20, 1995
AP		EQ 50MG BASE/ML	N63274 001
@		EQ 50MG BASE/ML	MAY 18, 1992
AP	SANOFI WINTHROP	EQ 250MG BASE/ML	N64098 001
AP		EQ 250MG BASE/ML	JUN 26, 1995
AP		EQ 250MG BASE/ML	N64099 001
		EQ 250MG BASE/ML	JUN 20, 1995

N64098 001	N64099 001
JUN 26, 1995	JUN 20, 1995
N63274 001	MAY 18, 1992
N64098 001	N63274 001
JUN 26, 1995	MAY 18, 1992
N64099 001	N64098 001
JUN 20, 1995	JUN 26, 1995

AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT	EQ 500MG BASE/100ML	N64146 001
--------	---------------------	------------

APR 02, 1997	N64146 001
--------------	------------

AMINO ACIDSINJECTABLE; INJECTIONAMINOSYN II 5%

ABBOTT

5%

N19438 002

APR 03, 1986

@

5%

N19438 002

APR 03, 1986

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE;  
POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM  
CHLORIDE

INJECTABLE; INJECTIONAMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM  
IN PLASTIC CONTAINER

ABBOTT

3.5%; 36.8MG/100ML; 25GM/100ML;

51MG/100ML; 22.4MG/100ML; 261MG/100ML;

205MG/100ML N19714 001

SEP 12, 1988

@

3.5%; 36.8MG/100ML; 25GM/100ML;

51MG/100ML; 22.4MG/100ML; 261MG/100ML;

205MG/100ML N19714 001

SEP 12, 1988

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/  
CALCIUM IN PLASTIC CONTAINER

ABBOTT

4.25%; 36.8MG/100ML; 20GM/100ML;

51MG/100ML; 22.4MG/100ML; 261MG/100ML;

205MG/100ML N19714 002

SEP 12, 1988

@

4.25%; 36.8MG/100ML; 20GM/100ML;

51MG/100ML; 22.4MG/100ML; 261MG/100ML;

205MG/100ML N19714 002

SEP 12, 1988

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/  
CALCIUM IN PLASTIC CONTAINER

ABBOTT

4.25%; 36.8MG/100ML; 25GM/100ML;

51MG/100ML; 22.4MG/100ML; 261MG/100ML;

205MG/100ML N19714 004

SEP 12, 1988

@

4.25%; 36.8MG/100ML; 25GM/100ML;

51MG/100ML; 22.4MG/100ML; 261MG/100ML;

205MG/100ML N19714 004

SEP 12, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE;  
POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM  
CHLORIDE

INJECTABLE; INJECTIONAMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM  
IN PLASTIC CONTAINER

ABBOTT

5%; 16.8MG/100ML; 25GM/100ML;

51MG/100ML; 22.4MG/100ML; 261MG/100ML;

205MG/100ML N19683 004

NOV 07, 1988

5%; 16.8MG/100ML; 25GM/100ML;

51MG/100ML; 22.4MG/100ML; 261MG/100ML;

205MG/100ML N19714 003

SEP 12, 1988

5%; 36.8MG/100ML; 25GM/100ML;

51MG/100ML; 22.4MG/100ML; 261MG/100ML;

205MG/100ML N19683 004

NOV 07, 1988

5%; 36.8MG/100ML; 25GM/100ML;

51MG/100ML; 22.4MG/100ML; 261MG/100ML;

205MG/100ML N19714 003

SEP 12, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE;  
POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTIONCLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/  
CALCIUM IN PLASTIC CONTAINER+ BAXTER HLTHCARE 2.75%; 33MG/100ML; 10GM/100ML;  
 51MG/100ML; 261MG/100ML; 217MG/100ML;  
 112MG/100ML N20678 002  
 MAR 26, 1997CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/  
CALCIUM IN PLASTIC CONTAINER+ BAXTER HLTHCARE 2.75%; 33MG/100ML; 25GM/100ML;  
 51MG/100ML; 261MG/100ML; 217MG/100ML;  
 112MG/100ML N20678 005  
 MAR 26, 1997CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/  
CALCIUM IN PLASTIC CONTAINER+ BAXTER HLTHCARE 2.75%; 33MG/100ML; 5GM/100ML;  
 51MG/100ML; 261MG/100ML; 217MG/100ML;  
 112MG/100ML N20678 001  
 MAR 26, 1997

## RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'97 - DEC'97

7

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE;  
POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/  
CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 4.25%;33MG/100ML;10GM/100ML;  
51MG/100ML;261MG/100ML;297MG/100ML;  
77MG/100ML N20678 009  
MAR 26, 1997

CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/  
CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 4.25%;33MG/100ML;20GM/100ML;  
51MG/100ML;261MG/100ML;297MG/100ML;  
77MG/100ML N20678 011  
MAR 26, 1997

CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/  
CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 4.25%;33MG/100ML;25GM/100ML;  
51MG/100ML;261MG/100ML;297MG/100ML;  
77MG/100ML N20678 012  
MAR 26, 1997

CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/  
CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 4.25%;33MG/100ML;5GM/100ML;  
51MG/100ML;261MG/100ML;297MG/100ML;  
77MG/100ML N20678 008  
MAR 26, 1997

CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/  
CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 5%;33MG/100ML;10GM/100ML;51MG/100ML;  
261MG/100ML;340MG/100ML;  
59MG/100ML N20678 016  
MAR 26, 1997

CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/  
CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 5%;33MG/100ML;15GM/100ML;51MG/100ML;  
261MG/100ML;340MG/100ML;  
59MG/100ML N20678 017  
MAR 26, 1997

CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/  
CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 5%;33MG/100ML;20GM/100ML;51MG/100ML;  
261MG/100ML;340MG/100ML;  
59MG/100ML N20678 018  
MAR 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE;  
POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/  
CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 5%;33MG/100ML;25GM/100ML;51MG/100ML;  
261MG/100ML;340MG/100ML;  
59MG/100ML N20678 019  
MAR 26, 1997

CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/  
CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 5%;33MG/100ML;35GM/100ML;51MG/100ML;  
261MG/100ML;340MG/100ML;  
59MG/100ML N20678 021  
MAR 26, 1997

AMINO ACIDS; DEXTROSE

## INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT 3.5%;25GM/100ML N19505 002  
NOV 07, 1986

3.5%;25GM/100ML N19713 006  
SEP 09, 1988

@ 3.5%;25GM/100ML N19505 002  
NOV 07, 1986

@ 3.5%;25GM/100ML N19713 006  
SEP 09, 1988

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT 3.5%;5GM/100ML N19506 001  
NOV 07, 1986

3.5%;5GM/100ML N19713 002  
SEP 09, 1988

@ 3.5%;5GM/100ML N19506 001  
NOV 07, 1986

@ 3.5%;5GM/100ML N19713 002  
SEP 09, 1988

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT 4.25%;10GM/100ML N19713 001  
SEP 09, 1988

@ 4.25%;10GM/100ML N19713 001  
SEP 09, 1988

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

ABBOTT 4.25%;20GM/100ML N19713 004  
SEP 09, 1988

@ 4.25%;20GM/100ML N19713 004  
SEP 09, 1988

AMINO ACIDS; DEXTROSE

## INJECTABLE; INJECTION

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER  
 ABBOTT 4.25%;25GM/100ML N19504 002  
           4.25%;25GM/100ML NOV 07, 1986  
           4.25%;25GM/100ML N19713 005  
 @       4.25%;25GM/100ML SEP 09, 1988  
 N19504 002  
 NOV 07, 1986  
 N19713 005  
 SEP 09, 1988  
 @       4.25%;25GM/100ML N19713 002  
           4.25%;25GM/100ML NOV 07, 1986  
 N19713 005  
           4.25%;25GM/100ML SEP 09, 1988  
 AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER  
 ABBOTT 5%;25GM/100ML N19713 003  
           5%;25GM/100ML SEP 09, 1988  
 @       5%;25GM/100ML N19713 003  
           5%;25GM/100ML SEP 09, 1988  
 CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC  
 CONTAINER  
 BAXTER HLTHCARE 2.75%;10% N20734 002  
           N20734 002  
           SEP 29, 1997  
 CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC  
 CONTAINER  
 BAXTER HLTHCARE 2.75%;25GM/100ML N20734 005  
           N20734 005  
           SEP 29, 1997  
 CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC  
 CONTAINER  
 BAXTER HLTHCARE 2.75%;5GM/100ML N20734 001  
           N20734 001  
           SEP 29, 1997  
 CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC  
 CONTAINER  
 BAXTER HLTHCARE 4.25%;10GM/100ML N20734 008  
           N20734 008  
           SEP 29, 1997  
 CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC  
 CONTAINER  
 BAXTER HLTHCARE 4.25%;20GM/100ML N20734 010  
           N20734 010  
           SEP 29, 1997  
 CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC  
 CONTAINER  
 BAXTER HLTHCARE 4.25%;25GM/100ML N20734 011  
           N20734 011  
           SEP 29, 1997  
 CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC  
 CONTAINER  
 BAXTER HLTHCARE 4.25%;5GM/100ML N20734 007  
           N20734 007  
           SEP 29, 1997  
 CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC  
 CONTAINER  
 BAXTER HLTHCARE 5%;10GM/100ML N20734 014  
           N20734 014  
           SEP 29, 1997

AMINO ACIDS; DEXTROSE

## INJECTABLE; INJECTION

CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC  
 CONTAINER  
 BAXTER HLTHCARE 5%;15GM/100ML N20734 015  
           N20734 015  
           SEP 29, 1997  
 CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC  
 CONTAINER  
 BAXTER HLTHCARE 5%;20GM/100ML N20734 016  
           N20734 016  
           SEP 29, 1997  
 CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC  
 CONTAINER  
 BAXTER HLTHCARE 5%;25GM/100ML N20734 017  
           N20734 017  
           SEP 29, 1997  
 CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC  
 CONTAINER  
 BAXTER HLTHCARE 5%;35GM/100ML N20734 018  
           N20734 018  
           SEP 29, 1997

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE;  
 POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM  
 CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN  
 DEXTROSE 10% IN PLASTIC CONTAINER  
 ABBOTT 4.25%;10GM/100ML;51MG/100ML;  
         176.5MG/100ML;22.4MG/100ML;  
         104.5MG/100ML;205MG/100ML N19682 003  
           N19682 003  
           NOV 01, 1988  
         4.25%;10GM/100ML;51MG/100ML;  
         176.5MG/100ML;22.4MG/100ML;  
         104.5MG/100ML;205MG/100ML N19712 002  
           N19712 002  
           SEP 08, 1988  
 @       4.25%;10GM/100ML;51MG/100ML;  
         176.5MG/100ML;22.4MG/100ML;  
         104.5MG/100ML;205MG/100ML N19682 003  
           N19682 003  
           NOV 01, 1988  
 @       4.25%;10GM/100ML;51MG/100ML;  
         176.5MG/100ML;22.4MG/100ML;  
         104.5MG/100ML;205MG/100ML N19712 002  
           N19712 002  
           SEP 08, 1988

## RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'97 - DEC'97

9

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

## INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER	ABROTEC	3.5%;5GM/100ML;30MG/100ML; 97MG/100ML;120MG/100ML; 49.3MG/100ML	N19712 001 SEP 08, 1988
@		3.5%;5GM/100ML;30MG/100ML; 97MG/100ML;120MG/100ML; 49.3MG/100ML	N19712 001 SEP 08, 1988

AMINOPHYLLINE

## INJECTABLE; INJECTION

AMINOPHYLLINE	AB * SEARGE	25MG/ML	N87243 001 MAY 24, 1982
	@	25MG/ML	N87243 001 MAY 24, 1982
AMINOPHYLLINE	AB Elixintation	25MG/ML	N87239 001
	AP + PHARMA SERV INC	25MG/ML	N87239 001
	AB PHARMA SERV INC	25MG/ML	N87387 001 JUN 03, 1983
	@	25MG/ML	N87387 001 JUN 03, 1983

TABLET; ORAL  
AMINOPHYLLINE

HALSTEX	BD	100MG	N84674 001
	@	100MG	N84674 001
PHYLLOCONTIN			
* PURDUE FREDERICK		225MG	N86760 001
@		225MG	N86760 001

AMITRIPTYLINE HYDROCHLORIDETABLET; ORAL  
AMITRIPTYLINE HCL

HALSTEX	BP	10MG	N85923 001
	BB	50MG	N85925 001

AMITRIPTYLINE HYDROCHLORIDETABLET; ORAL  
AMITRIPTYLINE HCL

HALSTEX	BP	25MG	N85926 001 MAY 20, 1983
	BP	100MG	N85927 001 MAY 20, 1983
	@	10MG	N85923 001
	@	50MG	N85925 001
	@	75MG	N85926 001 MAY 20, 1983
	@	100MG	N85927 001 MAY 20, 1983

AMITRIPTYLINE HYDROCHLORIDE

## VINTAGE PHARMS

HALSTEX	AB	10MG	N40218 001 SEP 11, 1997
	AB	25MG	N40218 002 SEP 11, 1997
	AB	50MG	N40218 003 SEP 11, 1997
	AB	75MG	N40218 004 SEP 11, 1997
	AB	100MG	N40218 005 SEP 11, 1997
	AB	150MG	N40218 006 SEP 11, 1997

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDETABLET; ORAL  
LIMBITROL

HALSTEX	AB	EQ 12.5MG BASE; 5MG	N16949 001
	AB	EQ 25MG BASE; 5MG	N16949 002
	AB	LIMBITROL DS	
	AB + ROCHE	EQ 25MG BASE; 10MG	N16949 002
	AB * ROCHE	EQ 25MG BASE; 10MG	N16949 002

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINETABLET; ORAL  
ZTRAFON A

ZTRAFON A	BP	10MG;4MG	N14713 002
	@	10MG;4MG	N14713 002
PERPHENAZINE AND AMITRIPTYLINE HCL			
ZENITH GOLDLINE	BB	10MG;2MG	N70935 001 SEP 11, 1986

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HCL

@	ZENITH GOLDLINE	10MG;4MG	N70937 001
@		25MG;2MG	SEP 11, 1986
@		25MG;4MG	N70936 001
@		50MG;4MG	SEP 11, 1986
AB	ZENITH LABS	10MG;2MG	N70938 001
AB		10MG;4MG	SEP 11, 1986
AB		25MG;2MG	N70937 001
AB		25MG;4MG	SEP 11, 1986
AB		50MG;4MG	N70939 001
AB	ZENITH LABS	10MG;2MG	SEP 12, 1986
AB		10MG;4MG	N70938 001
AB		25MG;2MG	SEP 11, 1986
AB		25MG;4MG	N70937 001
AB		50MG;4MG	SEP 11, 1986
> DLT >	TRIAVIL 2-10		N70938 001
> DLT >	AB LOTUS BIOCHEM	10MG;2MG	SEP 11, 1986
> ADD >	@	10MG;2MG	N70939 001
> DLT >	TRIAVIL 2-25		SEP 12, 1986
> DLT >	AB LOTUS BIOCHEM	25MG;2MG	N70938 001
> ADD >	@	25MG;2MG	N70937 001
> DLT >	TRIAVIL 4-10		SEP 11, 1986
> DLT >	AB LOTUS BIOCHEM	10MG;4MG	N70938 001
> ADD >	@	10MG;4MG	N70939 001
> DLT >	TRIAVIL 4-25		SEP 11, 1986
> DLT >	AB * LOTUS BIOCHEM	25MG;4MG	N70938 001
> ADD >	@	25MG;4MG	N70939 001
> DLT >	TRIAVIL 4-50		SEP 12, 1986
> DLT >	AB * LOTUS BIOCHEM	50MG;4MG	N14715 004
> ADD >	@	50MG;4MG	N14715 004

AMOXICILLIN

CAPSULE; ORAL

AMOXIL

AB *	SMITHKLINE BEECHAM	250MG	N60459 001
AB		250MG	N62216 001
AB	+	250MG	N62216 001
AB	*	500MG	N60459 002
AB	*	500MG	N62216 004
AB	+	500MG	N62216 004

AMOXICILLIN

CAPSULE; ORAL

AMOXIL

@	SMITHKLINE BEECHAM	250MG	N50459 001
@		500MG	N50459 002

## POWDER FOR RECONSTITUTION; ORAL

AMOXIL

AB *	SMITHKLINE BEECHAM	125MG/5ML	N50459 001
AB	+	125MG/5ML	N62226 001
AB	*	250MG/5ML	N50459 002
AB	*	50MG/ML	N50459 005
AB	*	50MG/ML	N62226 005
AB	*	125MG/5ML	N50460 001
AB	*	250MG/5ML	N50460 002
AB	*	50MG/ML	N50460 005

LAROTID

AB	SMITHKLINE BEECHAM	50MG/ML	N50459 005
@		50MG/ML	N50460 006

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

> ADD >	CAPSULE, TABLET, CAPSULE, EXTENDED RELEASE; ORAL	
> ADD >	PREVPAC	
> ADD >	+ TAP HOLDINGS	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A,
> ADD >		30MG N50757 001
> ADD >		DEC 02, 1997

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

## TABLET; ORAL

ADDERALL 10

RICHWOOD PHARM	2.5MG; 2.5MG; 2.5MG; 2.5MG	N11537 007
SHIRE RICHWOOD	2.5MG; 2.5MG; 2.5MG; 2.5MG	FEB 13, 1996

ADDERALL 20

RICHWOOD PHARM	5MG; 5MG; 5MG; 5MG	N11522 008
		FEB 13, 1996

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL  
 ADDERALL 20  
 SHIRE RICHWOOD 5MG; 5MG; 5MG; 5MG N11522 008  
 FEB 13, 1996  
 ADDERALL 30  
 + SHIRE RICHWOOD 7.5MG; 7.5MG; 7.5MG; 7.5MG N11522 010  
 MAY 12, 1997  
 ADDERALL 5  
 SHIRE RICHWOOD 1.25MG; 1.25MG; 1.25MG;  
 1.25MG N11522 009  
 MAY 12, 1997

AMPHOTERICIN B

INJECTABLE; INJECTION  
AMPHOTERICIN B  
 AP ABBOTT 50MG/VIAL N64141 001  
 DEC 23, 1996  
 N64141 001  
 DEC 23, 1996  
 INJECTABLE, LIPOSOMAL; INJECTION  
 AMBISOME  
 + FUJISAWA 50MG/VIAL N50740 001  
 AUG 11, 1997  
 OINTMENT; TOPICAL  
 FUNGTZONE  
 \* APOTHECON 3% N50313 001  
 @ 3% N50313 001

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION  
 UNASYN  
 + PFIZER EQ 10GM BASE/VIAL;  
 EQ 5GM BASE/VIAL N50608 005  
 DEC 10, 1993  
 > ADD >  
 > ADD >  
 > ADD >

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL  
AMPICILLIN TRIHYDRATE  
 @ ZENITH GOLDLINE EQ 250MG BASE N60765 001

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL  
AMPICILLIN TRIHYDRATE  
 @ ZENITH GOLDLINE EQ 500MG BASE N60765 002  
 ZENITH LABS EQ 250MG BASE N60765 001  
 EQ 500MG BASE N60765 002

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL  
 AGRYLIN  
 ROBERTS LABS EQ 0.5MG BASE N20333 001  
 MAR 14, 1997  
 + EQ 1MG BASE N20333 002  
 MAR 14, 1997

ANISOTROPINE METHYLBROMIDE

TABLET; ORAL  
 VALPIN 50  
 @ DUPONT MERCK 50MG N13428 001  
 @ ENDO PHARMS 50MG N13428 001

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION  
 GENESA  
 + GENSIA 0.05MG/ML N20420 001  
 SEP 12, 1997

ARDEPARIN SODIUM

INJECTABLE; INJECTION  
 NORMIFLO  
 + WYETH AYERST 5,000 UNITS/0.5ML N20227 002  
 MAY 23, 1997  
 + 10,000 UNITS/0.5ML N20227 001  
 MAY 23, 1997

ASPIRIN; BUTALBITAL

TABLET; ORAL  
AXOTAL  
\* SAVAGE LABS 650MG; 50MG  
@ 650MG; 50MG

N88305 001  
OCT 13, 1983  
N88305 001  
OCT 13, 1983

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL  
BUTALBITAL COMPOUND  
@ ZENITH GOLDLINE 325MG; 50MG; 40MG  
AB ZENITH LABS 325MG; 50MG; 40MG

N85441 002  
OCT 31, 1984  
N85441 002  
OCT 31, 1984

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL  
ORPHENEGESTIC  
@ PAR PHARM 385MG; 30MG; 25MG  
ORPHENEGESTIC FORTE  
@ PAR PHARM 770MG; 60MG; 50MG

N71642 001  
JUN 23, 1997  
N71643 001  
JUN 23, 1997

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL  
PROPOXYPHENE COMPOUND 65  
@ ZENITH GOLDLINE 389MG; 32.4MG; 65MG  
AB ZENITH LABS 389MG; 32.4MG; 65MG

N83077 002  
DEC 07, 1984  
N83077 002  
DEC 07, 1984

ASPIRIN; CARISOPRODOL

TABLET; ORAL  
CARISOPRODOL AND ASPIRIN  
AB AMIDE PHARM 325MG; 200MG

N40252 001  
DEC 10, 1997

&gt; ADD

&gt; ADD

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL  
OXYDOXY  
AA HATSEY 325MG; 4.5MG; 0.38MG  
@ 325MG; 4.5MG; 0.38MG

N87464 001  
JUL 01, 1982  
N87464 001  
JUL 01, 1982

PERCODAN  
AA \* DUPONT MERCK 325MG; 4.5MG; 0.38MG  
AA + ENDO PHARMS 325MG; 4.5MG; 0.38MG  
AA \* DUPONT MERCK 325MG; 2.25MG; 0.19MG  
AA + ENDO PHARMS 325MG; 2.25MG; 0.19MG

N07337 006  
N07337 006  
N07337 005  
N07337 005

ATENOLOL

TABLET; ORAL  
ATENOLOL  
AB MUTUAL PHARM 25MG  
AB SIDMAK LABS NJ 25MG  
AB 50MG  
AB 100MG

N74499 001  
JUL 30, 1997  
N74101 001  
JUL 17, 1997  
N74101 002  
JUL 17, 1997  
N74101 003  
JUL 17, 1997

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL  
ATENOLOL AND CHLORTHALIDONE  
AB SIDMAK LABS NJ 50MG; 25MG  
AB 100MG; 25MG

N74107 001  
SEP 24, 1997  
N74107 002  
SEP 24, 1997

ATRACURIUM BESYLATE

INJECTABLE; INJECTION  
ATRACURIUM BESYLATE  
AP ABBOTT 10MG/ML  
AP BEDFORD 10MG/ML

N74633 001  
DEC 23, 1996  
N74901 001  
JUL 18, 1997

ATRACURIUM BESYLATE

## INJECTABLE; INJECTION

<u>ATRACURIUM BESYLATE</u>		
AP	ESI LEDERLE	<u>10MG/ML</u>
AP	FAULDING	<u>10MG/ML</u>
AP	GENSIA	<u>10MG/ML</u>
AP	OHMEDA	<u>10MG/ML</u>
	<u>ATRACURIUM BESYLATE PRESERVATIVE FREE</u>	
AP	ABBOTT	<u>10MG/ML</u>
AP		<u>10MG/ML</u>
AP	BEDFORD	<u>10MG/ML</u>
AP	ESI LEDERLE	<u>10MG/ML</u>
AP	FAULDING	<u>10MG/ML</u>
AP	OHMEDA	<u>10MG/ML</u>
	<u>TRACRIUM</u>	
AP	* GLAXO WELLCOME	<u>10MG/ML</u>
AP	+	<u>10MG/ML</u>
	<u>TRACRIUM PRESERVATIVE FREE</u>	
AP	+ GLAXO WELLCOME	<u>10MG/ML</u>

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL		
	<u>DIPHENOXYLATE HCL AND ATROPINE SULFATE</u>	
AA	RONKAN	<u>0.025MG;2.5MG</u>
@		<u>0.025MG;2.5MG</u>
AA	<u>DIPHENOXYLATE HCL W/ ATROPINE SULFATE</u>	
AA	ZEN	<u>0.025MG;2.5MG</u>
@		<u>0.025MG;2.5MG</u>
AA	KY PHARM	<u>0.025MG;2.5MG</u>
@		<u>0.025MG;2.5MG</u>
AA	ZENITH GOLDLINE	<u>0.025MG;2.5MG</u>

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL		
AA	<u>DIPHENOXYLATE HCL W/ ATROPINE SULFATE</u>	
AA	ZENITH GOLDLINE	<u>0.025MG;2.5MG</u>

N86727 001

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION		
	ATROPINE AND DEMEROL	
+ ABBOTT		<u>0.4MG/ML;50MG/ML</u>
+		<u>0.4MG/ML;75MG/ML</u>
+		<u>0.4MG/ML;100MG/ML</u>
AA STERLING WINTHROP		<u>0.4MG/ML;50MG/ML</u>
AA		<u>0.4MG/ML;75MG/ML</u>
AA		<u>0.4MG/ML;100MG/ML</u>

N87853 001 NOV 26, 1982  
 N87847 001 NOV 26, 1982  
 N87848 001 NOV 26, 1982  
 N87852 001 NOV 26, 1982  
 N87843 001 NOV 26, 1982  
 N87844 001 NOV 26, 1982  
 N87845 001 NOV 26, 1982  
 N87846 001 NOV 26, 1982

AURANOFIN

CAPSULE; ORAL		
	RIDAURA	
+ CONNECTICS		<u>3MG</u>
AA SMITHKLINE BEECHAM		<u>3MG</u>

N18689 001 MAY 24, 1985  
 N18689 001 MAY 24, 1985

AZITHROMYCIN DIHYDRATE

INJECTABLE; INJECTION		
ZITHROMAX		
+ PFIZER		<u>EQ 500MG BASE/VIAL</u>

N50733 001 JAN 30, 1997

AZLOCILLIN SODIUM

INJECTABLE; INJECTION		
AZLIN		
* BAYER		<u>EQ 2GM BASE/VIAL</u>

N50662 001 SEP 03, 1982

AZLOCILLIN SODIUM

## INJECTABLE; INJECTION

AZLIN

BAYER

EQ 3GM BASE/VIAL

N50562 002

SEP 03, 1982

\*  
@

EQ 4GM BASE/VIAL

N50562 003

SEP 03, 1982

@

EQ 2GM BASE/VIAL

N50562 001

SEP 03, 1982

@

EQ 3GM BASE/VIAL

N50562 002

SEP 03, 1982

@

EQ 4GM BASE/VIAL

N50562 003

SEP 03, 1982

BACITRACIN

## INJECTABLE; INJECTION

BACITRACIN

AP PHARMA TEK

50,000 UNITS/VIAL

N64153 001

MAY 09, 1997

BACITRACIN

AP + PHARMACIA AND UPJOHN 50,000 UNITS/VIAL

N60733 002

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATEOINTMENT; TOPICAL  
CORTISPORIN

GLAXO WELLCOME

400 UNITS/GM; 1%; EQ 3.5MG BASE/GM;

5,000 UNITS/GM N50168 002

MAY 04, 1984

+ MONARCH PHARMS

400 UNITS/GM; 1%; EQ 3.5MG BASE/GM;

5,000 UNITS/GM N50168 002

MAY 04, 1984

BECLOMETHASONE DIPROPIONATE MONOHYDRATESPRAY, METERED; NASAL  
BECONASE AO

BN GLAXO WELLCOME

EQ 0.042MG DIPROP/SPRAY N19389 001

JUL 27, 1987

BN +

EQ 0.042MG DIPROP/SPRAY N19389 001

JUL 27, 1987

BENZQUINAMIDE HYDROCHLORIDESUPPOSITORY; RECTAL  
EMTEC CON

BAYER

@

EQ 100MG BASE

EQ 100MG BASE

N16818 006

N16818 006

BETAMETHASONE DIPROPIONATE

## CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

AB CLAY PARK

EQ 0.05% BASE

N74579 001

NOV 26, 1997

## LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

AB ALPHARMA

EQ 0.05% BASE

N71085 001

FEB 03, 1987

AB NYC

EQ 0.05% BASE

N71085 001

FEB 03, 1987

BETAMETHASONE VALERATE

## CREAM; TOPICAL

BETAMETHASONE VALERATE

AB FOUGERA

EQ 0.1% BASE

N18861 001

AUG 31, 1983

AB +

EQ 0.1% BASE

N18861 001

AUG 31, 1983

AB VALLISONE

EQ 0.1% BASE

N16322 001

N16322 002

AB \* SCHERING

EQ 0.01% BASE

N16322 002

@

EQ 0.01% BASE

N16322 001

@

EQ 0.1% BASE

## LOTION; TOPICAL

BETAMETHASONE VALERATE

AB FOUGERA

EQ 0.1% BASE

N18866 001

AUG 31, 1983

AB +

EQ 0.1% BASE

N18866 001

AUG 31, 1983

AB VALLISONE

EQ 0.1% BASE

N16932 001

N16932 001

@

EQ 0.1% BASE

## OINTMENT; TOPICAL

BETAMETHASONE VALERATE

AB FOUGERA

EQ 0.1% BASE

N18865 001

AUG 31, 1983

BETAMETHASONE VALERATE

OINTMENT; TOPICAL  
**BETAMETHASONE VALERATE**  
 AB + FOUGERA EQ 0.1% BASE  
 VALISONE  
 AB \* SCHERING EQ 0.1% BASE  
 @ EQ 0.1% BASE

N18865 001  
 AUG 31, 1983  
 N16740 001  
 N16740 001

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC  
 BETOPTIC PILO  
 + ALCON EQ 0.25% BASE; 1.75%  
 APR 17, 1997

BETHANECHOL CHLORIDE

TABLET; ORAL  
**BETHANECHOL CHLORIDE**  
 AB @ ZENITH GOLDLINE 25MG  
 ZENITH LABS 25MG

N84689 001  
 N84689 001

BLEOMYCIN SULFATE

INJECTABLE; INJECTION  
**BLENOXANE**  
 AP + BRISTOL MYERS SQUIBB EQ 30 UNITS BASE/VIAL  
 BLEOMYCIN SULFATE  
 AP PHARMACIA AND UPJOHN EQ 30 UNITS BASE/VIAL  
 \* EQ 30 UNITS BASE/VIAL

N50443 002  
 SEP 07, 1995  
 N64084 002  
 JUN 01, 1996  
 N64084 002  
 JUN 01, 1996

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION  
**BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER**  
 AP \* BAXTER HLTHCARE 200MG/100ML N19837 002  
 APR 12, 1989  
 AP \* 400MG/100ML N19837 001  
 APR 12, 1989

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION  
**BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER**  
 @ BAXTER HLTHCARE 200MG/100ML N19837 002  
 APR 12, 1989  
 @ 400MG/100ML N19837 001  
 APR 12, 1989

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC  
 ALPHAGAN  
 + ALLERGAN 0.5%  
 N20490 001  
 MAR 13, 1997

BROMFENAC SODIUM

CAPSULE; ORAL  
 DURACT  
 + WYETH AYERST EQ 25MG BASE  
 N20535 001  
 JUL 15, 1997

BROMPHENIRAMINE MALEATE

TABLET; ORAL  
 BROMPHENIRAMINE MALEATE  
 @ ZENITH GOLDLINE 4MG  
 ZENITH LABS 4MG  
 N84351 001  
 N84351 001

BUDESONIDE

AEROSOL, METERED; NASAL  
 RHINOCORT  
 \* ASTRA 0.03MG/INH  
 + 0.032MG/INH  
 N20233 001  
 FEB 14, 1994  
 N20233 001  
 FEB 14, 1994

POWDER, METERED; INHALATION

PULMICORT  
 + ASTRA 0.16MG/INH  
 N20441 002  
 JUN 24, 1997  
 @ 0.32MG/INH  
 N20441 003  
 JUN 24, 1997

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

<u>AP</u>	ABBOTT	<u>0.25MG/ML</u>	N74160 001 OCT 30, 1997
<u>AP</u>		<u>0.25MG/ML</u>	N74332 001 OCT 31, 1994
<u>AP</u>	GENSIA	<u>0.25MG/ML</u>	N74613 001 NOV 18, 1997
<u>AP</u>	SANOFI WINTHROP	<u>0.25MG/ML</u>	N74332 001 OCT 31, 1994

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENORPHINE HCL

<u>AP</u>	ABBOTT	<u>EQ 0.3MG BASE/ML</u>	N74137 001 JUN 03, 1996
<u>AP</u>	SANOFI WINTHROP	<u>EQ 0.3MG BASE/ML</u>	N74137 001 JUN 03, 1996

BUPROPION HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL  
WELLBUTRIN

+ GLAXO WELLCOME	100MG	N20358 002 OCT 04, 1996
	150MG	N20358 003 OCT 04, 1996
ZYBAN GLAXO WELLCOME	100MG	N20711 002 MAY 14, 1997
	150MG	N20711 003 MAY 14, 1997
+	100MG	N20711 002 MAY 14, 1997
+	150MG	N20711 003 MAY 14, 1997

BUTABARBITAL SODIUM

TABLET; ORAL

SODIUM BUTABARBITAL

@ ZENITH GOLDLINE

15MG

N83484 001  
N84040 001

30MG

BUTABARBITAL SODIUM

TABLET; ORAL

SODIUM BUTABARBITAL

@ ZENITH GABS

15MG

30MG

N83484 001

N84040 001

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT ONE

+ SYNTEX

2%

N19881 001

FEB 07, 1997

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE PRESERVATIVE FREE

<u>AP</u>	ABBOTT	<u>1MG/ML</u>	N74620 001 JAN 22, 1997
<u>AP</u>		<u>1MG/ML</u>	N74626 001 JAN 23, 1997
<u>AP</u>		<u>2MG/ML</u>	N74620 002 JAN 22, 1997
<u>AP</u>		<u>2MG/ML</u>	N74626 002 JAN 23, 1997
<u>AP</u>	<u>STADOL</u> + APOTHECON	<u>2MG/ML</u>	N17857 004
<u>AP</u>	<u>STADOL PRESERVATIVE FREE</u>		
<u>AP</u>	+ APOTHECON	<u>1MG/ML</u>	N17857 001
<u>AP</u>	+	<u>2MG/ML</u>	N17857 002

CALCIPOTRIENE

SOLUTION; TOPICAL

DOVONEX

+ BRISTOL MYERS SQUIBB 0.005%

N20611 001

MAR 03, 1997

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

## INJECTABLE; INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC

CONTAINER

MCGAW

4MG/100ML; 4GM/100ML; 6MG/100ML;  
120MG/100ML; 53MG/100ML N19634 002  
FEB 24, 1988

@

4MG/100ML; 4GM/100ML; 6MG/100ML;  
120MG/100ML; 62MG/100ML N19634 002  
FEB 24, 1988

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

AP MCGAW

20MG/100ML; 5GM/100ML; 30MG/100ML;  
600MG/100ML; 310MG/100ML N17510 001  
FEB 24, 1988

@

20MG/100ML; 5GM/100ML; 30MG/100ML;  
600MG/100ML; 310MG/100ML N17510 001  
FEB 24, 1988

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

## INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

MCGAN

35MG/100ML; 30MG/100ML; 74MG/100ML;  
640MG/100ML; 500MG/100ML;  
74MG/100ML N18899 001  
OCT 31, 1988

@

35MG/100ML; 30MG/100ML; 74MG/100ML;  
640MG/100ML; 500MG/100ML;  
74MG/100ML N18899 001  
OCT 31, 1988

## SOLUTION; IRRIGATION

BSS

+ ALCON

0.48MG/ML; 0.3MG/ML; 0.75MG/ML;  
3.9MG/ML; 6.4MG/ML;  
1.7MG/ML N20742 001  
DEC 10, 1997

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

## INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP MCGAW

20MG/100ML; 30MG/100ML; 600MG/100ML;  
310MG/100ML N18023 001

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

## INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

@ MCGAW

20MG/100ML; 30MG/100ML; 600MG/100ML;  
310MG/100ML N18023 001

CAPTOPRILTABLET; ORAL  
CAPOTEN

<u>AB</u>	<u>* BRISTOL MYERS SQUIBB</u>	<u>25MG</u>	<u>N18343 002</u>
<u>AB</u>	<u>CAPTOPRIL</u>	<u>25MG</u>	<u>N74748 002</u>
<u>AB</u>	<u>EGIS PHARMS</u>	<u>12.5MG</u>	<u>MAY 29, 1997</u>
<u>AB</u>		<u>25MG</u>	<u>N74748 002</u>
<u>AB</u>		<u>50MG</u>	<u>MAY 29, 1997</u>
<u>AB</u>		<u>100MG</u>	<u>N74748 003</u>
<u>AB</u>	<u>ENDO LABS</u>	<u>12.5MG</u>	<u>MAY 29, 1997</u>
<u>AB</u>		<u>12.5MG</u>	<u>N74418 001</u>
<u>AB</u>		<u>25MG</u>	<u>FEB 13, 1996</u>
<u>AB</u>		<u>100MG</u>	<u>N74418 001</u>
<u>AB</u>		<u>25MG</u>	<u>FEB 13, 1996</u>
<u>AB</u>		<u>25MG</u>	<u>N74418 002</u>
<u>AB</u>		<u>50MG</u>	<u>FEB 13, 1996</u>
<u>AB</u>		<u>100MG</u>	<u>N74418 002</u>
<u>AB</u>		<u>50MG</u>	<u>N74418 003</u>
<u>AB</u>		<u>50MG</u>	<u>FEB 13, 1996</u>
<u>AB</u>		<u>100MG</u>	<u>N74418 004</u>
<u>AB</u>	<u>PUREPAC PHARM</u>	<u>12.5MG</u>	<u>N74640 001</u>
<u>AB</u>		<u>25MG</u>	<u>MAR 31, 1997</u>
<u>AB</u>		<u>50MG</u>	<u>N74640 002</u>
<u>AB</u>		<u>100MG</u>	<u>MAR 31, 1997</u>
<u>AB</u>		<u>50MG</u>	<u>N74640 003</u>
<u>AB</u>		<u>100MG</u>	<u>MAR 31, 1997</u>
<u>AB</u>		<u>100MG</u>	<u>N74640 004</u>

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

<u>AB</u>	<u>STASON</u>	<u>12.5MG</u>
<u>AB</u>		<u>25MG</u>
<u>AB</u>		<u>50MG</u>
<u>AB</u>		<u>100MG</u>
<u>AB</u>	<u>WOCKHARDT</u>	<u>12.5MG</u>
<u>AB</u>		<u>25MG</u>
<u>AB</u>		<u>50MG</u>
<u>AB</u>		<u>100MG</u>

N74677 004	> <u>ADD</u> >
MAY 30, 1997	> <u>ADD</u> >
N74677 002	> <u>ADD</u> >
MAY 30, 1997	> <u>ADD</u> >
N74677 001	> <u>ADD</u> >
MAY 30, 1997	> <u>ADD</u> >
N74677 003	> <u>ADD</u> >
MAY 30, 1997	> <u>ADD</u> >
N74532 001	> <u>ADD</u> >
MAR 28, 1997	> <u>ADD</u> >
N74532 002	> <u>ADD</u> >
MAR 28, 1997	> <u>ADD</u> >
N74532 003	> <u>ADD</u> >
MAR 28, 1997	> <u>ADD</u> >
N74532 004	> <u>ADD</u> >
MAR 28, 1997	> <u>ADD</u> >

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

N74827 001
DEC 29, 1997
N74827 002
DEC 29, 1997
N74827 004
DEC 29, 1997
N74827 003
DEC 29, 1997
N74896 001
DEC 29, 1997
N74896 002
DEC 29, 1997
N74896 004
DEC 29, 1997
N74896 003
DEC 29, 1997

<u>AB</u>	<u>LEMMON</u>	<u>25MG; 15MG</u>
<u>AB</u>		<u>25MG; 25MG</u>
<u>AB</u>		<u>50MG; 15MG</u>
<u>AB</u>		<u>50MG; 25MG</u>
<u>AB</u>	<u>MYLAN</u>	<u>25MG; 15MG</u>
<u>AB</u>		<u>25MG; 25MG</u>
<u>AB</u>		<u>50MG; 15MG</u>
<u>AB</u>		<u>50MG; 25MG</u>

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPOZIDE 25/15

> <u>ADD</u> >	<u>AB</u>	<u>SQUIBB</u>	<u>25MG; 15MG</u>
> <u>ADD</u> >			
> <u>ADD</u> >	<u>AB</u>	+ <u>SQUIBB</u>	<u>25MG; 25MG</u>
> <u>ADD</u> >			
> <u>ADD</u> >	<u>AB</u>	+ <u>SQUIBB</u>	<u>50MG; 15MG</u>
> <u>ADD</u> >			
> <u>ADD</u> >	<u>AB</u>	<u>CAPOZIDE 50/25</u>	<u>50MG; 25MG</u>
> <u>ADD</u> >			
> <u>ADD</u> >	<u>AB</u>	<u>SQUIBB</u>	<u>50MG; 25MG</u>
> <u>ADD</u> >			
> <u>ADD</u> >	<u>AB</u>	<u>CAPTOPRIL AND HYDROCHLOROTHIAZIDE</u>	<u>50MG; 25MG</u>
> <u>ADD</u> >			
> <u>ADD</u> >	<u>AB</u>	<u>DANBURY PHARMA</u>	<u>50MG; 25MG</u>
> <u>ADD</u> >			
> <u>ADD</u> >	<u>AB</u>	<u>ENDO LABS</u>	<u>25MG; 15MG</u>
> <u>ADD</u> >			
> <u>ADD</u> >	<u>AB</u>		<u>25MG; 25MG</u>
> <u>ADD</u> >			
> <u>ADD</u> >	<u>AB</u>		<u>50MG; 15MG</u>
> <u>ADD</u> >			
> <u>ADD</u> >	<u>AB</u>		<u>50MG; 25MG</u>

N18709 001	
OCT 12, 1984	
N18709 002	
OCT 12, 1984	
N18709 004	
OCT 12, 1984	
N18709 003	
OCT 12, 1984	
N74832 001	
DEC 29, 1997	
N74788 001	
DEC 29, 1997	
N74788 002	
DEC 29, 1997	
N74788 004	
DEC 29, 1997	
N74788 003	
DEC 29, 1997	

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBATROL

N20712 001
SEP 30, 1997
N20712 002

+ <u>ATHENA</u>	200MG
+	300MG

TABLET; ORAL

EPITOL

N70541 001
SEP 17, 1986

<u>AB</u> <u>LEMMON</u>	<u>200MG</u>
<u>AB</u> <u>TEVA</u>	<u>200MG</u>

TABLET, CHEWABLE; ORAL

EPITOL

N73524 001
JUL 29, 1992

<u>AB</u> <u>LEMMON</u>	<u>100MG</u>
<u>AB</u> <u>TEVA</u>	<u>100MG</u>

## RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'97 - DEC'97

19

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	<u>LEMON</u>	<u>10MG; 100MG</u>	<u>N73618 001</u>
<u>AB</u>		<u>25MG; 100MG</u>	<u>AUG 28, 1992</u>
<u>AB</u>		<u>25MG; 250MG</u>	<u>N73589 001</u>
<u>AB</u>			<u>AUG 28, 1992</u>
<u>AB</u>	TEVA	<u>10MG; 100MG</u>	<u>N73607 001</u>
<u>AB</u>		<u>25MG; 100MG</u>	<u>AUG 28, 1992</u>
<u>AB</u>		<u>25MG; 250MG</u>	<u>N73618 001</u>

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

<u>AA</u>	AMIDE PHARM	<u>350MG</u>	<u>N40188 001</u>
<u>AA</u>	VINTAGE PHARMS	<u>350MG</u>	<u>MAR 07, 1997</u>

N40245 001  
SEP 08, 1997

CARVEDILOL

TABLET; ORAL

COREG

SMITHKLINE BEECHAM 3.125MG

N20297 004  
MAY 29, 1997

CEFACLOR

CAPSULE; ORAL

CEFACLOR

<u>AB</u>	RANBAXY	<u>EQ 250MG BASE</u>	
<u>AB</u>		<u>EQ 500MG BASE</u>	

N64156 001  
AUG 28, 1997

N64156 002  
AUG 28, 1997

> ADD >CEFDINIR> ADD > CAPSULE; ORAL

OMNICEF

> ADD > + PARKE DAVIS

300MG

N50739 001  
DEC 04, 1997

POWDER FOR RECONSTITUTION; ORAL

CEFACLOR

<u>AB</u>	RANBAXY	<u>EQ 125MG BASE/5ML</u>	

N64166 001  
OCT 02, 1997

> ADD > POWDER FOR RECONSTITUTION; ORAL

OMNICEF

> ADD > + PARKE DAVIS

125MG/5ML

N50749 001  
DEC 04, 1997CEFACLOR

POWDER FOR RECONSTITUTION; ORAL

CEFACLOR

<u>AB</u>	RANBAXY	<u>EQ 187MG BASE/5ML</u>	
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	
<u>AB</u>		<u>EQ 375MG BASE/5ML</u>	

N64165 001  
OCT 02, 1997

N64164 001  
OCT 02, 1997

N64155 001  
OCT 02, 1997

CEFAZOLIN SODIUMINJECTABLE; INJECTION  
CEFAZOLIN SODIUM

<u>AP</u>	LEMON	<u>EQ 250MG BASE/VIAL</u>	<u>N63016 001</u>
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>N63016 002</u>
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>N63016 003</u>
<u>AP</u>		<u>EQ 5GM BASE/VIAL</u>	<u>N63018 001</u>
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>N63018 002</u>
<u>AP</u>	TEVA	<u>EQ 250MG BASE/VIAL</u>	<u>N63016 001</u>
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>N63016 002</u>
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>N63016 003</u>
<u>AP</u>		<u>EQ 5GM BASE/VIAL</u>	<u>N63018 001</u>
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>N63018 002</u>

N63016 001  
MAR 14, 1989

N63016 002  
MAR 14, 1989

N63016 003  
MAR 14, 1989

N63018 001  
MAR 05, 1990

N63018 002  
MAR 05, 1990

N63016 001  
MAR 14, 1989

N63016 002  
MAR 14, 1989

N63016 003  
MAR 14, 1989

N63018 001  
MAR 05, 1990

N63018 002  
MAR 05, 1990

N63016 001  
MAR 14, 1989

N63016 002  
MAR 14, 1989

N63016 003  
MAR 14, 1989

N63018 001  
MAR 05, 1990

N63018 002  
MAR 05, 1990

N63016 001  
MAR 14, 1989

N63016 002  
MAR 14, 1989

N63016 003  
MAR 14, 1989

N63018 001  
MAR 05, 1990

N63018 002  
MAR 05, 1990

CEFPODOXIME PROXETIL

GRANULE, FOR RECONSTITUTION; ORAL  
VANTIN

> ADD > PHARMACIA AND UPJOHN EQ 50MG BASE/5ML  
> ADD >  
> ADD > + EQ 100MG BASE/5ML  
> ADD >  
> DLT > UPJOHN EQ 50MG BASE/5ML  
> DLT >  
> DLT > \* EQ 100MG BASE/5ML  
> DLT >

N50675 001  
AUG 07, 1992  
N50675 002  
AUG 07, 1992  
N50675 001  
AUG 07, 1992  
N50675 002  
AUG 07, 1992

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE; INJECTION  
ROCEPHIN KIT

+ ROCHE EQ 1GM BASE/VIAL, N/A; N/A,  
1% N50585 006  
MAY 08, 1996  
+ EQ 500MG BASE/VIAL, N/A; N/A,  
1% N50585 007  
MAY 08, 1996

CEFURGXIME AXETIL

POWDER FOR RECONSTITUTION; ORAL  
CEFTIN

\* GLAXO WELLCOME EQ 125MG BASE/5ML N50672 001  
JUN 30, 1994  
EQ 125MG BASE/5ML N50672 001  
JUN 30, 1994  
+ EQ 250MG BASE/5ML N50672 002  
APR 29, 1997

CEFURGXIME SODIUM

INJECTABLE; INJECTION  
CEFURGXIME SODIUM

AB HANFORD GC EQ 750MG BASE/VIAL N64125 001  
MAY 30, 1997  
AP EQ 1.5GM BASE/VIAL N64125 002  
MAY 30, 1997  
AP EQ 7.5GM BASE/VIAL N64124 001  
MAY 30, 1997

CEFURGXIME SODIUM

INJECTABLE; INJECTION  
KEFUROX

AB LILLY EQ 750MG BASE/VIAL N62591 001  
JAN 10, 1986  
AB EQ 750MG BASE/VIAL N62592 001  
JAN 10, 1986  
AP EQ 750MG BASE/VIAL N62591 001  
JAN 10, 1986  
AP EQ 750MG BASE/VIAL N62592 001  
JAN 10, 1986

ZINACEF  
AB + GLAXO WELLCOME EQ 750MG BASE/VIAL N50558 002  
OCT 19, 1983  
AP \* EQ 750MG BASE/VIAL N50558 002  
OCT 19, 1983

CEPHALEXIN

CAPSULE; ORAL  
CEPHALEXIN

AB APOTHECON EQ 250MG BASE N62973 001  
NOV 08, 1988  
AB EQ 500MG BASE N62974 001  
NOV 23, 1988  
@ EQ 250MG BASE N62973 001  
NOV 08, 1988  
@ EQ 500MG BASE N62974 001  
NOV 23, 1988  
AB PUREPAC PHARM EQ 250MG BASE N62809 001  
APR 22, 1987  
AB EQ 500MG BASE N62809 002  
APR 22, 1987  
@ EQ 250MG BASE N62809 001  
APR 22, 1987  
@ EQ 500MG BASE N62809 002  
APR 22, 1987

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION  
CEFADYL

APOTHECON EQ 1GM BASE/VIAL N62724 001  
DEC 23, 1986  
EQ 2GM BASE/VIAL N62724 002  
DEC 23, 1986

## RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'97 - DEC'97

21

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL  
@ APOTHECONEQ 1GM BASE/VIAL  
EQ 2GM BASE/VIALN62724 001  
DEC 23, 1986  
N62724 002  
DEC 23, 1986CEPHRADINECAPSULE; ORAL  
CEPHRADINE

@ ZENITH GOLDLINE

250MG

N62762 001

MAR 06, 1987 N62762 002

MAR 06, 1987 N62763 001

MAR 06, 1987 N62763 002

MAR 06, 1987 N62763 003

MAR 06, 1987 N62763 004

CERIVASTATIN SODIUMTABLET; ORAL  
BAYCOL  
@ BAYER

0.05MG

N20740 001

JUN 26, 1997 N20740 002

0.1MG JUN 26, 1997 N20740 003

0.2MG JUN 26, 1997 N20740 004

+ 0.3MG JUN 26, 1997 N20740 005

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATEOINTMENT; OPHTHALMIC  
OPHTHO-CORT  
@ PARKE DAVIS10MG/GM; 5MG/GM;  
10,000 UNITS/GM  
10MG/GM; 5MG/GM;  
10,000 UNITS/GM

N50201 003

N50201 002

CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL

CHLOROMYCETIN PALMITATE

PARKE DAVIS

EQ 150MG BASE/5ML

N62301 001

EQ 150MG BASE/5ML

N62301 001

CHLORDIAZEPOXIDECAPSULE, EXTENDED RELEASE; ORAL  
LIBRELEASE

@ ICN

30MG

N17813 001

&gt; ADD &gt;

30MG

SEP 12, 1983

&gt; DLT &gt;

30MG

N17813 001

&gt; DLT &gt;

TABLET; ORAL  
LIBRITABS

ROCHE

5MG

N85482 001

10MG

N85481 001

25MG

N85488 001

+

5MG

N85482 001

@

10MG

N85481 001

@

25MG

N85488 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HCL

@ ZENITH GOLDLINE

5MG

N83741 001

@

10MG

N83742 001

@

25MG

N83570 001

AB ZENITH LABS

5MG

5MG

N83741 001

AB

10MG

N83742 001

AB

25MG

N83570 001

LIBRIUM

@ ICN

5MG

N12249 002

@

10MG

N12249 001

@

25MG

N12249 003

ROCHE

5MG

N12249 002

&gt; DLT &gt;

10MG

N12249 001

&gt; DLT &gt;

25MG

N12249 003

INJECTABLE; INJECTION  
LIBRIUM

+ ICN

100MG/AMP  
100MG/AMP

N12301 001

ROCHE

N12301 001

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

<u>AT</u>	LEMON	<u>0.12%</u>
		N74522 001

<u>AT</u>	TEVA	<u>0.12%</u>
		N74522 001

DEC 15, 1995  
N74522 001  
DEC 15, 1995

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NESACAIN-E-MPF

<u>AP</u>	*	ASPIRA	<u>2%</u>
<u>AP</u>	+		<u>2%</u>
<u>AP</u>	*		<u>3%</u>
<u>AP</u>	+		<u>3%</u>
	@		<u>2%</u>
	@		<u>3%</u>

N09435 003  
N09435 006  
MAY 02, 1996  
N09435 004  
N09435 007  
MAY 02, 1996  
N09435 003  
N09435 004

CHLORPHENIRAMINE MALEATE

TABLET; ORAL

CHLORPHENIRAMINE MALEATE

<u>AA</u>	KV PHARM	<u>4MG</u>
@		4MG
@	ZENITH GOLDLINE	4MG
@	ZENITH LABS	4MG
	KILOMIN	
<u>AA</u>	HARVEY	<u>4MG</u>
@		4MG

N87164 001  
N87164 001  
N80779 001  
N80779 001  
N83629 001  
N83629 001

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HCL

@	ZENITH GOLDLINE	10MG
@		25MG
@		50MG
@		100MG
@		200MG
<u>BP</u>	ZENITH LABS	10MG
<u>BP</u>		25MG
<u>BP</u>		50MG

N83549 001  
N83549 002  
N83549 003  
N83574 001  
N83575 001  
N83549 001  
N83549 002  
N83549 003

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HCL

<u>BP</u>	ZENITH LABS	<u>100MG</u>	<u>N83574 001</u>
		200MG	N83575 001

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@	ZENITH GOLDLINE	100MG	N88840 001
<u>AB</u>	ZENITH LABS	250MG	OCT 25, 1984
<u>AB</u>		100MG	N88840 001
<u>AB</u>		250MG	OCT 25, 1984
			N87353 001

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

@	ZENITH	50MG	N88651 001
<u>AB</u>	PUREPAC PHARM	25MG	MAY 30, 1985
<u>AB</u>		50MG	N88139 001
<u>AB</u>		25MG	JUL 16, 1986
			N88140 001
			JUL 16, 1986
			N88139 001
			JUL 16, 1986
			N88140 001
			AUG 11, 1983
			N88651 001
			MAY 30, 1985
			N88164 001
			JAN 09, 1984

<u>AB</u>	ZENITH GOLDLINE	25MG	N88164 001
<u>AB</u>	@	50MG	JAN 09, 1984
<u>AB</u>	@	25MG	N87555 001
<u>AB</u>	@	50MG	N87947 001
			FEB 27, 1984
			N88164 001
			JAN 09, 1984
			N87176 001
			N87555 001
			N87947 001
			FEB 27, 1984
			N88164 001
			JAN 09, 1984
			N87176 001
			N87547 001
			FEB 27, 1984
			N87547 001
			N87555 001

CHLORTHALIDONE

TABLET; ORAL  
THALITONE

BX HORUS THERAP 25MG

\* 15MG

BX MONARCH PHARMS 25MG

+ 15MG

@ 25MG

N88051 001

NOV 12, 1992

N19574 001

DEC 20, 1988

N19574 002

FEB 12, 1992

N19574 001

DEC 20, 1988

N88051 001

NOV 12, 1982

CHLORZOXAZONE

TABLET; ORAL  
CHLORZOXAZONE

AA LENNON 300MG

AA TEVA 500MG

AA \* JOHNSON RW 250MG

@ 250MG

N89859 001

MAY 04, 1988

N89859 001

MAY 04, 1988

N11300 003

N11300 003

CHOLESTYRAMINE

POWDER; ORAL  
CHOLESTYRAMINE

AB BAKER NORTON EQ 4GM RESIN/PACKET

N74771 001

JUL 09, 1997

AB EQ 4GM RESIN/SCOOPFUL

N74771 002

JUL 09, 1997

CICLOPIROX

GEL; TOPICAL  
LOPROX

+ HOECHST MARION RSSL 0.77%

N20519 001

JUL 21, 1997

CIMETIDIINE

TABLET; ORAL  
CIMETIDIINE

AB ENDO LABS

200MG

300MG

400MG

800MG

200MG

300MG

400MG

800MG

200MG

400MG

800MG

200MG

300MG

400MG

800MG

200MG

300MG

400MG

800MG

200MG

300MG

400MG

800MG

N74281 001

MAY 17, 1994

N74281 002

MAY 17, 1994

N74281 003

MAY 17, 1994

N74281 001

MAY 17, 1994

N74281 002

MAY 17, 1994

N74281 003

MAY 17, 1994

N74329 001

MAY 17, 1994

N74365 001

FEB 28, 1995

N74365 002

FEB 28, 1995

N74365 003

FEB 28, 1995

N74365 004

FEB 28, 1995

N74568 001

FEB 27, 1997

N74568 002

FEB 27, 1997

N74568 003

FEB 27, 1997

N74566 001

FEB 27, 1997

N74365 001

FEB 28, 1995

N74365 002

FEB 28, 1995

N74365 003

FEB 28, 1995

N74365 004

FEB 28, 1995

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HCL

<u>AP</u>	ABBOTT	<u>EQ 300MG BASE/2ML</u>	N74296 001 MAR 28, 1997
<u>AP</u>		<u>EQ 300MG BASE/2ML</u>	N74412 001 MAR 28, 1997
<u>AP</u>	ENDO LABS	<u>EQ 300MG BASE/2ML</u>	N74005 001 AUG 31, 1994
<u>AP</u>	ENDO PHARMS	<u>EQ 300MG BASE/2ML</u>	N74005 001 AUG 31, 1994
<u>AP</u>	GENSIA	<u>EQ 300MG BASE/2ML</u>	N74252 001 NOV 26, 1997
<u>AP</u>	SANOFI	<u>EQ 300MG BASE/2ML</u>	N74296 001 MAR 28, 1997
<u>AP</u>		<u>EQ 300MG BASE/2ML</u>	N74412 001 MAR 28, 1997

SOLUTION; ORAL

CIMETIDINE HCL

<u>AB</u>	ENDO LABS	<u>EQ 300MG BASE/5ML</u>	N74251 001 DEC 22, 1994
<u>AB</u>	ENDO PHARMS	<u>EQ 300MG BASE/5ML</u>	N74251 001 DEC 22, 1994
<u>AB</u>	HI TECH PHARMA	<u>EQ 300MG BASE/5ML</u>	N74664 001 OCT 28, 1997
<u>AB</u>	MORTON GROVE	<u>EQ 300MG BASE/5ML</u>	N74757 001 OCT 17, 1997
<u>AB</u>	PHARM ASSOC	<u>EQ 300MG BASE/5ML</u>	N74553 001 JAN 27, 1997
<u>AB</u>	ROXANE	<u>EQ 300MG BASE/5ML</u>	N74541 001 AUG 05, 1997

CIPROFLOXACIN

POWDER FOR RECONSTITUTION; ORAL

## CIPRO

BAYER	250MG/5ML	N20780 001 SEP 26, 1997
+	500MG/5ML	N20780 002 SEP 26, 1997

CISAPRIDE MONOHYDRATETABLET; ORAL  
PROPULSID QUICKSOLV  
+ JANSSEN

EQ 20MG BASE

N20767 001  
NOV 07, 1997CLEMASTINE FUMARATESYRUP; ORAL  
CLEMASTINE FUMARATE

<u>AA</u>	LEMON	<u>EQ 0.5MG BASE/5ML</u>	N73399 001 JUN 30, 1994
> ADD >	<u>AA</u>	<u>SIILARX</u>	<u>EQ 0.5MG BASE/5ML</u> N74884 001 DEC 17, 1997
> ADD >	<u>AA</u>	<u>TEVA</u>	<u>EQ 0.5MG BASE/5ML</u> N73399 001 JUN 30, 1994

TABLET; ORAL  
CLEMASTINE FUMARATE

<u>AB</u>	LEMON	<u>2.68MG</u>	N73283 001 JAN 31, 1992
@		1.34MG	N73282 001 JAN 31, 1992
<u>AB</u>	TEVA	<u>2.68MG</u>	N73283 001 JAN 31, 1992
@		1.34MG	N73282 001 JAN 31, 1992

CLINDAMYCIN PHOSPHATEINJECTABLE; INJECTION  
CLINDAMYCIN PHOSPHATE

<u>AB</u>	QUAD PHARMS	<u>EQ 150MG BASE/ML</u>	N62795 001 DEC 21, 1987
@		EQ 150MG BASE/ML	N62795 001 DEC 21, 1987

SOLUTION; TOPICAL  
CLINDAMYCIN PHOSPHATE

<u>AT</u>	FOUGERA	<u>EQ 1% BASE</u>	N64159 001 JUN 05, 1997
<u>AT</u>	LEMON	<u>EQ 1% BASE</u>	N62930 001 JUN 28, 1989
<u>AT</u>	MORTON GROVE	<u>EQ 1% BASE</u>	N63304 001 JUL 15, 1997

<u>CLINDAMYCIN PHOSPHATE</u>		<u>CLOMIPRAMINE HYDROCHLORIDE</u>	
SOLUTION; TOPICAL <u>CLINDAMYCIN PHOSPHATE</u>		CAPSULE; ORAL <u>CLOMIPRAMINE HCL</u>	
AT TEVA	<u>EQ 1% BASE</u>	N62930 001 JUN 28, 1989	AB NOVOPHARM <u>25MG</u>
			AB <u>50MG</u>
			AB <u>75MG</u>
<u>CLOBETASOL PROPIONATE</u>			
CREAM; TOPICAL <u>CORMAX</u>		> ADD > AB TEVA <u>25MG</u>	
AB HEALTHPOINT	<u>0.05%</u>	N74220 001 MAY 16, 1997	> ADD > AB <u>50MG</u>
			> ADD > AB <u>75MG</u>
GEL; TOPICAL <u>CLOBETASOL PROPIONATE</u>			
AB STIEFEL	<u>0.05%</u>	N75027 001 OCT 31, 1997	
			<u>CLONAZEPAM</u>
AB + TEMOVATE	<u>0.05%</u>	N20337 001 APR 29, 1994	TABLET; ORAL <u>CLONAZEPAM</u>
			AB ALPHAPHARM <u>0.5MG</u>
<u>CLOCORTOLONE PIVALATE</u>			AB <u>1MG</u>
CREAM; TOPICAL <u>CLODERM</u>			AB <u>2MG</u>
* CTR LABS	<u>0.1%</u>	N17765 001	AB <u>0.5MG</u>
+ EM IND'S	<u>0.1%</u>	N17765 001	AB <u>1MG</u>
			AB <u>2MG</u>
<u>CLOMIPRAMINE HYDROCHLORIDE</u>			AB <u>0.5MG</u>
CAPSULE; ORAL <u>CLOMIPRAMINE HCL</u>			AB <u>1MG</u>
AB INVAMED	<u>25MG</u>	N74953 001 JUN 25, 1997	AB <u>2MG</u>
	<u>50MG</u>	N74953 002 JUN 25, 1997	AB <u>0.5MG</u>
	<u>75MG</u>	N74953 003 JUN 25, 1997	> ADD > AB WATSON LABS <u>0.5MG</u>
> DLT > AB LEMMON	<u>25MG</u>	N74958 001 AUG 26, 1997	> ADD > AB <u>1MG</u>
> DLT > AB	<u>50MG</u>	N74958 002 AUG 26, 1997	> ADD > AB <u>2MG</u>
> DLT > AB	<u>75MG</u>	N74958 003 AUG 26, 1997	> ADD > KLOONOPIN + ROCHE <u>0.125MG</u>
			N17533 005 APR 09, 1997

CLONAZEPAM

TABLET; ORAL  
 KLONOPI<sup>N</sup>  
 ROCHE 0.25MG  
 > ADD > KLONOPI<sup>N</sup> RAPIDLY DISINTEGRATING  
 > ADD > + ROCHE 0.125MG  
 > ADD >  
 > ADD > + 2MG

CLOPIDOGREL BISULFATE

TABLET; ORAL  
 PLAVIX  
 + SANOFI EQ 75MG BASE

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL  
CLORAZEPATE DIPOTASSIUM  
 AB ~~PUREPAC PHARM~~ 7.5MG  
 AB 15MG  
 @ 7.5MG  
 @ 15MG  
 TABLET; ORAL  
CLORAZEPATE DIPOTASSIUM  
 AB ~~PUREPAC PHARM~~ 3.75MG  
 AB 7.5MG  
 AB 15MG

N17533 006  
 APR 09, 1997  
 N20813 001  
 DEC 23, 1997  
 N20813 002  
 DEC 23, 1997  
 N20813 003  
 DEC 23, 1997  
 N20813 004  
 DEC 23, 1997  
 N20813 005  
 DEC 23, 1997

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL  
CLORAZEPATE DIPOTASSIUM  
 @ ~~PUREPAC PHARM~~ 3.75MG  
 @ 7.5MG  
 @ 15MG

N72330 001  
 AUG 08, 1988  
 N72331 001  
 AUG 08, 1988  
 N72332 001  
 AUG 08, 1988

CLOZAPINE

TABLET; ORAL  
CLOZAPINE  
 AB ZENITH GOLDLINE 25MG  
 AB 100MG

N74949 001  
 NOV 26, 1997  
 N74949 002  
 NOV 26, 1997

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL  
PROMETHAZINE W/ CODEINE  
 AA HALSEY 10MG/5ML; 6.25MG/5ML  
 @ 10MG/5ML; 6.25MG/5ML  
 AA PROMETHAZINE HCL AND CODEINE PHOSPHATE  
 HI TECH PHARMA 10MG/5ML; 6.25MG/5ML

N88739 001  
 DEC 23, 1988  
 N88739 001  
 DEC 23, 1988  
 N40151 001  
 AUG 26, 1997

CORTICOTROPIN

INJECTABLE; INJECTION  
ACTHAR  
 AB + RHONE POULENC RORER 40 UNITS/VIAL  
 AB 25 UNITS/VIAL  
 @ 25 UNITS/VIAL  
 @ 40 UNITS/VIAL  
 AB CORTICOTROPIN  
 STERILE 40 UNITS/VIAL  
 + 40 UNITS/VIAL

N07504 003  
 N07504 002  
 N07504 002  
 N07504 003  
 N88772 001  
 NOV 21, 1988  
 N88772 001  
 NOV 21, 1988

CORTISONE ACETATE

TABLET; ORAL  
CORTISONE ACETATE  
BP ~~PUREPAC PHARM~~ 25MG  
@ 25MG  
@ ZENITH GOLDLINE 25MG  
@ ~~ZENITH LABS~~ 25MG  
@ 25MG

N80493 001  
N80493 001  
N80630 001  
N83536 001  
N80630 001  
N83536 001

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION  
INTAL

\* Fisons 0.8MG/INH

N18887 001

DEC 05, 1985  
N18887 001  
DEC 05, 1985

CAPSULE; INHALATION

INTAL  
\* Fisons 20MG  
+ RHONE POULENC RORER 20MG

N16990 001  
N16990 001

SOLUTION; INHALATION

INTAL  
AN \* Fisons 10MG/ML  
AN + RHONE POULENC RORER 10MG/ML

N18596 001  
MAY 28, 1982  
N18596 001  
MAY 28, 1982

SOLUTION/DROPS; OPHTHALMIC  
OPTICROM

@ Fisons 4%

N18155 001  
OCT 03, 1984  
N18155 001  
OCT 03, 1984

SPRAY, METERED; NASAL

NASALCROM  
\* Fisons 5.2MG/SPRAY

N18306 001  
MAR 18, 1983

CYANOCOBALAMIN

INJECTABLE; INJECTION

COSAVIT

AP STERIS

0.1MG/ML

1MG/ML

N83013 001

N83084 001

N83013 001

N83084 001

CYANOCOBALAMIN

AP SOLOPAK

1MG/ML

N87551 001

FEB 29, 1984

@

1MG/ML

N87551 001

FEB 29, 1984

> DLT > AP

1MG/ML

N83120 001

> ADD >

0.1MG/ML

N83120 001

> ADD >

0.1MG/ML

N83120 001

N83120 001

AP STERIS

0.1MG/ML

@

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58

N/A; N/A

DICOPAC KIT

MEDI PHYSICS

NYCOMED AMERSHAM

N/A; N/A; N/A

N/A; N/A; N/A

N17406 001

N17406 001

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPENTOLATE

AT AKORN

1%

N85555 001

N85555 001

@

AKPENTOLATE

AT AKORN

1%

N40164 001

JAN 13, 1997

AT

2%

N40165 001

JAN 13, 1997

AT

CYCLOGYL

AT + ALCON

2%

N84108 001

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

AP ASTA

100MG/VIAL

N88371 001

JUL 03, 1986

AP

200MG/VIAL

N88372 001

JUL 03, 1986

CYCLOPHOSPHAMIDEINJECTABLE; INJECTION  
CYCLOPHOSPHAMIDE

<u>AP</u>	ASTA	<u>500MG/VIAL</u>	N88373 001
<u>AP</u>		<u>1GM/VIAL</u>	JUL 03, 1986
<u>AP</u>	ELKINS SINN	<u>100MG/VIAL</u>	N88374 001
<u>AP</u>		<u>200MG/VIAL</u>	SEP 24, 1986
<u>AP</u>		<u>500MG/VIAL</u>	N88371 001
<u>AP</u>		<u>1GM/VIAL</u>	JUL 03, 1986
<u>AP</u>		<u>2GM/VIAL</u>	N88372 001
<u>AP</u>		<u>5GM/VIAL</u>	JUL 03, 1986
<u>AP</u>		<u>10GM/VIAL</u>	N88373 001
<u>CYTOXAN</u>			JUL 03, 1986
<u>AP</u>	* BRISTOL MYERS SQUIBB	<u>100MG/VIAL</u>	N12142 001
<u>AP</u>	*	<u>200MG/VIAL</u>	N12142 002
<u>AP</u>	*	<u>500MG/VIAL</u>	N12142 003
<u>AP</u>	*	<u>1GM/VIAL</u>	N12142 004
<u>AP</u>	*	<u>2GM/VIAL</u>	AUG 30, 1982
@		<u>100MG/VIAL</u>	N12142 001
@		<u>200MG/VIAL</u>	N12142 002
@		<u>500MG/VIAL</u>	N12142 003
@		<u>1GM/VIAL</u>	N12142 004
@		<u>2GM/VIAL</u>	AUG 30, 1982

CYPROHEPTADINE HYDROCHLORIDETABLET; ORAL  
CYPROHEPTADINE HCL

<u>AB</u>	HARVEY	<u>4MG</u>	N89057 001
@		<u>4MG</u>	JUL 03, 1986
			N89057 001
			JUL 03, 1986

DAUNORUBICIN HYDROCHLORIDEINJECTABLE; INJECTION  
CERUBIDINE

<u>AP</u>	RHONE POULENC RORER	<u>EQ 20MG BASE/VIAL</u>	N61876 001
@		<u>EQ 20MG BASE/VIAL</u>	N61876 001

DAUNORUBICIN HYDROCHLORIDEINJECTABLE; INJECTION  
CERUBIDINE

<u>AP</u>	* WYETH AYERST	<u>EQ 20MG BASE/VIAL</u>	N50484 001
@		<u>EQ 20MG BASE/VIAL</u>	N50484 001
<u>AP</u>	DAUNORUBICIN HCL	<u>EQ 20MG BASE/VIAL</u>	N64103 001
			FEB 03, 1995
<u>AP</u>	BEDROPS	<u>EQ 20MG BASE/VIAL</u>	N64103 001
			FEB 03, 1995
	+	<u>EQ 20MG BASE/VIAL</u>	

DELAVIRDINE MESYLATE

TABLET; ORAL  
RESCRIPTOR  
+ PHARMACIA AND UPJOHN 100MG

N20705 001  
APR 04, 1997

DESERPIDINE

TABLET; ORAL  
HARMONY  
\* ABBOTT

0.25MG  
0.25MG

N10796 002  
N10796 002

DESIPIRAMINE HYDROCHLORIDE

TABLET; ORAL  
DESIPIRAMINE HCL  
SIDMAK LABS NJ

N71803 001  
MAY 29, 1997  
N71804 001  
MAY 29, 1997

AB 150MG

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION  
DDAVP  
RHONE POULENC RORER 0.004MG/ML

N18938 001  
MAR 30, 1984

AP DESMOPRESSIN ACETATE  
GENSIA 0.004MG/ML

N74888 001  
OCT 15, 1997

## RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'97 - DEC'97

29

DESMOPRESSIN ACETATESPRAY, METERED; NASAL  
DDAVP

\* PHONE POUJOLIN RORER 0.01MG/SPRAY  
@ 0.01MG/SPRAY  
+ 0.01MG/SPRAY

N17922 002  
FEB 06, 1989  
N17922 002  
FEB 06, 1989  
N17922 003  
AUG 07, 1996

DEXAMETHASONEELIXIR; ORAL  
DEXAMETHASONE

\* ALPHARMS 0.5MG/5ML  
@ 0.5MG/5ML

N88997 001  
OCT 10, 1986  
N88997 001  
OCT 10, 1986

GEL; TOPICAL  
DECADERM

\* MERCK SHARP DOHME 0.1%  
@ 0.1%

N13538 001  
N13538 001

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

\* DECAZERIN  
BAUSCH AND LOMB 0.1%; EQ 3.5MG BASE/GM;  
10,000 UNITS/GM N64063 001  
JUL 25, 1994

\* NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE  
BAUSCH AND LOMB 0.1%; EQ 3.5MG BASE/GM;  
10,000 UNITS/GM N64063 001  
JUL 25, 1994

DEXAMETHASONE SODIUM PHOSPHATECREAM; TOPICAL  
DECADRON

\* MERCK SHARP DOHME EQ 0.1% PHOSPHATE  
@ EQ 0.1% PHOSPHATE

N11983 002  
N11983 002

INJECTABLE; INJECTION  
DEXAMETHASONE SODIUM PHOSPHATE

\* STERIS EQ 4MG PHOSPHATE/ML N84355 001

DEXAMETHASONE SODIUM PHOSPHATEINJECTABLE; INJECTION  
DEXAMETHASONE SODIUM PHOSPHATE  
@ STERIS EQ 4MG PHOSPHATE/ML

N84355 001

DEXTROAMPHETAMINE SULFATETABLET; ORAL  
DEXTROAMPHETAMINE SULFATE  
REXOR 5MG  
+ 10MG

N84051 001

\* DEXTROSTAT  
SHIRE RICHWOOD 5MG  
+ 10MG

N84051 002

N84051 001

N84051 002

DEXTROSE; POTASSIUM CHLORIDEINJECTABLE; INJECTION  
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC  
CONTAINER

MCGAW 5GM/100ML; 37MG/100ML N19699 001  
SEP 29, 1989

@ 5GM/100ML; 37MG/100ML N19699 001  
SEP 29, 1989

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC  
CONTAINER

MCGAW 5GM/100ML; 75MG/100ML N19699 002  
SEP 29, 1989

@ 5GM/100ML; 75MG/100ML N19699 002  
SEP 29, 1989

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC  
CONTAINER

MCGAW 5GM/100ML; 110MG/100ML N19699 003  
SEP 29, 1989

@ 5GM/100ML; 110MG/100ML N19699 003  
SEP 29, 1989

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC  
CONTAINER

MCGAW 5GM/100ML; 220MG/100ML N19699 005  
SEP 29, 1989

N19699 005

N19699 005

N19699 005

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE

0.033%

AP MCGAW 5GM/100ML; 75MG/100ML;  
200MG/100ML N18268 009@ 5GM/100ML; 75MG/100ML;  
200MG/100ML N18268 009DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE

0.15% IN PLASTIC CONTAINER

AP MCGAW 5GM/100ML; 150MG/100ML;  
200MG/100ML N18268 004@ 5GM/100ML; 150MG/100ML;  
200MG/100ML N18268 004DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE

0.15% IN PLASTIC CONTAINER

AP MCGAW 5GM/100ML; 220MG/100ML;  
200MG/100ML N18268 005@ 5GM/100ML; 220MG/100ML;  
200MG/100ML N18268 005DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE

0.15% IN PLASTIC CONTAINER

AP MCGAW 5GM/100ML; 300MG/100ML;  
200MG/100ML N18268 006@ 5GM/100ML; 300MG/100ML;  
200MG/100ML N18268 006DEXTROSE 5%, SODIUM CHLORIDE 0.3% AND POTASSIUM CHLORIDE

0.075% IN PLASTIC CONTAINER

AP MCGAW 5GM/100ML; 75MG/100ML;  
330MG/100ML N18268 011@ 5GM/100ML; 75MG/100ML;  
330MG/100ML N18268 011DEXTROSE 5%, SODIUM CHLORIDE 0.3% AND POTASSIUM CHLORIDE

0.15% IN PLASTIC CONTAINER

AP MCGAW 5GM/100ML; 150MG/100ML;  
330MG/100ML N18268 012@ 5GM/100ML; 150MG/100ML;  
330MG/100ML N18268 012DEXTROSE 5%, SODIUM CHLORIDE 0.3% AND POTASSIUM CHLORIDE

0.15% IN PLASTIC CONTAINER

AP MCGAW 5GM/100ML; 220MG/100ML;  
330MG/100ML N18268 013@ 5GM/100ML; 220MG/100ML;  
330MG/100ML N18268 013DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE

0.125% IN PLASTIC CONTAINER

AP MCGAW 5GM/100ML; 220MG/100ML;  
330MG/100ML N18268 013

JAN 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE

0.130% IN PLASTIC CONTAINER

AP MCGAW 5GM/100ML; 300MG/100ML;  
330MG/100ML N18268 014

JAN 18, 1986

@ 5GM/100ML; 300MG/100ML;  
330MG/100ML N18268 014

JAN 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE

0.075%

AP MCGAW 5GM/100ML; 75MG/100ML;  
450MG/100ML N18268 010

JAN 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE

0.15% IN PLASTIC CONTAINER

AP MCGAW 5GM/100ML; 150MG/100ML;  
450MG/100ML N18268 001

JAN 18, 1986

@ 5GM/100ML; 150MG/100ML;  
450MG/100ML N18268 001

JAN 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE

0.225% IN PLASTIC CONTAINER

AP MCGAW 5GM/100ML; 220MG/100ML;  
450MG/100ML N18268 002

JAN 18, 1986

@ 5GM/100ML; 220MG/100ML;  
450MG/100ML N18268 002

JAN 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE

0.3% IN PLASTIC CONTAINER

AP MCGAW 5GM/100ML; 300MG/100ML;  
450MG/100ML N18268 003

JAN 18, 1986

@ 5GM/100ML; 300MG/100ML;  
450MG/100ML N18268 003

JAN 18, 1986

DEXTROSE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP MCGAW 10GM/100ML; 900MG/100ML N18047 001

JAN 18, 1986

@ 10GM/100ML; 900MG/100ML N18047 001

JAN 18, 1986

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP MCGAW 5GM/100ML; 900MG/100ML N18046 001

JAN 18, 1986

## RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'97 - DEC'97

31

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER  
© MCGAW 5GM/100ML, 900MG/100ML N18026 001DEXTROTHYROXINE SODIUM

TABLET; ORAL

CHOLEXIN  
KNOLL PHARM

*	1MG	N12302 005
@	2MG	N12302 002
*	4MG	N12302 004
@	1MG	N12302 005
@	2MG	N12302 002
@	4MG	N12302 004

DIAZEPAMGEL; RECTAL  
DIASTAT  
+ ATHENA

	2.5MG/0.5ML	N20648 001
	5MG/ML	JUL 29, 1997
	10MG/2ML	N20648 002
	15MG/3ML	JUL 29, 1997
+	20MG/4ML	N20648 003
		JUL 29, 1997
		N20648 004
		JUL 29, 1997
		N20648 005
		JUL 29, 1997

INJECTABLE; INJECTION

DIAZEPAM

AP ABBOTT 5MG/ML

AP STERIS 5MG/ML

@ 5MG/ML

AP STERLING WINTHROP 5MG/ML

TABLET; ORAL

DIAZEPAM

AB HALESEY 2MG

DIAZEPAM

TABLET; ORAL

DIAZEPAM

AB	HALESEY	5MG	N70996 001
AB		10MG	AUG 15, 1986
@		2MG	N70987 001
@		5MG	N70996 001
@		10MG	AUG 15, 1986
AB	ZENITH GOLDLINE	10MG	N70956 001
@		2MG	AUG 15, 1986
@		5MG	N70362 001
@		10MG	SEP 04, 1985
AB	ZENITH LABS	2MG	N70360 001
@		5MG	SEP 04, 1985
@		10MG	N70361 001
AB		2MG	SEP 04, 1985
@		5MG	N70360 001
@		10MG	SEP 04, 1985
AB		2MG	N70361 001
@		5MG	SEP 04, 1985

DICLOFENAC SODIUMTABLET, DELAYED RELEASE; ORAL  
DICLOFENAC SODIUM

AB	COPLEY PHARM	25MG	N74459 001
AB		50MG	JUN 25, 1997
AB		75MG	N74459 002
			JUN 25, 1997
			N74459 003
			JUN 25, 1997

DICLOFENAC SODIUM; MISOPROSTOLTABLET, DELAYED RELEASE; ORAL  
ARTHROTEC

+ SEARLE 50MG; 0.2MG

&gt; ADD &gt; + 75MG; 0.2MG

&gt; ADD &gt; +

&gt; ADD &gt; +

&gt; ADD &gt; +

&gt; ADD &gt; +

N20607 001

DEC 24, 1997

N20607 002

DEC 24, 1997

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL  
DICYCLOMINE HCL  
AB WEST WARD 10MG N40204 001  
FEB 28, 1997

SYRUP; ORAL  
BENTYL  
AB \* HOECHST MARION RSSL 10MG/5ML N07961 002  
OCT 15, 1984  
+ 10MG/5ML N07961 002  
OCT 15, 1984

DICYCLOMINE HCL  
ALPHARMA 10MG/5ML N84479 001  
@ 10MG/5ML N84479 001

DIETHYLDIENESTROL  
TABLET; ORAL  
DIETHYLDIENESTROL  
HIMLY 1MG N04041 004  
\* 5MG N04041 005  
@ 1MG N04041 004  
@ 5MG N04041 005

STILBESTROL  
TABLICAPS 0.5MG N83004 001  
@ 0.5MG N83004 001

STILBESTROL TAB  
SMITH MILLER PATCH 25MG N06194 001 >ADD > SPRAY, METERED; NASAL  
>ADD > MIGRANAL  
>ADD > + NOVARTIS 0.5MG/INH  
>ADD >

DIFLUNISAL  
TABLET; ORAL  
DIFLUNISAL  
AB DANBURY PHARMA 250MG N74400 001  
JUL 17, 1997  
AB 500MG N74400 002  
JUL 17, 1997

DIGOXIN  
INJECTABLE; INJECTION  
DIGOXIN  
AP ABBOTT 0.25MG/ML N40093 001  
MAY 16, 1996

DIGOXIN

INJECTABLE; INJECTION  
DIGOXIN  
AP SANOFI WINTHROP 0.25MG/ML N40093 001  
MAY 16, 1996

DIGOXIN PEDIATRIC  
AP ABBOTT 0.1MG/ML N40092 001  
APR 25, 1996  
AP SANOFI WINTHROP 0.1MG/ML N40092 001  
APR 25, 1996

TABLET; ORAL  
LANOXIN  
@ GLAXO WELLCOME 0.0625MG  
0.125MG  
@ 0.1875MG  
+ 0.25MG  
@ 0.375MG  
@ 0.5MG

DIHYDROERGOTAMINE MESYLATE  
N06194 001 >ADD > SPRAY, METERED; NASAL  
>ADD > MIGRANAL  
>ADD > + NOVARTIS 0.5MG/INH  
>ADD >

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
CARDIZEM SR  
AB \* HOECHST MARION RSSL 60MG N19471 001  
JAN 23, 1989  
AB + 60MG N19471 001  
JAN 23, 1989  
AB \* 90MG N19471 002  
JAN 23, 1989  
AB + 90MG N19471 002  
JAN 23, 1989

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
CARDIZEM SR

AB \* HOECHST MARION RSSL 120MG

N19471 003

JAN 23, 1989

AB1 + 120MG

N19471 003

JAN 23, 1989

DILACOR XR

AB2 + WATSON LABS 120MG

N20092 001

MAY 29, 1992

AB2 + 180MG

N20092 002

MAY 29, 1992

AB2 + 240MG

N20092 003

MAY 29, 1992

DILTIAZEM HCL

AB2 ANDRX 120MG

N74852 001

OCT 10, 1997

AB2 180MG

N74852 002

OCT 10, 1997

AB2 240MG

N74852 003

OCT 10, 1997

AB MYLAN 60MG

N74910 003

MAY 02, 1997

AB1 60MG

N74910 001

MAY 02, 1997

AB 90MG

N74910 002

MAY 02, 1997

AB1 90MG

N74910 002

MAY 02, 1997

AB 120MG

N74910 003

MAY 02, 1997

AB1 PROGRAPHARM 120MG

N74079 001

NOV 30, 1993

AB 60MG

N74079 002

NOV 30, 1993

AB 120MG

N74079 003

NOV 30, 1993

AB1 TEVA 60MG

N74079 001

NOV 30, 1993

AB1 90MG

N74079 002

NOV 30, 1993

AB1 120MG

N74079 003

NOV 30, 1993

INJECTABLE; INJECTION  
CARDIZEM

AP + HOECHST MARION RSSL 100MG/VIAL

N20792 001

SEP 05, 1997

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

DILTIAZEM HCL

AP GENSIA 5MG/ML

N74894 001

AUG 26, 1997

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

AP ELKINS SINK 50MG/ML

N84767 001

N84767 001

DIMERCAROL

INJECTABLE; INJECTION

BAL

+ AKORN 10%

N05939 001

@ BECTON DICKINSON 10%

N05939 001

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HCL

AA EON 25MG

N80845 002

AA 50MG

N80845 001

@ ZENITH GOLDLINE 25MG

N80845 002

@ 50MG

N80762 001

ZENITH LABS 25MG

N80762 002

AA 50MG

N80762 002

ELIXIR; ORAL

DIPHENHYDRAMINE HCL

> DLT > AA BUNDE 12.5MG/5ML

N83674 001

> ADD > AA @ 12.5MG/5ML

N83674 001

INJECTABLE; INJECTION

BENADRYL

AP \* PARKE DAVIS 10MG/ML

N06146 001

AP \* 50MG/ML

N09486 001

@ 10MG/ML

N06146 001

AP BENADRYL PRESERVATIVE FREE 50MG/ML

N09486 001

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HCL

<u>AB</u>	FUJISAWA	50MG/ML	N80586 002
<u>AP</u>	INT'L MEDICATION	50MG/ML	N84094 001
<u>AP</u>	STERIS	10MG/ML	N80873 001
<u>AP</u>		10MG/ML	N83533 004
+ @		10MG/ML	N80873 001
		10MG/ML	N83533 001
	<u>DIPHENHYDRAMINE HCL PRESERVATIVE FREE</u>		
<u>AP</u>	FUJISAWA	50MG/ML	N80586 002
<u>AP</u>	INT'L MEDICATION	50MG/ML	N84094 001
<u>AP</u>	STERIS	50MG/ML	N80873 003

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

> <u>ADD</u> >	<u>AP</u>	ABBOTT	5MG/ML	N74601 001
> <u>ADD</u> >	<u>AP</u>	GENSIA	5MG/ML	DEC 19, 1997

TABLET; ORAL

DIPYRIDAMOLE

<u>AB</u>	CHELSEA LABS	50MG	N87160 001
			JUN 07, 1996

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

DYNABAC

@ 111111

250MG

+ 250MG

N50678 001  
JUN 19, 1995  
N50678 001  
JUN 19, 1995> DLT > AB PURSPAC PHARM> DLT > AB> DLT > AB</u

## RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'97 - DEC'97

35

DOXYCYCLINE HYCLATE

## CAPSULE; ORAL

DOXYCYCLINE HYCLATE

> DLT > AB ~~ROCHE~~ PHARM EQ 50MG BASE  
> DLT > AB ~~ROCHE~~ EQ 100MG BASE  
> DLT > AB @ EQ 50MG BASE  
> ADD > @ N62479 001 DEC 23, 1983  
> ADD > @ EQ 100MG BASE N62479 002 DEC 23, 1983  
> ADD > @ EQ 50MG BASE N62479 001 DEC 23, 1983  
> ADD > @ EQ 100MG BASE N62479 002 DEC 23, 1983

CAPSULE, COATED PELLETS; ORAL  
DORYX

AB ~~PARKER DAVIS~~ EQ 100MG BASE N62653 001 OCT 30, 1985  
AB WARNER CHILCOTT EQ 100MG BASE N62653 001 OCT 30, 1985

DROPERIDOLINJECTABLE; INJECTION  
DROPERIDOL

AP ABBOTT 2.5MG/ML N72272 001 AUG 31, 1995  
AB SANOFI NINTHROP 2.5MG/ML N72272 001 AUG 31, 1995

ECONAZOLE NITRATECREAM; TOPICAL  
SPECTAZOLE  
+ J AND J 1%

\* JOHNSON & JOHNSON 1% N18751 001 DEC 23, 1982

EDROPHONIUM CHLORIDEINJECTABLE; INJECTION  
TENSILON

> ADD > AP + ICN 10MG/ML N07959 001  
> DLT > AB \* ROCHE 10MG/ML N07959 001  
> ADD > AP + ICN 10MG/ML N07959 002

EDROPHONIUM CHLORIDE

## INJECTABLE; INJECTION

TENSILON PRESERVATIVE FREE

> DLT > AB \* ROCHE 10MG/ML N07959 002  
> ADD > EMEDASTINE DIFUMARATE  
> ADD > SOLUTION/DROPS; OPHTHALMIC  
> ADD > EMADINE  
> ADD > + ALCON 0.05%  
> ADD >

N20706 001

DEC 29, 1997

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

## INJECTABLE; INJECTION

ALPHACETYL HCl w/ EPINEPHRINE

AP CARBISITE 0.01MG/ML; 2% N84720 001  
AP @ 0.01MG/ML; 2% N84732 001  
AP @ 0.02MG/ML; 2% N84720 001  
N84732 001

EPROSARTAN MESYLATE

> ADD > TABLET; ORAL  
> ADD > TEVETEN  
> ADD > SMITHKLINE BEECHAM EQ 300MG BASE  
> ADD > + EQ 400MG BASE  
> ADD >

N20738 004

DEC 22, 1997

N20738 005

DEC 22, 1997

ERGOLOID MESYLATES

TABLET; SUBLINGUAL  
HYDROGENATED ERGOT ALKALOIDS  
@ ZENITH GOLDLINE 0.5MG  
@ ZENITH LABS 0.5MG

N87186 001

N87186 001

ERYTHROMYCIN

GEL; TOPICAL  
ERYTHROMYCIN

AT ALTANA 2% N64184 001

SEP 30, 1997

ERYTHROMYCINSOLUTION; TOPICAL  
ERYTHROMYCIN

<u>AT</u>	ALTANA	<u>2%</u>
<u>AT</u>	STIEFEL	<u>2%</u>

ERYTHROMYCIN ESTOLATECAPSULE; ORAL  
ERYTHROMYCIN ESTOLATE

@ ZENITH GOLDLINE	EQ 250MG BASE
<u>AB</u> ZENITH LABS	<u>EQ 250MG BASE</u>

ESTAZOLAMTABLET; ORAL  
ESTAZOLAM

<u>AB</u>	ROYCE LABS	<u>1MG</u>
<u>AB</u>		<u>2MG</u>

<u>AB</u>	TEVA	<u>1MG</u>
<u>AB</u>		<u>2MG</u>

<u>AB</u>	ZENITH GOLDLINE	<u>1MG</u>
<u>AB</u>		<u>2MG</u>

<u>AB</u>	PROSOM	<u>1MG</u>
<u>AB</u>	ABBOTT	<u>1MG</u>

<u>AB</u>	+	<u>2MG</u>
-----------	---	------------

ESTRADIOLTABLET; ORAL  
ESTRADIOL

<u>AB</u>	BARR	<u>0.5MG</u>
<u>AB</u>		<u>1MG</u>

ESTRADIOLTABLET; ORAL  
ESTRADIOL

<u>AB</u>	BARR	<u>2MG</u>	<u>N40197 003</u>
> ADD >	<u>AB</u>	<u>0.5MG</u>	OCT 22, 1997
> ADD >	<u>AB</u>	<u>1MG</u>	<u>N40212 001</u>
> ADD >	<u>AB</u>	<u>2MG</u>	DEC 29, 1997
> ADD >	<u>AB</u>	<u>1.5MG</u>	<u>N40212 002</u>
> ADD >			DEC 29, 1997
> ADD >			<u>N40212 004</u>
> ADD >			DEC 29, 1997
> ADD >			<u>N40212 003</u>
> ADD >			DEC 29, 1997

ESTROGENS, ESTERIFIEDTABLET; ORAL  
ESTRATAB

> DLT >	<u>RS</u>	<u>SCIVAX</u>	<u>1.25MG</u>	<u>N83856 001</u>
> ADD >		@ MENEST	1.25MG	<u>N83856 001</u>
> DLT >	<u>BS</u>	SMITHKLINE BECHAM	<u>1.25MG</u>	<u>N84950 001</u>
> ADD >			1.25MG	<u>N84950 001</u>

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

ALESSE	+ WYETH AYERST	0.02MG; 0.1MG	<u>N20683 001</u>
JUL 10, 1997			MAR 27, 1997
N74818 002			
AUG 19, 1997			
N74818 001			
JUL 10, 1997			
N74921 001			
JUL 10, 1997			
N74921 002			
AUG 19, 1997			
N74826 001			
JUL 03, 1997			
N74826 002			
JUL 03, 1997			
PROSOM			
ABBOTT			
+			
> ADD >	<u>AB</u>	<u>TRIPHASICL-21</u>	<u>0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG,</u>
> ADD >		+ WYETH AYERST	<u>0.125MG</u>
> ADD >			<u>N19192 001</u>
> ADD >			NOV 01, 1984
> ADD >	<u>AB</u>	<u>TRIVORA-21</u>	<u>0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG,</u>
> ADD >		SEARLE	<u>0.125MG</u>
> ADD >			<u>N74538 001</u>
> ADD >			DEC 18, 1997

TABLET; ORAL-28

ALESSE	+ WYETH AYERST	0.02MG; 0.1MG	<u>N20683 002</u>
WYETH AYERST			MAR 27, 1997
N40197 001			
OCT 22, 1997			
N40197 002			
OCT 22, 1997			
> ADD >	<u>AB</u>	<u>TRIPHASICL-28</u>	<u>0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG,</u>
> ADD >		WYETH AYERST	<u>0.125MG</u>
> ADD >			<u>N19190 001</u>
> ADD >			NOV 01, 1984

## RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'97 - DEC'97

37

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

TRIVORA-28

> ADD > AB SEARLE 0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG,  
 > ADD > AB N74538 002  
 > ADD > AB 0.125MG  
 > ADD > AB DEC 18, 1997

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

GENCEPT 0.5/35-21

> ADD > AB BARR 0.035MG; 0.5MG N72692 001  
 > ADD > AB GENCON 0.035MG; 0.5MG N72692 001  
 > DLT > AB FEB 28, 1992

GENCEPT 1/35-21

> ADD > AB BARR 0.035MG; 1MG N72693 001  
 > ADD > AB GENCON 0.035MG; 1MG N72693 001  
 > DLT > AB FEB 28, 1992

GENCEPT 10/11-21

> ADD > AB BARR 0.035MG, 0.035MG; 0.5MG, 1MG N72694 001  
 > ADD > AB GENCON 0.035MG, 0.035MG; 0.5MG, 1MG N72694 001  
 > DLT > AB FEB 28, 1992

TABLET; ORAL-28

GENCEPT 0.5/35-28

> ADD > AB BARR 0.035MG; 0.5MG N72695 001  
 > ADD > AB GENCON 0.035MG; 0.5MG N72695 001  
 > DLT > AB FEB 28, 1992

GENCEPT 1/35-28

> ADD > AB BARR 0.035MG; 1MG N72696 001  
 > ADD > AB GENCON 0.035MG; 1MG N72696 001  
 > DLT > AB FEB 28, 1992

GENCEPT 10/11-28

> ADD > AB BARR 0.035MG, 0.035MG; 0.5MG, 1MG N72697 001  
 > ADD > AB GENCON 0.035MG, 0.035MG; 0.5MG, 1MG N72697 001  
 > DLT > AB FEB 28, 1992

ETODOLAC

CAPSULE; ORAL

ETODOLAC

> ADD > AB ENDO PHARMS 200MG N74842 001  
 > ADD > AB 300MG JUL 17, 1997

> ADD > AB GENEVA PHARMS 200MG N74840 002  
 > ADD > AB 300MG JUL 17, 1997

> ADD > AB INVAMED 200MG N74840 001  
 > ADD > AB 300MG AUG 29, 1997

> ADD > AB MYLAN 200MG N74942 001  
 > ADD > AB 300MG SEP 30, 1997

> ADD > AB WATSON LABS 200MG N74942 002  
 > ADD > AB 300MG SEP 30, 1997

> ADD > AB ZENITH GOLDLINE 200MG N74844 001  
 > ADD > AB 300MG MAY 16, 1997

> ADD > AB ZENITH GOLDLINE 200MG N74844 002  
 > ADD > AB 300MG DEC 23, 1997

> ADD > AB ZENITH GOLDLINE 200MG N74899 001  
 > ADD > AB 300MG DEC 23, 1997

> ADD > AB ZENITH GOLDLINE 200MG N74899 002  
 > ADD > AB 300MG JUL 08, 1997

> ADD > AB WYETH AYERST 200MG N18922 002  
 > ADD > AB 300MG JAN 31, 1991

> ADD > AB + 300MG N18922 003  
 > ADD > AB JAN 31, 1991

> ADD > AB AESGEN 400MG N74927 001  
 > ADD > AB 400MG OCT 30, 1997

> ADD > AB ENDO PHARMS 400MG N74841 001  
 > ADD > AB 400MG JUN 27, 1997

> ADD > AB EON 400MG N74903 001  
 > ADD > AB 400MG APR 11, 1997

> ADD > AB GENEVA PHARMS 400MG N74839 001  
 > ADD > AB 400MG JUL 11, 1997

> ADD > AB INVAMED 400MG N74846 001  
 > ADD > AB 400MG FEB 28, 1997

> ADD > AB PUREPAC PHARM 400MG N74819 001  
 > ADD > AB FEB 28, 1997

ETODOLAC

TABLET; ORAL

ETODOLAC

<u>AB</u>	ROYCE LABS	<u>400MG</u>	N74892 001 APR 16, 1997
<u>AB</u>	TEVA	<u>400MG</u>	N75009 001 NOV 26, 1997
<u>AB</u>	ZENITH GOLDLINE	<u>400MG</u>	N74883 001 FEB 28, 1997
<u>AB</u>	<u>LODINE</u> WYETH AYERST	<u>400MG</u>	N18922 004 JUL 29, 1993

ETOPOSIDE

INJECTABLE; INJECTION

ETOPOSIDE

> DLT >	<u>AB</u>	<u>GENSTA</u>	<u>20MG/ML</u>	N74510 001 JUN 29, 1995
> DLT >		@	20MG/ML	N74510 001 JUN 29, 1995
> ADD >				N74513 001 MAR 14, 1996
> ADD >	<u>AB</u>	<u>IMMUNEX</u>	<u>20MG/ML</u>	N74513 001 MAR 14, 1996
	<u>AB</u>	PIERRE FABRE	<u>20MG/ML</u>	N74813 001 JUL 09, 1997
	<u>AB</u>	SUPERGEN	<u>20MG/ML</u>	N74513 001 MAR 14, 1996

FAMOTIDINE

INJECTABLE; INJECTION

## PEPCID IN PLASTIC CONTAINER

+ MERCK 0.4MG/ML

			N20249 001 FEB 18, 1994
		PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER + MERCK 0.4MG/ML	N20249 001 FEB 18, 1994

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

## CORLOPAM

+ NEUREX

EQ 10MG BASE/ML

N19922 001  
SEP 23, 1997FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

<u>AP</u>	ABBOTT	<u>EQ 0.05MG BASE/ML</u>	N72786 001 SEP 24, 1991
<u>AP</u>	STERLING WINTHROP	<u>EQ 0.05MG BASE/ML</u>	N72786 001 SEP 24, 1991

> ADD > FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

> ADD > TABLET, EXTENDED RELEASE; ORAL

> ADD > ALLEGRA-D

> ADD > + HOECHST MARION RSSL 60MG;120MG

> ADD >

N20786 001  
DEC 24, 1997FINASTERIDE

TABLET; ORAL

## PROPECIA

+ MERCK 1MG

N20788 001  
DEC 19, 1997FLECAINIDE ACETATETABLET; ORAL  
TAMBOCOR

@ 30	50MG	N18830 004 AUG 23, 1988
@	100MG	N18830 001 OCT 31, 1985
@	150MG	N18830 003 JUN 03, 1988
	50MG	N18830 004 AUG 23, 1988
	100MG	N18830 001 OCT 31, 1985
	150MG	N18830 003 JUN 03, 1988

FLUCONAZOLE

INJECTABLE; INJECTION

## DIFLUCON

+ PRIZER 200MG/100ML

N19950 001  
JAN 29, 1990

FLUCONAZOLE

INJECTABLE; INJECTION  
 DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER  
 + PFIZER 200MG/100ML N19950 003 SEP 29, 1992  
 @ 2MG/ML N19950 005 JUL 08, 1994

DIFLUCAN IN SODIUM CHLORIDE 0.9%  
 + PFIZER 200MG/100ML N19950 001 JAN 29, 1990

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER  
 + PFIZER 200MG/100ML N19950 002 JAN 29, 1990  
 @ 2MG/ML N19950 004 JUL 08, 1994

FLUCYTOSINE

CAPSULE; ORAL  
 ANCOCOBON  
 ICN 250MG N17001 001  
 + SYNTEX 500MG N17001 002  
 \* 250MG N17001 003  
 \* 500MG N17001 004

FLUNISOLIDE

SPRAY, METERED; NASAL  
 NASALIDE  
 BX + DURA 0.025MG/SPRAY N18148 001  
 BX # SYNTEX 0.025MG/SPRAY N18148 002  
 NASAREL  
 BX + DURA 0.025MG/SPRAY N20409 001 MAR 08, 1995  
 BX # SYNTEX 0.025MG/SPRAY N20409 002 MAR 08, 1995

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL  
 FLUOCET  
 @ ALPHARMA 0.025% N88360 001 JAN 16, 1984  
 AT NYC 0.025% N88360 001 JAN 16, 1984

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL  
FLUOCINOLONE ACETONIDE  
 @ ALPHARMA 0.01% N88361 001 JAN 16, 1984  
 AT NYC 0.01% N88361 001 JAN 16, 1984

SYNALAR  
 AT + MEDICIS 0.01% N12787 004  
 AT + 0.025% N12787 002  
 AT + 0.025% N12787 005  
 AT # SYNTEX 0.01% N12787 004  
 AT # 0.025% N12787 002  
 AT # 0.025% N12787 005  
 SYNALAR-HP  
 + MEDICIS 0.2% N16161 002  
 \* SYNTEX 0.2% N16161 002

OINTMENT; TOPICAL

SYNALAR  
 AT + MEDICIS 0.025% N13960 001  
 AT # SYNTEX 0.025% N13960 001

SOLUTION; TOPICAL

SYNALAR  
 AT + MEDICIS 0.01% N15296 001  
 AT # SYNTEX 0.01% N15296 001

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL  
 NEO-SYNALAR  
 + MEDICIS 0.025%; EQ 3.5MG BASE/GM  
 # SYNTEX 0.025%; EQ 3.5MG BASE/GM N60700 001

FLUOCINONIDE

CREAM; TOPICAL  
LIDEX  
 AB + MEDICIS 0.05% N16908 002  
 AB # SYNTEX 0.05% N16908 002  
 LIDEX-E  
 AB MEDICIS 0.05% N16908 003  
 AB SYNTEX 0.05% N16908 003

FLUOCINONIDE

GEL; TOPICAL

FLUOCINONIDEAB TARO 0.05%

N74935 001

JUL 29, 1997

LIDEXAB + MEDICIS 0.05%  
AB \* SYNTEX 0.05%N17373 001  
N17373 001

OINTMENT; TOPICAL

FLUOCINONIDEAB ALTANA 0.05%

N74905 001

AUG 26, 1997

LIDEXAB + MEDICIS 0.05%  
AB \* SYNTEX 0.05%N16909 002  
N16909 002

SOLUTION; TOPICAL

LIDEXAT + MEDICIS 0.05%  
AT \* SYNTEX 0.05%N18849 001  
N18849 001

APR 06, 1984

N18849 001

APR 06, 1984

FLUOROURACILCREAM; TOPICAL  
EFUDEX> ADD > + ICN 5%  
> DLT > \* ROCHE 5%N16831 003  
N16831 003SOLUTION; TOPICAL  
EFUDEX> ADD > + ICN 2%  
> ADD > + 5%  
> DLT > \* ROCHE 2%  
> DLT > \* 5%N16831 001  
N16831 002  
N16831 003  
N16831 002FLURANDRENOLIDECREAM; TOPICAL  
CORDRAN SPAB \* LILLY 0.025%  
AB + OCLASSEN 0.025%  
AB + OCLASSEN 0.05%N12806 003  
N12806 002  
N12806 003  
N12806 002FLURANDRENOLIDE

LOTION; TOPICAL

CORDRANAT \* LILLY 0.05%  
AT + OCLASSEN 0.05%N13790 001  
N13790 001

OINTMENT; TOPICAL

CORDRANAB \* LILLY 0.025%  
AB + OCLASSEN 0.025%  
AB + OCLASSEN 0.05%N12806 004  
N12806 001  
N12806 004  
N12806 001

TAPE; TOPICAL

CORDRANAB \* LILLY 0.004MG/SQ CM  
AB + OCLASSEN 0.004MG/SQ CMN16455 001  
N16455 001FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HCLAB \* HANSON 15MGN71808 001  
JAN 07, 1988AB \* 30MGN71809 001  
JAN 07, 1988

@

15MG

@

30MG

@

N71808 001

@

JAN 07, 1988

@

N71809 001

@

JAN 07, 1988

AB \* HANSON 15MGN71808 001  
JAN 07, 1988AB \* 30MGN71809 001  
JAN 07, 1988AB \* SIDMAK LABS NJ 50MGN74647 001  
APR 01, 1997AB \* 100MGN74647 002  
APR 01, 1997AB \* WARNER CHILCOTT 100MGN74560 002  
MAY 16, 1997FLURBIPROFEN

TABLET; ORAL

FLURBIPROFENAB \* SIDMAK LABS NJ 50MGN74647 001  
APR 01, 1997AB \* 100MGN74647 002  
APR 01, 1997AB \* WARNER CHILCOTT 100MGN74560 002  
MAY 16, 1997

FLUTICASONE PROPIONATE

POWDER; INHALATION  
FLOVENT  
+ GLAXO WELLCOME 0.044MG/INH  
+ 0.088MG/INH  
+ 0.22MG/INH

N20549 001  
NOV 07, 1997  
N20549 002  
NOV 07, 1997  
N20549 003  
NOV 07, 1997

FOLIC ACID

TABLET; ORAL  
FOLIC ACID  
AA DANBURY PHARMA 1MG  
AA + 1MG  
AA \* FOLIVITE 1MG  
AA @ Lederle 1MG

N80680 001  
N80680 001  
N05897 004  
N05897 004

FOLLITROPIN ALFA/BETA

INJECTABLE; INJECTION  
FOLLISTIM  
BX ORGANON 75 IU/VIAL  
BX 150 IU/VIAL  
BX GONAL-F SERONO 75 IU/VIAL  
BX 150 IU/VIAL

N20582 001  
SEP 29, 1997  
N20582 002  
SEP 29, 1997  
N20378 001  
SEP 29, 1997  
N20378 002  
SEP 29, 1997  
> DLT >  
> DLT >  
> ADD >  
> ADD >  
> ADD >  
> ADD >

> ADD > FOMEPIZOLE

> ADD > INJECTABLE; INJECTION  
> ADD > ANTIZOL  
> ADD > + ORPHAN MEDCL 1GM/ML  
> ADD >

N20696 001  
DEC 04, 1997

FUROSEMIDE

INJECTABLE; INJECTION  
FUROSEMIDE

AP	ABBOTT	10MG/ML	N70578 001
AP		10MG/ML	JUL 08, 1987
AP		10MG/ML	N72080 001
AP	SANOFI WINTHROP	10MG/ML	AUG 13, 1991
AP	STERLING WINTHROP	10MG/ML	N74337 001
AP		10MG/ML	OCT 31, 1994
AP		10MG/ML	N74337 002
AP		10MG/ML	OCT 31, 1994
AP		10MG/ML	N70578 001
AP		10MG/ML	JUL 08, 1987
AP		10MG/ML	N72080 001
AP		10MG/ML	AUG 13, 1991

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION  
NEOSCAN

BS	MEDI PHYSICS	2mCi/ML	N17655 001
BS	NYCOMED AMERSHAM	2mCi/ML	N17655 001

GANCICLOVIR

CAPSULE; ORAL  
CYTOVENE

*	SYNTEX	250MG	N20460 001
> DLT >		250MG	DEC 24, 1994
> ADD >		250MG	N20460 001
> ADD >		500MG	DEC 22, 1994
> ADD >		500MG	N20460 002
> ADD >	+		DEC 12, 1997

GENTAMICIN SULFATE

CREAM; TOPICAL  
GENTAMICIN SULFATE  
@ ALPHARMA

AT	MMC	EQ 0.1% BASE	N62471 001
		EQ 0.1% BASE	SEP 27, 1983
		EQ 0.1% BASE	N62471 001
		EQ 0.1% BASE	SEP 27, 1983

OINTMENT; TOPICAL  
GENTAMICIN SULFATE  
@ ALPHARMA

		EQ 0.1% BASE	N62496 001
		EQ 0.1% BASE	MAR 14, 1984

GENTAMICIN SULFATE

OINTMENT; TOPICAL  
GENTAMICIN SULFATE

AT NMC EQ 0.1% BASE

N62495 003

MAR 14, 1994

GLIPIZIDE

TABLET; ORAL  
GLIPIZIDE

AB DURAMED 5MG

N74550 001

SEP 11, 1997

AB ENDO LABS 10MG

N74550 002

SEP 11, 1997

AB ENDO LABS 5MG

N74378 001

NOV 28, 1994

AB ENDO LABS 10MG

N74378 002

NOV 28, 1994

AB ENDO PHARMS 5MG

N74378 001

NOV 28, 1994

AB ENDO PHARMS 10MG

N74378 002

NOV 28, 1994

AB SIDMAK LABS NJ 5MG

N74619 001

APR 04, 1997

AB SIDMAK LABS NJ 10MG

N74619 002

APR 04, 1997

GLUTETHIMIDE

TABLET; ORAL  
GLUTETHIMIDE

AB HAESEY 500MG

N89459 001

OCT 10, 1986

@ 500MG

N89459 001

OCT 10, 1986

GLYBURIDE

TABLET; ORAL  
GLYBURIDE (MICRONIZED)

> ADD > AB MOVA 1.5MG

N74591 001

DEC 22, 1997

> ADD > AB 3MG

N74591 002

DEC 22, 1997

GLYBURIDE

TABLET; ORAL

GLYBURIDE (MICRONIZED)

> ADD > AB MOVA 6MG

4.5MG

N74591 004

DEC 22, 1997

N74591 003

DEC 22, 1997

> ADD > AB + PHARMACIA AND UPJOHN 6MG

N20051 004

SEP 24, 1993

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL

RAXAR

+ GLAXO WELLCOME EQ 200MG BASE

N20695 001

NOV 06, 1997

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

GRIFULVIN V

+ J AND J

125MG/5ML

125MG/5ML

N50448 001

N62483 001

JAN 26, 1984

JOHNSON & WILSON

25MG/5ML

25MG/5ML

N50448 001

N62483 001

JAN 26, 1984

TABLET; ORAL

GRIFULVIN V

J AND J

250MG

250MG

N60618 002

N62279 002

AB

500MG

N60618 003

AB

500MG

N62279 003

AB

125MG

N60618 001

AB

125MG

N62279 001

AB

250MG

N60618 002

AB

250MG

N62279 002

AB

500MG

N60618 003

AB

500MG

N62279 003

AB

125MG

N60618 001

AB

125MG

N62279 001

GUANFACINE HYDROCHLORIDE

TABLET; ORAL  
GUANFACINE HCL  
AB AMIDE PHARM

<u>EQ 1MG BASE</u>	N74673 001
	FEB 28, 1997
<u>EQ 2MG BASE</u>	N74673 002
	FEB 28, 1997
<u>EQ 1MG BASE</u>	N74796 001
AB MYLAN	JAN 27, 1997
<u>EQ 2MG BASE</u>	N74796 002
	JAN 27, 1997
<u>EQ 1MG BASE</u>	N74762 001
AB ROYCE LABS	JUN 25, 1997
<u>EQ 2MG BASE</u>	N74762 002
	JUN 25, 1997

HALCINONIDE

CREAM; TOPICAL  
HALOG  
WESTWOOD SQUIBB  
@ 0.025%

N17818 001  
N17818 001

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION  
HALDOL  
> ADD > AO + JOHNSON RW EQ 50MG BASE/ML  
> ADD > AO + EQ 100MG BASE/ML  
> ADD > AO + HALOPERIDOL DECANOATE  
> ADD > AO FUJISAWA EQ 50MG BASE/ML  
> ADD > AO EQ 100MG BASE/ML

N18701 001  
JAN 14, 1986  
N18701 002  
JAN 31, 1997  
N74893 001  
DEC 19, 1997  
N74893 002  
DEC 19, 1997

HALOPERIDOL LACTATE

INJECTABLE; INJECTION  
HALOPERIDOL  
> DLT > AP SONOPAK EQ 5MG BASE/ML  
> DLT > @ EQ 5MG BASE/ML

N70800 001  
DEC 14, 1987  
N70800 001  
DEC 14, 1987

HEPARIN SODIUMINJECTABLE; INJECTION  
HEP FLUSH KIT IN PLASTIC CONTAINER

AB FUJISAWA	10 UNITS/ML	N17029 017 DEC 05, 1985
AB	100 UNITS/ML	N17029 018 DEC 05, 1985
@	10 UNITS/ML	N17029 017 DEC 05, 1985
@	100 UNITS/ML	N17029 018 DEC 05, 1985
AP ABBOTT	HEPARIN LOCK FLUSH 10 UNITS/ML	N40082 001 FEB 28, 1995
AP	10 UNITS/ML	N88097 001 APR 28, 1983
AP	10 UNITS/ML	N88346 001 MAY 18, 1983
AP	100 UNITS/ML	N40082 002 FEB 28, 1995
AP	100 UNITS/ML	N88098 001 APR 28, 1983
AP	100 UNITS/ML	N88347 001 MAY 18, 1983
AP SANOFI WINTHROP	10 UNITS/ML	N40082 001 FEB 28, 1995
AP	100 UNITS/ML	N40082 002 FEB 28, 1995
AP	10 UNITS/ML	N87903 001 APR 20, 1983
AP	10 UNITS/ML	N88097 001 APR 28, 1983
AP	10 UNITS/ML	N88346 001 MAY 18, 1983
AP	100 UNITS/ML	N88098 001 APR 28, 1983
AP	100 UNITS/ML	N88347 001 MAY 18, 1983
AP ABBOTT	HEPARIN SODIUM 2,500 UNITS/ML	N88099 001 APR 28, 1983
AP	5,000 UNITS/ML	N88100 001 APR 28, 1983
AP	10,000 UNITS/ML	N40095 001 JUL 26, 1996
AP FUJISAWA	20,000 UNITS/ML	N17029 004



HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

## CAPSULE; ORAL

HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 100/50  
 @ ZENITH GOLDLINE 100MG;50MG N88358 001  
 APR 10, 1984  
 N88358 003  
 APR 10, 1984

HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 25/25  
 @ ZENITH GOLDLINE 25MG;25MG N88356 001  
 APR 10, 1984  
 N88356 003  
 APR 10, 1984

HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 50/50  
 @ ZENITH GOLDLINE 50MG;50MG N88357 001  
 APR 10, 1984  
 N88357 003  
 APR 10, 1984

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

## TABLET; ORAL

HYDRALAZINE HCL; HYDROCHLOROTHIAZIDE AND RESERPINE  
 BP @ ZENITH GOLDLINE 25MG;15MG;0.1MG N84291 001  
 BP @ ZENITH LABS 25MG;15MG;0.1MG N84291 003  
 HYDROSERPINE PLUS (R-H-H)  
 BP @ ZENITH GOLDLINE 25MG;15MG;0.1MG N83877 001  
 BP @ ZENITH LABS 25MG;15MG;0.1MG N83877 003  
 UNIPRES  
 BP SOLVAY 25MG;15MG;0.1MG N86298 001  
 @ 25MG;15MG;0.1MG N86298 003

HYDROCHLOROTHIAZIDE

## TABLET; ORAL

HYDROCHLOROTHIAZIDE  
 @ ZENITH GOLDLINE 50MG N84658 001  
 @ ZENITH LABS 60MG N84658 003

HYDROCHLOROTHIAZIDE; IRBESARTAN

## TABLET; ORAL

IRBESARTAN-HYDROCHLOROTHIAZIDE  
 @ SANOFI 12.5MG;75MG N20758 001  
 SEP 30, 1997

HYDROCHLOROTHIAZIDE; IRBESARTAN

## TABLET; ORAL

IRBESARTAN-HYDROCHLOROTHIAZIDE  
 + SANOFI 12.5MG;150MG

N20758 002  
 SEP 30, 1997

HYDROCHLOROTHIAZIDE; METHYLDOPA

## TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE  
 AB PUREPAC PHARM 15MG;250MG

N70853 001  
 OCT 08, 1986

AB 25MG;250MG

N70688 001  
 APR 24, 1986

AB 30MG;500MG

N70854 001  
 OCT 08, 1986

@ 15MG;250MG

N70853 001  
 OCT 08, 1986

@ 25MG;250MG

N70688 001  
 APR 24, 1986

@ 30MG;500MG

N70854 001  
 OCT 08, 1986

@ 15MG;250MG

OCT 08, 1986

@ 25MG;250MG

N71458 001  
 MAR 08, 1988

@ 30MG;500MG

N71459 001  
 MAR 08, 1988

@ 30MG;500MG

N71460 001  
 MAR 08, 1988

@ 50MG;500MG

N71461 001  
 MAR 08, 1988

@ 15MG;250MG

N71458 001  
 MAR 08, 1988

@ 25MG;250MG

N71459 001  
 MAR 08, 1988

@ 30MG;500MG

N71460 001  
 MAR 08, 1988

@ 30MG;500MG

N71461 001  
 MAR 08, 1988

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

## TABLET; ORAL

UNIRETIC  
 SCHWARZ PHARMA 12.5MG;7.5MG

N20729 001  
 JUN 27, 1997

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL  
UNIRETIC  
+ SCHWARZ PHARMA 25MG;15MG N20729 002  
JUN 27, 1997

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL  
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE  
@ ZENITH GOLDLINE 25MG;40MG N71552 001  
DEC 01, 1988  
N71553 001  
DEC 01, 1988  
N71552 001  
DEC 01, 1988  
N71553 001  
DEC 01, 1988

AB ZENITH LABS 25MG;40MG  
AB 25MG;80MG

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL  
HYDROCHLOROTHIAZIDE W/ RESERPINE  
@ ZENITH GOLDLINE 25MG;0.1MG N83572 001  
25MG;0.125MG N83571 001  
50MG;0.1MG N83568 001  
50MG;0.125MG N83573 001  
25MG;0.125MG N83571 001  
50MG;0.125MG N83573 001  
25MG;0.1MG N83572 001  
50MG;0.1MG N83568 001

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL  
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE  
AB DUPONT PHARM 25MG;25MG N87999 001  
NOV 06, 1985  
@ 25MG;25MG N87999 001  
NOV 06, 1985  
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE  
@ ZENITH GOLDLINE 25MG;25MG N87004 002  
MAY 24, 1982  
AB ZENITH LABS 25MG;25MG N87004 002  
MAY 24, 1982

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL  
TRIAMTERENE AND HYDROCHLOROTHIAZIDE  
AB GENEVA PHARMS 25MG;37.5MG N74821 001  
JUN 05, 1997  
AB NOVARTIS 25MG;37.5MG N74857 001  
SEP 09, 1997

TABLET; ORAL  
TRIAMTERENE AND HYDROCHLOROTHIAZIDE  
B\* PAR PHARM 50MG;75MG N72337 001  
MAY 11, 1988

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL  
VICOPROFEN  
+ KNOLL PHARM 7.5MG;200MG N20716 001  
SEP 23, 1997

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL  
HYCOMINE  
DUPONT MERCK 5MG/5ML;25MG/5ML N19410 001  
AUG 17, 1990  
+ ENDO PHARMS 5MG/5ML;25MG/5ML N19410 001  
AUG 17, 1990  
HYCOMINE PEDIATRIC  
DUPONT MERCK 2.5MG/5ML;12.5MG/5ML N19411 001  
AUG 17, 1990  
ENDO PHARMS 2.5MG/5ML;12.5MG/5ML N19411 001  
AUG 17, 1990

HYDROCORTISON

CREAM; TOPICAL  
DERMACORT  
AT MONARCH PHARMS 1% N83011 002  
AT SOLVAY 1% N83011 002  
HYDROCORTISON  
@ ALPHARMA 2.5% N89754 001  
FEB 01, 1989  
N89754 001  
FEB 01, 1989

HYDROCORTISONE

CREAM; TOPICAL  
PROCTOCORT  
AT MONARCH PHARMS 1% N83011 001  
AT SOLVAY 1% N83011 001  
SYNACORT  
AT MEDICIS 1% N87458 001  
AT 2.5% N87457 001  
@ 0.5% N87459 001  
AT SYNEPEX 1% N87458 001  
AT 2.5% N87457 001  
@ 0.5% N87459 001

## TABLET; ORAL

HYDROCORTISONE  
BP PUREPAC PHARM 10MG N84247 003  
BP 20MG N84247 002  
@ 10MG N84247 003  
AUG 31, 1982  
AUG 31, 1982  
AUG 31, 1982  
AUG 31, 1982  
@ 20MG N84247 002

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC  
CORTISPORIN  
AT \* GLAXO WELLCOME 1%; EQ 3.5MG BASE/ML; N50479 001  
10,000 UNITS/ML  
AT + MONARCH PHARMS 1%; EQ 3.5MG BASE/ML; N50479 001  
10,000 UNITS/ML  
OTOCORT  
AT STERIS 1%; EQ 3.5MG BASE/ML; N60730 002  
10,000 UNITS/ML  
@ 1%; EQ 3.5MG BASE/ML; N60730 002  
10,000 UNITS/ML

## SUSPENSION/DROPS; OTIC

> DLT > AT \* GLAXO WELLCOME 1%; EQ 3.5MG BASE/ML; N60613 001  
10,000 UNITS/ML  
> DLT > @ 1%; EQ 3.5MG BASE/ML; N60613 001  
10,000 UNITS/ML  
> ADD >  
> ADD > AT \* GLAXO WELLCOME 1%; EQ 3.5MG BASE/ML; N62521 001  
10,000 UNITS/ML  
JUL 11, 1985

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC  
OTOCORT  
AT STERIS 1%; EQ 3.5MG BASE/ML; N62521 001  
10,000 UNITS/ML JUL 11, 1985  
AT PEDIOTIC GLAXO WELLCOME 1%; EQ 3.5MG BASE/ML; N62822 001  
10,000 UNITS/ML SEP 29, 1987  
AT MONARCH PHARMS 1%; EQ 3.5MG BASE/ML; N62822 001  
10,000 UNITS/ML SEP 29, 1987

HYDROCORTISONE; UREA

CREAM; TOPICAL  
ALPHADERM  
AT BIOGLAN 1%; 10% N86008 001  
@ VIVAN 1%; 10% N86008 001

HYDROCORTISONE ACETATE

CREAM; TOPICAL  
HEMSOL-HC  
AT TABLE 1% N81274 001  
+ 1% N81274 001  
JUN 19, 1992  
AT \* PUREPAC PHARM 1% N86052 001  
0.5% N86050 001  
@ 0.5% N86050 001  
@ 1% N86052 001

INJECTABLE; INJECTION  
HYDROCORTISONE ACETATE

BP AKORN 25MG/ML N09637 001  
50MG/ML N09637 002  
BP @ 25MG/ML N09637 001  
50MG/ML N09637 002  
BP STERIS 25MG/ML N83759 001  
50MG/ML N83759 002  
BP @ 25MG/ML N83759 001  
50MG/ML N83759 002  
BP \* MERCK SHARP DOHME 50MG/ML N08228 004

HYDROCORTISONE ACETATE

INJECTABLE; INJECTION  
HYDROCORTONE  
+ MERCK SHARP DOHME 50MG/ML N08228 004

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL  
CORTISPORIN  
\* GLAXO WELLCOME 0.5%; EQ 3.5MG BASE/GM;  
10,000 UNITS/GM N50218 001  
AUG 09, 1985  
+ MONARCH PHARMS 0.5%; EQ 3.5MG BASE/GM;  
10,000 UNITS/GM N50218 001  
AUG 09, 1985

HYDROCORTISONE BUTEPRATE

CREAM; TOPICAL  
PANDEL  
+ SAVAGE LABS 0.1% N20453 001  
FEB 28, 1997 > DLT >  
> ADD >

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL  
LOCOID LIPOCREAM  
YAMANOUCHI 0.1% N20769 001  
SEP 08, 1997

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION  
HYDROCORTISONE SODIUM SUCCINATE  
RP EKINS SINK EQ 1GM BASE/VIAL N87569 001  
@ EQ 1GM BASE/VIAL N87569 001

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL  
RESERPINE AND HYDROFLUMETHIAZIDE  
@ ZENITH GOLDLINE 50MG;0.125MG N88932 001  
JAN 11, 1985

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL  
RESERPINE AND HYDROFLUMETHIAZIDE  
BP ZENITH LABS 50MG;0.125MG N88932 001  
JAN 11, 1985

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION  
HYDROMORPHONE HCL  
AP ABBOTT 10MG/ML N74598 001  
JUN 19, 1997  
AP SANOFI 10MG/ML N74598 001  
JUN 19, 1997

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION  
HYDROXYZINE HCL  
AP ABBOTT 25MG/ML N87416 001  
AP 50MG/ML N87546 001  
AP SOLOPAK 50MG/ML N87596 001  
AP @ 50MG/ML N87596 001  
AP STERLING WINTHROP 25MG/ML N87416 001  
AP 50MG/ML N87546 001

TABLET; ORAL  
HYDROXYZINE HCL

AB HALSEY	25MG	N89117 001
@	25MG	MAY 03, 1988
AB XV PHARM	10MG	N89117 001
AB	25MG	MAY 02, 1988
AB	50MG	N87819 001
AB	50MG	JUN 23, 1982
AB	25MG	N87820 001
AB	50MG	JUN 23, 1982
AB	100MG	N87821 001
AB	100MG	JUN 23, 1982
AB	100MG	N87821 001
AB	100MG	JUN 23, 1982
AB	10MG	N87819 001
AB	25MG	JUN 23, 1982
AB	50MG	N87820 001
AB	50MG	JUN 23, 1982

HYDROXYZINE HYDROCHLORIDETABLET; ORAL  
HYDROXYZINE HCL

@ KV PHARM	100MG	N87822 001	> ADD >	<u>AB</u>	<u>IBU</u>	<u>BASF</u>	<u>600MG</u>	N70099 001
AB	PUREPAC PHARM	JUN 23, 1982	> ADD >	<u>AB</u>			<u>800MG</u>	MAR 29, 1985
AB		N88120 001	> ADD >	<u>AB</u>				N70745 001
AB		SEP 25, 1984	> ADD >	<u>AB</u>				JUL 23, 1986
AB		N88121 001	> ADD >	<u>AB</u>				N70088 001
AB		SEP 25, 1984	> ADD >	<u>AB</u>				FEB 08, 1985
AB		N88122 001	> DLT >	<u>AB</u>				N18197 001
AB		SEP 25, 1984	> DLT >	<u>AB</u>				N70093 001
AB		N88120 001	> DLT >	<u>AB</u>				FEB 22, 1985
AB		SEP 25, 1984	> DLT >	<u>AB</u>				N70088 003
AB		N88121 001	> DLT >	<u>AB</u>				FEB 08, 1985
AB		SEP 25, 1984	> DLT >	<u>AB</u>				N70099 001
AB		N88122 001	> DLT >	<u>AB</u>				MAR 29, 1985
AB		SEP 25, 1984	> DLT >	<u>AB</u>				N70745 001
AB	ZENITH GOLDLINE	10MG	N87216 001	> DLT >	<u>AB</u>			JUL 23, 1986
AB		25MG	N887410 001		<u>IBUPROFEN</u>			
AB		50MG	N87411 001		PUREPAC PHARM			N71123 001
AB	ZENITH LABS	10MG	N87216 001					SEP 19, 1986
AB		25MG	N87410 001					N71124 001
AB		50MG	N87411 001					SEP 19, 1986
AB		100MG						N71125 001

HYDROXYZINE PAMOATECAPSULE; ORAL  
HY-PAM

AB	EON	<u>EQ 25MG HCL</u>	N87479 001	@	300MG	N71123 001
AB	HYDROXYZINE PAMOATE			@	400MG	SEP 19, 1986
AB	EON	<u>EQ 25MG HCL</u>	N87479 001	@	600MG	N71124 001

IBUPROFENSUSPENSION; ORAL  
IBU

EX	KNOX PHARM	100MG/5ML	N19784 001	<u>AB</u>	<u>MOTRIN</u>	<u>MCNEIL</u>	<u>300MG</u>	N17463 003
			DEC 18, 1989	<u>AB</u>			<u>400MG</u>	N17463 002
			N19784 001	<u>AB</u>			<u>600MG</u>	N17463 004
@		100MG/5ML	DEC 18, 1989	<u>AB</u>			<u>800MG</u>	N17463 005

TABLET; ORAL  
IBU

> ADD >	<u>AB</u>	<u>BASF</u>	400MG	N18197 001	<u>AB</u>	<u>PHARMACIA AND UPJOHN</u>	<u>300MG</u>	N17463 003
> ADD >	<u>AB</u>		400MG	N70083 001	<u>AB</u>		<u>400MG</u>	N17463 002
> ADD >				FEB 22, 1985	<u>AB</u>		<u>600MG</u>	N17463 004

IBUPROFENTABLET; ORAL  
IBU

				<u>AB</u>	<u>RUFEN</u>	<u>@ BASF</u>	<u>600MG</u>	N18197 002
				> ADD >				MAR 05, 1984
				> ADD >				

IBUPROFENTABLET; ORAL  
RUFEN> DLT > @ KNOELL PHARM 400MG  
> DLT >> ADD >  
N18197 002  
MAR 05, 1994IDARUBICIN HYDROCHLORIDEINJECTABLE; INJECTION  
IDAMYCIN PFS  
+ PHARMACIA AND UPJOHN 1MG/MLN50734 001  
FEB 17, 1997IFOSFAMIDEINJECTABLE; INJECTION  
IFEX  
\* BRISTOL MYERS SQUIBB 1GM/VIAL  
\* 3GM/VIAL  
@ 1GM/VIAL  
@ 3GM/VIALN19763 001  
DEC 30, 1988  
N19763 002  
DEC 30, 1988  
N19763 001  
DEC 30, 1988  
N19763 002  
DEC 30, 1988IFOSFAMIDE; MESNAINJECTABLE; INJECTION  
IFEX/MESNEX KIT  
+ BRISTOL MYERS SQUIBB 1GM/VIAL;100MG/ML  
+ 3GM/VIAL;100MG/MLN19763 003  
OCT 10, 1992  
N19763 004  
OCT 10, 1992IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

> DLT > AB JANIMINE  
> DLT > AB ABBOTT 10MG  
> DLT > AB 25MG  
> DLT > AB  
> ADD > @  
> ADD > @N17895 001  
N17895 002  
N17895 003  
N17895 001  
N17895 002IMIPRAMINE HYDROCHLORIDETABLET; ORAL  
JANIMINE> ADD >  
@ ABBOTT 50MG

N17895 003

IMIQUIMODCREAM; TOPICAL  
ALDARA  
+ 3M

5%

N20723 001

FEB 27, 1997

INDAPAMIDETABLET; ORAL  
INDAPAMIDE  
AB MYLAN 1.25MG  
AB NOVOPHARM 1.25MG  
AB 2.5MGN74461 002  
MAR 26, 1997  
N74665 001  
APR 04, 1997  
N74665 002  
APR 04, 1997INDIUM IN-111 OXYQUINOLINEINJECTABLE; INJECTION  
INDIUM IN-111 OXYQUINOLINE  
MEIDI PHYSICS 1mCi/ML  
NYCOMED AMERSHAM 1mCi/MLN19044 001  
DEC 23, 1985  
N19044 001  
DEC 23, 1985INDIUM IN-111 PENTETATE DISODIUMINJECTABLE; INTRATHECAL  
MPI INDIUM DTPA IN 111  
MEIDI PHYSICS 1mCi/ML  
NYCOMED AMERSHAM 1mCi/MLN17707 001  
FEB 18, 1982  
N17707 001  
FEB 18, 1982

INDOCYANINE GREENINJECTABLE; INJECTION  
CARDIO-GREEN

+ AKORN	25MG/VIAL
+ BECTON DICKINSON	50MG/VIAL
	25MG/VIAL
	50MG/VIAL

IODIXANOLINJECTABLE; INJECTION  
VISIPAQUE 270

NYCOMED 55%

VISIPAQUE 320  
NYCOMED 65.2%IODOHIPPURATE SODIUM, I-131

INJECTABLE; INJECTION

HIPPURATE	
BRACCO	1-2mCi/VIAL
@	1-2mCi/VIAL
IODOHIPPURATE SODIUM I-131	
@ CIS	0.2mCi/ML
SORIN	0.2mCi/ML

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-200  
ABBOTT 41%

&gt; ADD &gt; AP

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-300

AP	ABBOTT	61%
> ADD >	AP	61%
> ADD >	AP	61%
	FUJISAWA	61%

N74638 001
APR 30, 1997
N74898 003
DEC 30, 1997
N74679 002
APR 02, 1997

IOPAMIDOL-300 IN PLASTIC CONTAINER

> ADD >	AP	ABBOTT	61%
> ADD >	AP		61%

N74636 003
DEC 30, 1997
N74637 001
APR 03, 1997

IOPAMIDOL-370

> ADD >	AP	ABBOTT	76%
> ADD >	AP	FUJISAWA	76%

N74898 004
DEC 30, 1997
N74679 003
APR 02, 1997

IOPAMIDOL-370 IN PLASTIC CONTAINER

> ADD >	AP	ABBOTT	76%
> ADD >	AP		76%

N74636 004
DEC 30, 1997

ISOVUE-250

AP	+ BRACCO	51%
AP	+	51%

N18735 007
JUL 06, 1992
N20327 002
OCT 12, 1994

IPODATE CALCIUMGRANULE, ORAL  
CRAGAFIN CALCIUM

BRACCO	1GM/PACKET
@	3GM/PACKET

N12968 001
N12968 001

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ATROVENT	
AN + BOEHRINGER INGELHEIM	0.02%

N20228 001
SEP 29, 1993

IPRATROPIUM BROMIDE	
AN DEY	0.02%

N74755 001
JAN 10, 1997

&gt; ADD &gt; AP

&gt; ADD &gt; AP

&gt; ADD &gt; AP

IRBESARTAN

TABLET; ORAL  
AVAPRO  
SANOFI

75MG	N20757 001
150MG	SEP 30, 1997
+	N20757 002
300MG	SEP 30, 1997
	N20757 003
	SEP 30, 1997

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION  
ISOETHARINE HCL

AN ~~NEOPHARMA~~ 1%  
@ ~~NEOPHARMA~~ 1%

N20757 001  
SEP 30, 1997  
N20757 002  
SEP 30, 1997  
N20757 003  
SEP 30, 1997

ISOFLUROPHATE

OINTMENT; OPHTHALMIC  
FLUOROPRYL  
MERCK SHARP & DOWME  
@

N87101 001  
N87101 001  
N10656 001  
N10656 001

ISONIAZID

SYRUP; ORAL  
ISONIAZID  
AA + CAROLINA MEDCL 50MG/5ML  
  
\* 50MG/5ML  
  
AA MIKART 50MG/5ML  
  
AA ~~LANTAZID~~ 50MG/5ML  
@ 50MG/5ML  
  
TABLET; ORAL  
ISONIAZID  
AA MIKART 100MG

N88235 001  
NOV 10, 1983  
N88235 001  
NOV 10, 1983  
N81118 001  
JUL 21, 1997  
N89243 001  
FEB 03, 1986  
N89243 001  
FEB 03, 1986  
N40090 001  
JUN 26, 1997

ISONIAZID

TABLET; ORAL  
ISONIAZID  
AA MIKART 300MG  
@ ZENITH GOLDLINE 100MG  
@ ZENITH LARS 300MG  
@ ZENITH LARS 100MG  
@ ZENITH LARS 300MG

N40090 002  
JUN 26, 1997  
N80270 001  
N83610 001  
N80270 001  
N83610 001

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION  
ISOPROTERENOL HCL

BN \* 3M 0.12MG/INH N10375 004  
+ NEOPHARMA 0.12MG/INH N10375 004  
BN ~~NEOPHARMA~~ 0.12MG/INH N85904 001  
@ NEOPHARMA 0.12MG/INH N85904 001

INJECTABLE; INJECTION

ISUPREL  
AP + ABBOTT 0.2MG/ML N10515 001  
AP + SANOFI WINTHROP 0.2MG/ML N10515 001

ITRACONAZOLE

SOLUTION; ORAL  
SPORANOX  
+ JANSSEN 10MG/ML

N20657 001  
FEB 21, 1997

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION  
KETAMINE HCL

AP ABBOTT EQ 50MG BASE/ML N74549 001  
AP EQ 100MG BASE/ML N74549 002  
AP SANOFI WINTHROP EQ 50MG BASE/ML N74549 001  
AP EQ 100MG BASE/ML N74549 002

JUN 27, 1996  
JUN 27, 1996  
JUN 27, 1996  
JUN 27, 1996

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL  
 > ADD > KETOPROFEN  
 > ADD > AB ELAN PHARM 200MG  
 > ADD > ORUVAIL  
 > ADD > AB + WYETH AYERST 200MG  
 > ADD >

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION  
KETOROLAC TROMETHAMINE  
 AP ABBOTT 15MG/ML  
 AP 15MG/ML  
 AP 30MG/ML  
 AP 30MG/ML  
 AP + TORADOL 15MG/ML  
 AP + SYNTEX 15MG/ML  
 AP + 30MG/ML

SOLUTION/DROPS; OPHTHALMIC  
 ACULAR PRESERVATIVE FREE  
 + SYNTEX 0.5%

## TABLET; ORAL

KETOROLAC TROMETHAMINE  
 AB CHELSEA LABS 10MG  
 AB MYLAN 10MG  
 AB ROXANE 10MG  
 AB TEVA 10MG  
 AB + TORADOL 10MG  
 AB + SYNTEX 10MG

N74879 001  
 DEC 10, 1997  
 N19816 001  
 SEP 24, 1993

KRYPTON, KR-81M

GAS; INHALATION  
 MPI KRYPTON 81M GAS GENERATOR  
 MEDIPHYSICS N/A  
 NYCOMED AMERSHAM N/A

N18088 001  
 N18088 001

LACTULOSE

> ADD >  
 > ADD > LACTULOSE  
 > ADD > INALCO 10GM/PACKET  
 > ADD >  
 > ADD > + 20GM/PACKET  
 > ADD >

N74712 001  
 DEC 10, 1997  
 N74712 002  
 DEC 10, 1997

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL  
 COMBIVIR  
 + GLAXO WELLCOME 150MG;300MG

N20857 001  
 SEP 26, 1997

LANSOPRAZOLE

CAPSULE, DELAYED REL GRANULES; ORAL  
 PREVACID  
 TAP HOLDINGS 15MG  
 + 30MG

N20406 001  
 MAY 10, 1995  
 N20406 002  
 MAY 10, 1995

CAPSULE, DELAYED REL PELLETS; ORAL  
 PREVACID  
 TAP HOLDINGS 15MG

N20406 001  
 MAY 10, 1995  
 N20406 002  
 MAY 10, 1995

LETROZOLE

TABLET; ORAL  
 FEMARA  
 + NOVARTIS 2.5MG

N20726 001  
 JUL 25, 1997

LEUCOVORIN CALCIUMINJECTABLE; INJECTION  
LEUCOVORIN CALCIUM

<u>AP</u>	+ ABBOTT	<u>EQ 10MG BASE/ML</u>	N40147 001
<u>AP</u>	+ BEDFORD	<u>EQ 200MG BASE/VIAL</u>	JUN 25, 1997
	*	<u>EQ 200MG BASE/VIAL</u>	N40056 001
			MAY 23, 1995
			N40056 001
			MAY 23, 1995
<u>AP</u>	GENSIA	<u>EQ 350MG BASE/VIAL</u>	N40174 001
<u>AP</u>	+ IMMUNEX	<u>EQ 350MG BASE/VIAL</u>	JUN 12, 1997
<u>AP</u>	PHARMACHEMIE	<u>EQ 50MG BASE/VIAL</u>	N08107 005
<u>AP</u>		<u>EQ 100MG BASE/VIAL</u>	APR 05, 1989

TABLET; ORAL  
LEUCOVORIN CALCIUM

<u>AB</u>	PAR PHARM	<u>EQ 5MG BASE</u>	N74544 001
<u>AB</u>		<u>EQ 25MG BASE</u>	AUG 28, 1997
<u>AB</u>		<u>EQ 5MG BASE</u>	N74544 002
<u>AB</u>	PHARMACHEMIE	<u>EQ 25MG BASE</u>	AUG 28, 1997

LEUPROLIDE ACETATEINJECTABLE; INJECTION  
LUPRON DEPOT-3  
+ TAP HOLDINGS11.25MG/VIAL  
N20708 001  
MAR 07, 1997LUPRON DEPOT-4  
+ TAP HOLDINGS30MG/VIAL  
N20517 002  
MAY 30, 1997LIDOCAINE HYDROCHLORIDEINJECTABLE; INJECTION  
LIDOCAINE HCL

<u>AP</u>	ABBOTT	<u>1%</u>	N40013 001
			JUN 23, 1995

LIDOCAINE HYDROCHLORIDEINJECTABLE; INJECTION  
LIDOCAINE HCL

<u>AP</u>	ABBOTT	<u>2%</u>	N40078 001
<u>AP</u>	SANOFI WINTHROP	<u>1%</u>	JUN 23, 1995
<u>AP</u>		<u>2%</u>	N40078 001

LIOTHYRONINE SODIUMTABLET; ORAL  
CYTOMEL

JONES MEDCL INDS	EQ 0.005MG BASE	N10379 001
	EQ 0.025MG BASE	N10379 002
	EQ 0.05MG BASE	N10379 003
+	SMITHKLINE BEECHAM	N10379 001
	EQ 0.005MG BASE	N10379 002
	EQ 0.025MG BASE	N10379 003
	EQ 0.05MG BASE	N10379 003

LITHIUM CARBONATETABLET, EXTENDED RELEASE; ORAL  
LITHOBID

SOLVAY	300MG	N18027 001
+	300MG	N18027 001

LORAZEPAMINJECTABLE; INJECTION  
LORAZEPAM

<u>AP</u>	ABBOTT	<u>2MG/ML</u>	N74243 001
<u>AP</u>		<u>2MG/ML</u>	APR 12, 1994
<u>AP</u>		<u>4MG/ML</u>	N74300 001
<u>AP</u>		<u>4MG/ML</u>	APR 12, 1994
<u>AP</u>		<u>4MG/ML</u>	N74243 002
<u>AP</u>		<u>4MG/ML</u>	APR 12, 1994
<u>AP</u>	STERLING WINTHROP	<u>2MG/ML</u>	N74300 003
<u>AP</u>		<u>2MG/ML</u>	MAR 19, 1997
			N74243 001
			APR 12, 1994
			N74300 001
			APR 12, 1994

LORAZEPAMINJECTABLE; INJECTION  
LORAZEPAM

AB STERLING WINTHROP 4MG/ML

N74243 002  
APR 12, 1994SOLUTION; ORAL  
LORAZEPAM  
+ ROXANE

0.5MG/5ML

N74648 001  
MAR 18, 1997LOXAPINE HYDROCHLORIDECONCENTRATE; ORAL  
LOXITANE C+ COCENSYS  
\* LEDERLEEQ 25MG BASE/ML  
EQ 25MG BASE/MLN17658 001  
N17658 001INJECTABLE; INJECTION  
LOXITANE IM+ COCENSYS  
\* LEDERLEEQ 50MG BASE/ML  
EQ 50MG BASE/MLN18039 001  
N18039 001LOXAPINE SUCCINATECAPSULE; ORAL  
LOXITANEAB COCENSYS  
AB EQ 5MG BASE  
AB EQ 10MG BASE  
AB + EQ 25MG BASE  
AB EQ 50MG BASE  
AB \* LEDERLE  
AB EQ 5MG BASE  
AB EQ 10MG BASE  
AB EQ 25MG BASE  
AB EQ 50MG BASEN17525 001  
N17525 002  
N17525 003  
N17525 004  
N17525 001  
N17525 002  
N17525 003  
N17525 004LYPRESSIN> DLT > SOLUTION; NASAL  
> DLT > DIAPID  
> DLT > \* NOVARTIS 0.185MG/ML  
> ADD > @ 0.185MG/MLMAGNESIUM SULFATEINJECTABLE; INJECTION  
MAGNESIUM SULFATE

FUJISAWA 500MG/ML

N19316 001  
SEP 08, 1986+ 500MG/ML N19316 001  
SEP 08, 1986MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER  
ABEOTT 1GM/100ML N20488 001  
JUL 11, 1995+ 1GM/100ML N20488 001  
JUL 11, 1995MAGNESIUM SULFATE IN PLASTIC CONTAINER  
ABEOTT 4GM/100ML N20309 001

JUN 24, 1994

+ 80MG/ML N20309 002  
JUN 24, 1994+ 4GM/100ML N20309 001  
JUN 24, 1994+ 80MG/ML N20309 002  
JUN 24, 1994MALATHIONLOTION; TOPICAL  
OVIDE

\* GENDERL 0.5% N18613 001

AUG 02, 1982

@ 0.5% N18613 001  
AUG 02, 1982MANGAFODIPIR TRISODIUMINJECTABLE; INJECTION  
TESLASCAN

+ NYCOMED 37.9MG/ML N20652 001

NOV 26, 1997

MANGANESE CHLORIDE TETRAHYDRATEPOWDER FOR RECONSTITUTION; ORAL  
LUMENHANCE

+ BRACCO 3.49MG/GM N20686 001

DEC 19, 1997

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HCL

<u>AA</u>	KY PHARM	<u>12.5MG</u>	N85524 001
<u>AA</u>	@	<u>12.5MG</u>	N85523 001
<u>AA</u>	@	<u>25MG</u>	N85524 001
<u>AA</u>	VINTAGE PHARMS	<u>12.5MG</u>	N85523 001
<u>AA</u>		<u>25MG</u>	N40179 001
<u>AA</u>		<u>25MG</u>	JAN 30, 1997
<u>AA</u>	ZENITH GOLDLINE	<u>12.5MG</u>	N40179 002
<u>AA</u>		<u>25MG</u>	JAN 30, 1997
<u>AA</u>	@ ZENITH LABS	<u>12.5MG</u>	N84975 001
<u>AA</u>	ZENITH LABS	<u>12.5MG</u>	N84657 001
<u>AA</u>		<u>12.5MG</u>	N83784 001
<u>AA</u>		<u>25MG</u>	N84975 001
<u>AA</u>		<u>25MG</u>	N84657 001

TABLET, CHEWABLE; ORAL

MECLIZINE HCL

<u>AA</u>	@ ZENITH GOLDLINE	<u>25MG</u>	N84976 001
<u>AA</u>	ZENITH LABS	<u>25MG</u>	N84976 001

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION

HUMEGON

<u>AB</u>	*	ORGANON	<u>75 IU/VIAL; 75 IU/VIAL</u>	N20328 001
<u>AB</u>			<u>75 IU/VIAL; 75 IU/VIAL</u>	SEP 01, 1994
<u>AB</u>	*		<u>150 IU/VIAL; 150 IU/VIAL</u>	N20328 002
<u>AB</u>			<u>150 IU/VIAL; 150 IU/VIAL</u>	SEP 01, 1994
<u>AB</u>			<u>150 IU/VIAL; 150 IU/VIAL</u>	N20328 002
<u>AB</u>			<u>150 IU/VIAL; 150 IU/VIAL</u>	SEP 01, 1994
> DLT >		REPRONAL	<u>75 IU/VIAL; 75 IU/VIAL</u>	N73598 001
> DLT >	<u>AB</u>	FERRING	<u>75 IU/VIAL; 75 IU/VIAL</u>	JAN 30, 1997
> DLT >	<u>AB</u>		<u>150 IU/VIAL; 150 IU/VIAL</u>	N73599 001
> DLT >	<u>AB</u>		<u>150 IU/VIAL; 150 IU/VIAL</u>	JAN 30, 1997
> ADD >		REPRONEX	<u>75 IU/VIAL; 75 IU/VIAL</u>	N73598 001
> ADD >	<u>AB</u>	FERRING	<u>75 IU/VIAL; 75 IU/VIAL</u>	JAN 30, 1997
> ADD >	<u>AB</u>		<u>150 IU/VIAL; 150 IU/VIAL</u>	N73599 001
> ADD >			<u>150 IU/VIAL; 150 IU/VIAL</u>	JAN 30, 1997

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HCL

<u>AP</u>	MALLINCKRODT	<u>10MG/ML</u>	N40163 001
<u>AA</u>	ROXANE	<u>50MG</u>	MAY 12, 1997
<u>AA</u>		<u>100MG</u>	N40110 001
<u>AA</u>	ROYCE LABS	<u>50MG</u>	MAR 12, 1997
<u>AA</u>		<u>100MG</u>	N40110 002
<u>AA</u>		<u>100MG</u>	MAR 12, 1997
<u>AA</u>		<u>100MG</u>	N40186 001
<u>AA</u>		<u>100MG</u>	JUN 30, 1997
<u>AA</u>		<u>100MG</u>	N40186 002
<u>AA</u>		<u>100MG</u>	JUN 30, 1997

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

<u>AA</u>	PUREPAC PHARM	<u>200MG</u>	N84804 001
<u>AA</u>	@	<u>400MG</u>	N84804 002
<u>AA</u>	@	<u>200MG</u>	N84804 001
<u>AA</u>	@ ZENITH GOLDLINE	<u>400MG</u>	N84804 002
<u>AA</u>	ZENITH LABS	<u>600MG</u>	N84181 001
<u>AA</u>		<u>600MG</u>	N84181 001

METAPROTERENOL SULFATE

SYRUP; ORAL

METAPROTERENOL SULFATE

<u>AA</u>	3IVE	<u>10MG/5ML</u>	N74702 001
<u>AA</u>	MORTON GROVE	<u>10MG/5ML</u>	MAR 24, 1997
<u>AA</u>		<u>10MG/5ML</u>	N71656 001
<u>AA</u>		<u>10MG/5ML</u>	OCT 13, 1987
<u>AA</u>		<u>10MG/5ML</u>	N74702 001
<u>AA</u>		<u>10MG/5ML</u>	MAR 24, 1997
<u>AA</u>		<u>10MG/5ML</u>	N71656 001
<u>AA</u>		<u>10MG/5ML</u>	OCT 13, 1987

METFORMIN HYDROCHLORIDE

TABLET; ORAL  
GLUCOPHAGE  
BRISTOL MYERS SQUIBB 500MG  
850MG  
500MG  
+ 850MG

N20357 001  
DEC 29, 1994  
N20357 002  
DEC 29, 1994  
N20357 001  
MAR 03, 1995  
N20357 002  
MAR 03, 1995

METHOTREXATE SODIUM

INJECTABLE; INJECTION  
FOLEY FFS  
AP PHARMACIA AND UPJOHN EQ 25MG BASE/ML  
@ EQ 25MG BASE/ML  
MEXATE-AQ PRESERVED  
AP BRISTOL MYERS EQ 25MG BASE/ML  
@ BRISTOL MYERS SQUIBB EQ 25MG BASE/ML

N81242 001  
AUG 23, 1991  
N81242 001  
AUG 23, 1991  
N89887 001  
APR 14, 1989  
N89887 001  
APR 14, 1989

METHACHOLINE CHLORIDE

POWDER FOR RECONSTITUTION; INHALATION  
PROVOCHOLINE  
METHAPHARM 100MG/VIAL  
ROCHE 100MG/VIAL

N19193 001  
OCT 31, 1986  
N19193 001  
OCT 31, 1986

METHOXSALEN

CAPSULE; ORAL  
OXSORALEN-ULTRA  
+ ICN 10MG  
CAPSULE; LIQUID FILLED; ORAL  
OXSORALEN-ULTRA  
+ ICN 10MG

N19600 001  
OCT 30, 1986  
N19600 001  
OCT 30, 1986

METHAZOLAMIDE

TABLET; ORAL  
METHAZOLAMIDE  
AB APPLIED ANAL 25MG  
AB 50MG

N40011 001  
JUL 17, 1997  
N40011 002  
JUL 17, 1997

METHYCLOTHIAZIDE

TABLET; ORAL  
METHYCLOTHIAZIDE  
AB ZENITH GOLDLINE 2.5MG  
@ 5MG  
AB ZENITH LABS 2.5MG  
AB 5MG

N87913 001  
JUN 03, 1982  
N87786 001  
MAY 18, 1982  
N87913 001  
JUN 03, 1982  
N87786 001  
MAY 18, 1982

METHOCARBAMOL

TABLET; ORAL  
METHOCARBAMOL  
AA COREPAC PHARM 500MG  
AA 750MG  
@ 500MG  
@ 750MG  
@ ZENITH GOLDLINE 500MG  
@ 750MG  
AA ZENITH LABS 500MG  
AA 750MG

N85718 001  
N85718 002  
N85718 001  
N85718 002  
N84648 001  
N84649 001  
N84648 001  
N84649 001

METHYLDOPA

TABLET; ORAL  
METHYLDOPA  
AB HALSEY 12.5MG

N71751 001  
MAR 28, 1988

METHYLDOPATABLET; ORAL  
METHYLDOPA

AB HESSEY

250MG

N71752 001

MAR 28, 1988

@ 125MG

N71751 001

@ 250MG

MAR 28, 1988

N71752 001

MAR 28, 1988

AB PUREPAC PHARM

125MG

N70749 001

FEB 07, 1986

AB

250MG

N70750 001

FEB 07, 1986

AB

500MG

N70452 001

FEB 07, 1986

@ 125MG

N70749 001

@ 250MG

FEB 07, 1986

N70750 001

@ 500MG

FEB 07, 1986

N70452 001

FEB 07, 1986

METHYLPHENIDATE HYDROCHLORIDETABLET; ORAL  
METHYLPHENIDATE HCL

AB DANBURY PHARMA

5MG

N40220 001

AUG 29, 1997

AB

10MG

N40220 002

AUG 29, 1997

AB

20MG

N40220 003

AUG 29, 1997

METHYLPREDNISOLONE

TABLET; ORAL

MEDROL

AB PHARMACIA AND UPJOHN

8MG

N11153 004

METHYLPREDNISOLONE

AB CHELSEA LABS

4MG

N40232 001

OCT 16, 1997

AB INVAMED

4MG

N40194 001

OCT 31, 1997

AB TRIGEN

4MG

N40189 001

OCT 31, 1997

METHYLPREDNISOLONETABLET; ORAL  
METHYLPREDNISOLONE

AB TRIGEN

8MG

N40189 002

OCT 31, 1997

METOCLOPRAMIDE HYDROCHLORIDEINJECTABLE; INJECTION  
METOCLOPRAMIDE HCL

AP ABBOTT

EQ 5MG BASE/ML

N74147 001

AUG 02, 1996

N71990 001

JAN 18, 1989

N71990 001

JAN 18, 1989

N74147 001

AUG 02, 1996

SOLUTION; ORAL  
METOCLOPRAMIDE

AA JVL

EQ 5MG BASE/5ML

N74703 001

OCT 31, 1997

METOCLOPRAMIDE HCL

AA MORTON GROVE

EQ 5MG BASE/5ML

N70949 001

MAR 06, 1987

N70949 001

MAR 06, 1987

TABLET; ORAL  
METOCLOPRAMIDE HCL

AB MUTUAL PHARM

EQ 5MG BASE

N71536 002

JAN 16, 1997

METOLAZONE

TABLET; ORAL

MYKROX

MEDEVA

0.5MG

N19532 001

OCT 30, 1987

N19532 001

OCT 30, 1987

METOPROLOL TARTRATE

INJECTABLE; INJECTION  
**METOPROLOL TARTRATE**  
AP ABBOTT 1MG/ML  
AP STERLING-WINTROP 1MG/ML

N74133 001  
 DEC 21, 1993  
 N74133 001  
 DEC 21, 1993

METRONIDAZOLE

CREAM; TOPICAL  
 NORITATE  
 + DERMIC LABS 1%

N20743 001  
 SEP 26, 1997

GEL; VAGINAL  
 METROGEL-VAGINAL  
 + 3M 0.75%

N20208 001  
 AUG 17, 1992  
 N20208 001  
 AUG 17, 1992

INJECTABLE; INJECTION  
**METRONIDAZOLE**  
AP STERIS 500MG/100ML  
 @ 500MG/100ML

N70042 001  
 DEC 20, 1984  
 N70042 001  
 DEC 20, 1984

TABLET, EXTENDED RELEASE; ORAL  
 FLAGYL ER  
 + SEARLE 750MG

N20868 001  
 NOV 26, 1997

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL  
**MEXILETINE HCL**  
AB WATSON LABS 150MG  
AB 200MG  
AB 250MG

N74711 001  
 FEB 26, 1997  
 N74711 002  
 FEB 26, 1997  
 N74711 003  
 FEB 26, 1997

MIBEFRADIL DIHYDROCHLORIDE

TABLET; ORAL  
 POSICOR  
 ROCHE  
 + EQ 50MG BASE  
 EQ 100MG BASE

N20689 001  
 JUN 20, 1997  
 N20689 002  
 JUN 20, 1997

MICONAZOLE

INJECTABLE; INJECTION  
**MONISTAT**  
 \* JANSEN  
 @ 10MG/ML  
 10MG/ML

N18040 001  
 N18040 001

MICONAZOLE NITRATE

CREAM; TOPICAL  
 MONISTAT-DERM  
 + J AND J  
 @ JOHNSON & WILLENS  
 2%

N17494 001  
 N17494 001

LOTION; TOPICAL  
 MONISTAT-DERM  
 @ J AND J  
 @ JOHNSON & WILLENS  
 2%

N17739 001  
 N17739 001

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL  
**MINOCYCLINE HCL**  
 LEDERLE  
 \* EQ 50MG BASE  
 EQ 100MG BASE  
 @ EQ 50MG BASE  
 @ EQ 100MG BASE

N50451 003  
 AUG 10, 1982  
 N50451 004  
 AUG 10, 1982  
 N50451 003  
 AUG 10, 1982  
 N50451 002  
 AUG 10, 1982

MIRTAZAPINE

TABLET; ORAL  
REMERON  
\* ORGANON

30MG

N20415 002  
JUN 14, 1996

30MG

N20415 002  
JUN 14, 1996

+ 45MG

N20415 003  
MAR 17, 1997> ADD > MUPIROCIN CALCIUM

> ADD > CREAM, AUGMENTED; TOPICAL  
> ADD > BACTROBAN  
> ADD > + SMITHKLINE BEECHAM 2%

N50746 001  
DEC 11, 1997MOLINDONE HYDROCHLORIDE

CAPSULE; ORAL  
MOBAN

\* DUPONT MERCK  
25MG  
@ ENDO PHARMS  
5MG  
@ 10MG  
@ 25MG

5MG

N17111 001

10MG

N17111 002

25MG

N17111 003

5MG

N17111 001

10MG

N17111 002

25MG

N17111 003

CONCENTRATE; ORAL  
MOBAN

\* DUPONT MERCK  
+ ENDO PHARMS

20MG/ML

N17938 001

20MG/ML

N17938 001

TABLET; ORAL

MOBAN  
DUPONT MERCK

5MG

N17111 004

10MG

N17111 005

25MG

N17111 006

50MG

N17111 007

100MG

N17111 008

\* ENDO PHARMS  
5MG

10MG

N17111 004

25MG

N17111 005

+ ENDO PHARMS  
50MG

50MG

N17111 006

+ ENDO PHARMS  
100MG

100MG

N17111 008

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL  
NASONEX

+ SCHERING PLOUGH

EQ 0.05MG BASE/SPRAY

N20762 001

OCT 01, 1997

> ADD > CREAM, AUGMENTED; TOPICAL  
> ADD > BACTROBAN  
> ADD > + SMITHKLINE BEECHAM 2%

N50746 001  
DEC 11, 1997MYCOPHENOLATE MOFETIL

TABLET; ORAL  
CELLCEPT  
+ SYNTEX

500MG

N50723 001  
JUN 19, 1997NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NUBAIN  
AP \* DUPONT MERCK  
10MG/ML  
20MG/ML

N18024 001  
N18024 002  
MAY 27, 1982

AP + ENDO PHARMS  
10MG/ML  
20MG/ML

N18024 001  
N18024 002  
MAY 27, 1982NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HCL  
AP ABBOTT  
0.02MG/ML

N70171 001  
SEP 24, 1986

AP  
0.4MG/ML

N70172 001  
SEP 24, 1986

AP \* SOLOPAK  
0.02MG/ML

N71672 001  
NOV 17, 1987

AP  
0.4MG/ML

N71683 001  
NOV 17, 1987

AP @  
0.02MG/ML

N71672 001  
NOV 17, 1987

AP @  
0.4MG/ML

N71683 001  
NOV 17, 1987

AP STERLING WINSTROP  
0.02MG/ML

N70171 001  
SEP 24, 1986

AP  
0.4MG/ML

N70172 001  
SEP 24, 1986

AP \* DUPONT MERCK  
0.02MG/ML

N15634 002

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NARCAN

<u>AP</u>	+	DUPONT MERCK	0.4MG/ML 1MG/ML	N16636 001 N16636 003 JUN 14, 1982
<u>AP</u>	*			
<u>AP</u>	+	ENDO PHARMS	0.02MG/ML	N16636 002
<u>AP</u>	+		0.4MG/ML	N16636 001
<u>AP</u>	+		1MG/ML	N16636 003

JUN 14, 1982

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

PENTAZOCINE AND NALOXONE HYDROCHLORIDES

<u>AB</u>	ROYCE LABS	EQ 0.5MG BASE; EQ 50MG BASE	N74736 001 JAN 21, 1997
<u>AB</u>	TALWIN NX	EQ 0.5MG BASE; EQ 50MG BASE	N18733 001 DEC 16, 1982

NANDROLONE DECANOATE

INJECTABLE; INJECTION

NANDROLONE DECANOATE

<u>AO</u>	STERIS	50MG/ML	N87598 001 OCT 06, 1983
<u>AO</u>		100MG/ML	N87599 001 OCT 06, 1983
@		50MG/ML	N87598 001 OCT 06, 1983
@		100MG/ML	N87599 001 OCT 06, 1983

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

TILADE

+	BRISTOL	1.75MG/INH	N19660 001 DEC 30, 1992
+	RHONE POULENC RORER	1.75MG/INH	N19660 001 DEC 30, 1992

NEDOCROMIL SODIUM

SOLUTION; INHALATION

TILADE

+ RHONE POULENC RORER 0.5%

N20750 001  
OCT 01, 1997NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

SERZONE

@ BRISTOL MYERS SQUIBB 50MG

+ 50MG

N20152 001  
DEC 22, 1994  
N20152 001  
DEC 22, 1994NELFINAVIR MESYLATE

POWDER FOR RECONSTITUTION; ORAL

VIRACEPT

+ AGOURON EQ 50MG BASE/SCOOPFUL

N20778 001  
MAR 14, 1997

TABLET; ORAL

VIRACEPT

+ AGOURON EQ 250MG BASE

N20779 001  
MAR 14, 1997NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING

NEO-RX

AA PHARMA TEK 100%

N61579 001  
N61579 001NEOMYCIN SULFATE

AA PADDOCK 100%

N62385 001  
JUN 01, 1982NIACIN

TABLET; ORAL

NIACIN@ HALSEY 500MG  
AA PUREPAC PHARM 500MGN83453 001  
N83453 001  
N83271 001

NIACIN

TABLET; ORAL

NIACIN

@ PUREPAC PHARM	500MG	N83271 001
@ ZENITH GOLDLINE	500MG	N83180 001
@ ZENITH LABS	500MG	N83180 001

TABLET, EXTENDED RELEASE; ORAL

NIASPAN

+ KOS	375MG	N20381 001 JUL 28, 1997
+	500MG	N20381 002 JUL 28, 1997
+	750MG	N20381 003 JUL 28, 1997
+	1GM	N20381 004 JUL 28, 1997
NIASPAN TITRATION STARTER PACK		N20381 005 JUL 28, 1997
+ KOS	375MG;500MG;750MG	

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

HABITROL

AB + NOVARTIS	<u>7MG/24HR</u>	N20076 001 NOV 27, 1991
AB +	<u>14MG/24HR</u>	N20076 002 NOV 27, 1991
AB +	<u>21MG/24HR</u>	N20076 003 NOV 27, 1991
AB <u>NICOTINE</u>		
AB SANO	<u>7MG/24HR</u>	N74645 001 OCT 20, 1997
AB	<u>14MG/24HR</u>	N74611 001 OCT 20, 1997
AB	<u>21MG/24HR</u>	N74612 001 OCT 20, 1997

INHALANT; INHALATION

NICOTROL

+ PHARMACIA AND UPJOHN 4MG/CARTRIDGE

N20714 001  
MAY 02, 1997NITROFURANTOIN

TABLET; ORAL

NITROFURANTOIN

@ ZENITH GOLDLINE	50MG	N80078 002
@	100MG	N80078 001
@ ZENITH LABS	50MG	N80078 002
@	100MG	N80078 003

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTION

<u>AB</u>	<u>MYLAN</u>	<u>100MG</u>	<u>N74967 002</u>
			JUL 09, 1997

NITROFURANTOIN

<u>AB</u>	<u>MYLAN</u>	<u>50MG</u>	<u>N74967 001</u>
			JUL 09, 1997

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

LEVOPHED

+ ABBOTT	EQ 1MG BASE/ML	N07513 001
AB SANOFI WINTHROP	EQ 1MG BASE/ML	N07513 002

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HCL

<u>AB</u>	<u>INVAMED</u>	<u>EQ 10MG BASE</u>	<u>N74835 001</u>
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>N74835 002</u>
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>N74835 003</u>
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>N74835 004</u>
			JUN 30, 1997

NYSTATIN

CREAM; TOPICAL

MYKINAC

@ ALPHARMA	100,000 UNITS/GM	N62387 001
		JUL 29, 1982

NYSTATINCREAM; TOPICAL  
MYKINAC

AT NMC 100,000 UNITS/GM N62387 001 JUL 29, 1982

OINTMENT; TOPICAL  
MYCOSTATINAT \* SQUIBB 100,000 UNITS/GM N60571 001  
@ WESTWOOD SQUIBB 100,000 UNITS/GM N60571 001

AT @ ALPHARMA 100,000 UNITS/GM N62731 001 SEP 22, 1986

AT NMC 100,000 UNITS/GM N62731 001 SEP 22, 1986

NILSTATAT FEDEREE 100,000 UNITS/GM N61444 001  
AT + 100,000 UNITS/GM N61444 001SUSPENSION; ORAL  
NYSTATINAA ALPHARMA 100,000 UNITS/ML N62571 001 OCT 29, 1985  
@ 100,000 UNITS/ML N62571 001 OCT 29, 1985OFLOXACIN> ADD > SOLUTION/DROPS; OTIC FLOXIN  
> ADD > + DAIICHI 0.3% N20799 001 DEC 16, 1997ONDANSETRON HYDROCHLORIDESOLUTION; ORAL ZOFRAN  
+ GLAXO WELLCOME EQ 4MG BASE/5ML N20605 001 JAN 24, 1997OXACILLIN SODIUMCAPSULE; ORAL  
BACTOCILL  
AB SMITHKLINE BEECHAM EQ 250MG BASE N61336 001OXACILLIN SODIUMCAPSULE; ORAL  
BACTOCILLAB + SMITHKLINE BEECHAM EQ 250MG BASE N61336 001  
OXACILLIN SODIUM APOTHECON EQ 250MG BASE N61450 002  
AB @ EQ 500MG BASE N61450 001  
@ EQ 250MG BASE N61450 002  
@ EQ 500MG BASE N61450 001OXTRIPTYLLINETABLET, EXTENDED RELEASE; ORAL CHOLEDYL SA PARKE DAVIS 600MG  
+ WARNER CHILCOTT 600MG N86742 001OXYBUTYNIN CHLORIDESYRUP; ORAL  
OXYBUTYNIN CHLORIDE  
AA MORTON GROVE 5MG/5ML N74868 001  
AA NU PHARM 5MG/5ML FEB 12, 1997  
N74997 001 OCT 15, 1997TABLET; ORAL  
OXYBUTYNIN CHLORIDE

AB VINTAGE PHARMS 5MG N75079 001 OCT 31, 1997

OXYCODONE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL  
OXYCONTIN  
PURDUE FREDERICK 10MG N20553 001  
20MG N20553 002  
40MG N20553 003  
+ PURDUE PHARMA 10MG DEC 12, 1995  
+ 20MG N20553 001  
N20553 002 DEC 12, 1995  
N20553 002 DEC 12, 1995

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL  
OXYCONTIN

+ PURDUE PHARMA 40MG  
+ 80MG

N20553 003 > DLT >  
DEC 12, 1995 > DLT >  
N20553 004 > ADD >  
JAN 06, 1997 > ADD >

PACLITAXEL

INJECTABLE; INJECTION  
TAXOL

BRISTOL MYERS SQUIBB 6MG/ML  
+ 6MG/ML

N20262 001  
DEC 29, 1992  
N20262 001  
DEC 29, 1992

OXYMETHOLONE

TABLET; ORAL  
ANADROL-50

\* SYNTEX 50MG  
+ UNIMED 50MG

N16848 001  
N16848 001

PAROMOMYCIN SULFATE

CAPSULE; ORAL  
HUMATIN

AB + PARKE DAVIS EQ 250MG BASE  
AB PAROMOMYCIN SULFATE EQ 250MG BASE  
AB CARACO EQ 250MG BASE

N60521 001  
N62310 001  
N64171 001  
JUN 30, 1997

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION  
NUMORPHAN

\* DUPONT MERCK 1MG/ML  
\* 1.5MG/ML  
+ ENDO PHARMS 1MG/ML  
+ 1.5MG/ML

N11707 002  
N11707 003  
N11707 002  
N11707 001

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL  
PAXIL

+ SMITHKLINE BEECHAM EQ 10MG BASE/5ML

N20710 001  
JUN 25, 1997

SUPPOSITORY; RECTAL  
NUMORPHAN

\* DUPONT MERCK 5MG  
+ ENDO PHARMS 5MG

N11738 002  
N11738 004

PENICILLIN G POTASSIUM

TABLET; ORAL  
PENICILLIN G POTASSIUM

AB @ ZENITH GOLDLINE 400,000 UNITS  
AB ZENITH LABS 400,000 UNITS

N60073 004  
N60073 004

OXYTOCIN

INJECTABLE; INJECTION  
OXYTOCIN

\* NYETH AYERST 10 USP UNITS/ML  
@ 10 USP UNITS/ML

N18243 001  
N18243 001

PENICILLIN V POTASSIUM

TABLET; ORAL  
PENICILLIN V POTASSIUM

AB @ ZENITH GOLDLINE EQ 125MG BASE  
AB @ EQ 250MG BASE

N60518 001  
N60518 002

AB @ EQ 500MG BASE  
AB ZENITH LABS EQ 125MG BASE

N60518 003  
N60518 001  
N60518 002

AB AB EQ 250MG BASE  
AB EQ 500MG BASE

N60518 003  
N60518 001  
N60518 002

SOLUTION; NASAL

\* SYNTOCINON 40 USP UNITS/ML  
@ NOVARTIS 40 USP UNITS/ML

N12285 001  
N12285 001

V-CILLIN K

AB \* ELLINIK EQ 125MG BASE

N60003 001

## RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'97 - DEC'97

65

PENICILLIN V POTASSIUM

TABLET; ORAL  
**V-CILLIN K**  
+ LILLY EQ 125MG BASE N60003 001

PENTAZOCINE LACTATE

INJECTABLE; INJECTION  
TALWIN  
+ ABBOTT EQ 30MG BASE/ML N16194 001  
+ SANOFI WINTHROP EQ 30MG BASE/ML N16194 002

PENTOBARBITAL SODIUM

CAPSULE; ORAL  
**SODIUM PENTOBARBITAL**  
@ ZENITH GOLDLINE 50MG N83461 001  
@ 100MG N83461 002  
**ZENITH LABS** 60MG N83461 003  
60MG N83461 004

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL  
**PENTOXIFYLLINE**  
AB ESI LEDERLE 400MG N74877 001 JUL 08, 1997  
AB MYLAN 400MG N74425 001 JUL 08, 1997  
AB PUREPAC PHARM 400MG N74878 001 JUL 09, 1997  
AB + TRENTAL HOECHST MARION RSSL 400MG N18631 001 AUG 30, 1984

PERINDOPRIL ERBUMINE

TABLET; ORAL  
ACEON  
RHONE POULENC RORER 2MG N20184 001  
4MG N20184 002

PERINDOPRIL ERBUMINE

TABLET; ORAL  
ACEON  
\* RHONE POULENC RORER 2MG  
@ 2MG  
@ 4MG  
@ 8MG

N20184 001  
DEC 30, 1993  
N20184 001  
DEC 30, 1993  
N20184 002  
DEC 30, 1993  
N20184 003  
DEC 30, 1993

PERMETHRIN

CREAM; TOPICAL  
ELIMITE  
+ ALLERGAN 5%  
> ADD >  
> ADD >  
> DLT >  
> DLT >

N19855 001  
AUG 25, 1989  
N19855 001  
AUG 25, 1989

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL  
BONTRIL  
BC MALLINCKRODT 105MG N88021 001 SEP 21, 1982  
BC PHENDIMETRAZINE TARTRATE  
GRAHAM DM 105MG N87214 001 MAY 26, 1982  
BC 105MG N88020 001 AUG 16, 1982  
BC 105MG N88021 001 SEP 21, 1982  
BC 105MG N88028 001 AUG 16, 1982  
BC 105MG N88062 001 SEP 13, 1982  
BC 105MG N88063 001 SEP 10, 1982  
BC 105MG N88111 001 OCT 19, 1982  
BC 105MG N87214 001 MAY 26, 1982  
BC 105MG N88020 001 AUG 16, 1982

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL  
PHENDIMETRAZINE TARTRATE

@ GRAHAM DM 105MG  
@ 105MG  
@ 105MG  
@ 105MG  
@ 105MG

TABLET; ORAL  
PHENDIMETRAZINE TARTRATE

 INWOOD LABS 35MG  
 35MG  
 35MG  
 35MG  
@ 35MG  
@ 35MG  
@ 35MG  
@ 35MG  
 XV PHARM 35MG  
 35MG  
 35MG  
@ 35MG  
@ 35MG  
@ 35MG  
@ 35MG  
@ ZENITH GOLDLINE 35MG  
@ 35MG  
@ 35MG  
 ZENITH LABS 35MG  
 35MG  
 35MG

PHENTERMINE HYDROCHLORIDEPHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL  
PHENTERMINE HCL

N88028 001 > ADD > AA EON 37.5MG  
AUG 16, 1982 > ADD > AA KING PHARMS 30MG  
N88062 001 SEP 13, 1982 @ ZENITH GOLDLINE 30MG  
N88063 001 SEP 10, 1982 @ ZENITH LABS 30MG  
N88111 001 OCT 18, 1982

TABLET; ORAL  
PHENTERMINE HCL

AA AMIDE PHARM 37.5MG  
@ EON 8MG  
@ 8MG  
+ 30MG  
> ADD > @ ZENITH GOLDLINE 8MG  
> ADD > @ ZENITH LABS 8MG  
UMI-PEX 30 @ PERNDALE LABS 30MG  
> DLT > @ PERNDALE LABS 30MG  
> DLT >

N88414 001 OCT 19, 1983 N40083 001 MAR 07, 1997 N86329 001 N86329 001  
N40190 001 MAY 30, 1997 N85689 001 N85689 001 N85689 001 N88605 001 SEP 28, 1987 N85553 001 N85553 001 N88605 001 SEP 28, 1987

PHENYLBUTAZONE

CAPSULE; ORAL  
PHENYLBUTAZONE  
@ ZENITH GOLDLINE 100MG  
N83682 001  
N85611 001  
N85612 001 @ ZENITH LABS 100MG

N88218 001 JUN 24, 1983 N88218 001 JUN 24, 1983

PHENYTOIN SODIUM

INJECTABLE; INJECTION  
PHENYTOIN SODIUM  
AP ABBOTT 50MG/ML  
AP WINTHROP 50MG/ML

N89744 001 DEC 18, 1987 N89744 001 DEC 18, 1987

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

DAPEX-37.5  
PERNDALE LABS 37.5MG

N88414 001  
OCT 19, 1983

PHENTERMINE HCL

AA AMIDE PHARM 30MG

N40227 001  
JUN 18, 1997  
N40228 001  
JUN 19, 1997

> DLT >  
> DLT >

AA

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL  
DILANTIN  
BARKER DAVIS  
+  
30MG

N84349 001  
N84349 001

PIMOZIDE

TABLET; ORAL  
ORAP  
TEVA  
1MG

N17473 003  
AUG 27, 1997

PINDOLOL

TABLET; ORAL  
PINDOLOL  
AB LENNON  
5MG  
  
AB 10MG  
  
AB TEVA 5MG  
  
AB 10MG

N74123 001  
APR 17, 1997  
N74123 002  
APR 17, 1997  
N74123 001  
APR 17, 1997  
N74123 002  
APR 17, 1997

PIROXICAM

CAPSULE; ORAL  
PIROXICAM  
AB EGIS 10MG  
  
AB 20MG

N74808 001  
JUL 08, 1997  
N74808 002  
JUL 08, 1997

PODOFILOX

GEL; TOPICAL  
CONDYLOX  
+ OCLASSEN  
0.5%

N20529 001  
MAR 13, 1997

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC  
POLYTRIM  
AT + ALLERGAN 10,000 UNITS/ML;  
EQ 1MG BASE/ML  
  
AT BAUSCH AND LOMB 10,000 UNITS/ML;  
EQ 1MG BASE/ML

N50567 001  
OCT 20, 1988  
  
N64120 001  
FEB 14, 1997

POTASSIUM CHLORIDE

INJECTABLE; INJECTION  
POTASSIUM CHLORIDE 10MEO IN PLASTIC CONTAINER  
AP \* ABBOTT 745MG/100ML  
AP \* 14.9MG/ML  
@ 745MG/100ML  
@ 14.9MG/ML  
AP \* BAXTER HEALTHCARE 745MG/100ML  
AP \* 14.9MG/ML  
+ 746MG/100ML  
+ 14.9MG/ML

N20161 001  
NOV 30, 1992  
N20161 005  
NOV 30, 1992  
N20161 001  
NOV 30, 1992  
N20161 005  
NOV 30, 1992  
N19904 005  
DEC 17, 1990  
N19904 001  
DEC 26, 1989  
N19904 005  
DEC 17, 1990  
N19904 001  
DEC 26, 1989

POTASSIUM CHLORIDE 20MEO IN PLASTIC CONTAINER  
AP \* ABBOTT 1.49GM/100ML  
AP \* 1.49GM/100ML  
AP \* BAXTER HEALTHCARE 1.49GM/100ML  
+ 1.49GM/100ML

N20161 002  
NOV 30, 1992  
N20161 002  
NOV 30, 1992  
N19904 006  
DEC 17, 1990  
N19904 006  
DEC 17, 1990

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL  
POTASSIUM CITRATE  
MISSION PHARMA 5MEO

N19071 001  
AUG 30, 1985

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL  
POTASSIUM CITRATE  
+ MISSION PHARMA 10MEQ

UNIV TX

5MEQ

\*

10MEQ

N19071 002  
AUG 31, 1992  
N19071 003  
AUG 30, 1984  
N19071 002  
AUG 31, 1992

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL  
MIRAPEX  
+ PHARMACIA AND UPJOHN 0.125MG

0.25MG

1MG

@

1.25MG

+

1.5MG

N20667 001  
JUL 01, 1997  
N20667 002  
JUL 01, 1997  
N20667 003  
JUL 01, 1997  
N20667 004  
JUL 01, 1997  
N20667 005  
JUL 01, 1997

PREDNISOLONE

TABLET; ORAL  
PREDNISOLONE  
BX PUREPAC PHARM 5MG

@

ZENITH GOLDLINE 5MG

BX ZENITH TABS 5MG

N80325 001  
N80325 001  
N80378 001  
N80378 001

PREDNISOLONE ACETATE

INJECTABLE; INJECTION  
PREDNISOLONE ACETATE  
STERIS 25MG/ML

@

25MG/ML

N83654 003  
N83654 001

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL  
PEDIAFRED

\* FISONS

+ MEDEVA

EQ 5MG BASE/5ML

EQ 5MG BASE/5ML

N19157 001

MAY 28, 1986

N19157 001

MAY 28, 1986

PREDNISONE

TABLET; ORAL  
PREDNISONE

AB HALSEY

@

@ ZENITH GOLDLINE

@

@

BX ZENITH TABS

BX @

5MG

5MG

10MG

20MG

SMG

10MG

20MG

N80300 001

N80300 001

N80283 001

N84133 001

N84134 001

N84134 001

N84134 001

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION  
PROCAINAMIDE HCL

AP ABBOTT

500MG/ML

N89537 001

AUG 25, 1987

N88532 001

MAR 04, 1985

N88532 001

MAR 04, 1985

N89537 001

AUG 25, 1987

> DLT > AP SOLOPAK 500MG/ML  
> DLT > @ 500MG/ML  
> ADD > @  
> ADD > AP WINTHROP 500MG/ML

PREDNISOLONE ACETATE

AB INNOVOD LABS

500MG

N89840 001

MAR 06, 1989

N89840 001

MAR 06, 1989

@ 500MG

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION  
NOVOCAIN

AP + ABBOTT

1%

N85362 003

PROCAINE HYDROCHLORIDE

## INJECTABLE; INJECTION

NOVOCAIN

**AP** + ABBOTT 2%  
**AP** + STERLING WINSTROP 1%  
**AB** \* STERLING WINSTROP 2%  
**AB** \* STERLING WINSTROP 10%

PROCaine HCl

**AP** STERIS 1%  
**BP** STERIS 2%  
**@** 1%  
**@** 2%

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

## INJECTABLE; INJECTION

TETRACYCIN

\* PFIZER 40MG/VIAL; 250MG/VIAL  
 @ 40MG/VIAL; 250MG/VIAL

N85362 004  
 N86797 001  
 N85362 003  
 N85362 004  
 N86797 001  
 N83535 001  
 N83535 002  
 N83535 001  
 N83535 002

> DLT >  
 > ADD >

PROCYCLIDINE HYDROCHLORIDE

## TABLET; ORAL

KEMADRIN

\* GLAXO WELLCOME  
 + MONARCH PHARMS

5MG  
 5MG

N09818 003  
 N09818 003

PROGESTERONE

## GEL; VAGINAL

CRINONE

COLUMBIA RES LABS

4%

N20701 001  
 JUL 31, 1997  
 N20701 002  
 JUL 31, 1997  
 N20756 001  
 MAY 13, 1997

+  
 +  
 +

8%  
 8%  
 8%

PROCHLORPERAZINE EDISYLATE

## INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

**AP** ABBOTT EQ 5MG BASE/ML  
**AP** STERIS EQ 5MG BASE/ML  
**@** EQ 5MG BASE/ML  
**AB** STERLING WINSTROP EQ 5MG BASE/ML

N89703 001  
 APR 07, 1988  
 N89605 001  
 JUL 08, 1988  
 N89605 001  
 JUL 08, 1987  
 N89703 001  
 APR 07, 1988

PROCHLORPERAZINE MALEATE

## TABLET; ORAL

PROCHLORPERAZINE MALEATE

**AB** DURAMED EQ 5MG BASE  
**AB** EQ 10MG BASE

N40207 001  
 MAY 01, 1997  
 N40207 002  
 MAY 01, 1997

PROMETHAZINE HYDROCHLORIDE

## INJECTABLE; INJECTION

PROMETHAZINE HCl

**AP** ABBOTT 50MG/ML  
**AP** STERIS 25MG/ML  
**AP** STERIS 50MG/ML  
**@** 25MG/ML  
**@** 50MG/ML  
**AB** STERLING WINSTROP 50MG/ML

N83838 002  
 N83532 001  
 N83532 002  
 N83532 001  
 N83532 002  
 N83838 002

TABLET; ORAL  
PROMETHAZINE HCl

@ ZENITH GOLDLINE 12.5MG  
 @ ZENITH GOLDLINE 25MG  
 @ ZENITH GOLDLINE 50MG  
**BP** ZENITH LABS 12.5MG  
**BP** ZENITH LABS 25MG  
**@** 50MG

N83604 001  
 N83603 001  
 N83613 001  
 N83604 001  
 N83603 001  
 N83613 001

PROPANTHELINE BROMIDE

## TABLET; ORAL

PROPANTHELINE BROMIDE

**BP** PAR PHARM 15MG  
**@** 15MG

N88377 001  
 DEC 08, 1983  
 N88377 001  
 DEC 08, 1983

## PROPIOMAZINE HYDROCHLORIDE

> DLT > INJECTABLE, INJECTION  
> DLT > LARSON  
> DLT > MYETH AVERST 20MG/ML  
> ADD @ 20MG/ML

## **PROPOXYPHENONE HYDROCHLORIDE**

**CAPSULE; ORAL**  
**PROPOXYPHENE HCL**  
**Roxane®**  
 @  
 @  
 @ ZENITH GOLDLINE  
 ZENITH LABS

## **PROPRANOLOL HYDROCHLORIDE**

INJECTABLE; INJECTION  
PROPRANOLOL HCL  
SOLUDEX 1MG/

**TABLET; ORAL  
PROPRANOLOL HCL**

<u>AB</u>	<u>ROXANE</u>	<u>10MG</u>
<u>AB</u>		<u>20MG</u>
<u>AB</u>		<u>40MG</u>
<u>AB</u>		<u>60MG</u>
<u>AB</u>		<u>80MG</u>
<u>AB</u>		<u>90MG</u>
@		<u>10MG</u>
@		<u>20MG</u>
@		<u>40MG</u>

## PROPRANOLOL HYDROCHLORIDE

<u>TABLET; ORAL</u>			
<u>PROPRANOLOL HCL</u>			
@ ROXANE	60MG	N70519	001
@	80MG	SEP 24,	1986
@	90MG	N70520	001
@	90MG	JUL 07,	1986
@	10MG	N70521	001
@ ZENITH GOLDLINE	10MG	SEP 24,	1986
@	20MG	N72063	001
@	20MG	JUL 29,	1988
@	40MG	N72066	001
@	60MG	JUL 29,	1988
@	80MG	N72067	001
ZENITH LABS	10MG	JUL 29,	1988
	20MG	N72068	001
	40MG	JUL 29,	1988
	60MG	N72069	001
	80MG	JUL 29,	1988
	10MG	N72063	001
	20MG	JUL 29,	1988
	40MG	N72066	001
	60MG	JUL 29,	1988
	80MG	N72067	001
	10MG	JUL 29,	1988
	20MG	N72069	001
	40MG	JUL 29,	1988
	60MG	N72068	001
	80MG	JUL 29,	1988

## **PROPYLTHIOURACIL**

TABLET; ORAL  
PROPYLTIOURACIL  
@ ZENITH GOLDLINE 50MG N80215 001  
@ ZENITH LABS 50MG N80215 001

**PSEUDOEPHEDRINE HYDROCHLORIDE : TRIPROLIDINE HYDROCHLORIDE**

TABLET; ORAL  
TRIPLORIDINE HCL AND PSEUDOEPHEDRINE HCL  
@ ZENITH GOLDLINE 60MG; 2.5MG N85273 001  
ZENITH LABS 60MG; 2.5MG DEC 12, 1984 N85273 001

PYRIDOSTIGMINE BROMIDEINJECTABLE; INJECTION  
MESTINONAP + ICN  
AB \* ROCHE5MG/ML  
5MG/MLN09830 001  
N09830 001SYRUP; ORAL  
MESTINON+ ICN  
\* ROCHE60MG/5ML  
60MG/5MLN15193 001  
N15193 001TABLET; ORAL  
MESTINON+ ICN  
\* ROCHE60MG  
60MGN09829 002  
N09829 002TABLET, EXTENDED RELEASE; ORAL  
MESTINON+ ICN  
\* ROCHE180MG  
360MGN11665 001  
N11665 001PYRIDOXINE HYDROCHLORIDEINJECTABLE; INJECTION  
PYRIDOXINE HCLAP STERIS  
@100MG/ML  
100MG/MLN83760 001  
N83760 001QUETIAPINE FUMARATETABLET; ORAL  
SEROQUEL

ZENECA

EQ 25MG BASE

N20639 001

EQ 100MG BASE

SEP 26, 1997

+ EQ 200MG BASE

N20639 002

SEP 26, 1997

N20639 003

SEP 26, 1997

QUINIDINE SULFATECAPSULE; ORAL  
CIN-QUIN

SOLVAY

200MG  
300MGN85296 001  
N85297 001QUINIDINE SULFATE

CAPSULE; ORAL

CIN-QUIN

@ SOLVAY

200MG  
300MGN85296 001  
N85297 001TABLET; ORAL  
CIN-QUIN

@ SOLVAY

180MG  
200MG  
300MGN85299 001  
N84932 001  
N85298 001QUINIDINE SULFATE  
AB ZENITH GOLDLINE  
ZENITH LABS200MG  
200MGN84549 001  
N84549 001TABLET, EXTENDED RELEASE; ORAL  
QUINIDEX  
AB \* ROCHE'S AH  
AB + WYETH AYERST300MG  
300MGN12796 002  
N12796 002RALOXIFENE HYDROCHLORIDE> ADD > TABLET; ORAL  
EVISTA  
+ LILLY 60MGN20815 001  
DEC 09, 1997RANITIDINE HYDROCHLORIDECAPSULE; ORAL  
RANITIDINE HCL  
GENEVA PHARMS

EQ 150MG BASE

N74655 001  
OCT 22, 1997  
N74655 002

AB EQ 300MG BASE

OCT 22, 1997

AB ZANTAC 150  
GLAXO WELLCOME

EQ 150MG BASE

N20095 001  
MAR 08, 1994AB ZANTAC 300  
+ GLAXO WELLCOME

EQ 300MG BASE

N20095 002  
MAR 08, 1994

RANITIDINE HYDROCHLORIDE

TABLET; ORAL  
**RANITIDINE HCL**

<u>AB</u>	BOEHRINGER INGELHEIM	<u>EQ 150MG BASE</u>	N74662 001 AUG 29, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	N74662 002 AUG 29, 1997
<u>AB</u>	CHELSEA LABS	<u>EQ 150MG BASE</u>	N74864 001 OCT 20, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	N74864 002 OCT 20, 1997
<u>AB</u>	GENEVA PHARMS	<u>EQ 150MG BASE</u>	N74467 001 > <u>ADD</u> > <b>REPAGLINIDE</b>
<u>AB</u>		<u>EQ 300MG BASE</u>	N74467 002 > <u>ADD</u> > TABLET; ORAL
<u>AB</u>	GENPHARM	<u>EQ 150MG BASE</u>	N74023 001 > <u>ADD</u> > PRANDIN
<u>AB</u>		<u>EQ 300MG BASE</u>	N74023 002 > <u>ADD</u> > NOVO NORDISK
<u>AB</u>	GRANUTEC PHARMS	<u>EQ 150MG BASE</u>	AUG 22, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	N74488 001 > <u>ADD</u> > +
<u>AB</u>	TORPHARM	<u>EQ 150MG BASE</u>	JUL 31, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	N74488 002 > <u>ADD</u> >
<u>AB</u>	ZANTAC 150 GLAXO WELLCOME	<u>EQ 150MG BASE</u>	JUL 31, 1997
<u>AB</u>	ZANTAC 300 + GLAXO WELLCOME	<u>EQ 300MG BASE</u>	N74680 001 SEP 12, 1997
<u>AB</u>			N74680 002 SEP 12, 1997

RAUWOLFIA SERPENTINA

BB	RAUWOLFIA SERPENTINA PAK PAK	50MG 100MG	N09108 002 N09108 004
*		50MG	N09108 002
@		100MG	N09108 004
@			
BB	RAUWOLFIA SERPENTINA DANBURY PHARMA	50MG 100MG	N80907 001 N80907 003
BB	GLOBAL PHARM	50MG 100MG	N09273 001 N09273 002

RAUWOLFIA SERPENTINA

TABLET; ORAL  
**RAUWOLFIA SERPENTINA**

@	GLOBAL PHARM	50MG	N09273 001
@	ZENITH GOLDLINE	100MG	N09273 002
@	ZENITH LABS	50MG	N11521 001
@	ZENITH LABS	100MG	N11521 002
BB	PUREPAC PHARM	0.1MG	N80753 002
BB		0.25MG	N80753 004
@		0.1MG	N80753 002
@		0.25MG	N80753 001
BB	TABLETCAPS	0.25MG	N85207 001
@		0.25MG	N85207 001
@	ZENITH GOLDLINE	0.1MG	N85207 001
@	ZENITH GOLDLINE	0.25MG	N85207 001
@	ZENITH LABS	0.1MG	N11185 001
@	ZENITH LABS	0.25MG	N11185 002
@	ZENITH LABS	0.1MG	N11185 003
@	ZENITH LABS	0.25MG	N11185 004

RIFAMPIN

CAPSULE; ORAL  
**RIFAMPIN**

<u>AB</u>	EON	<u>300MG</u>	<u>N64150 001</u>
			MAY 28, 1997

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL  
REQUIP  
+ SMITHKLINE BEECHAM EQ 0.25MG BASE N20658 001 SEP 19, 1997  
EQ 0.5MG BASE N20658 002 SEP 19, 1997  
EQ 1MG BASE N20658 003 SEP 19, 1997  
EQ 2MG BASE N20658 004 SEP 19, 1997  
+ EQ 5MG BASE N20658 005 SEP 19, 1997

SALMETEROL XINAFOATE

POWDER; INHALATION SEREVENT  
+ GLAXO WELLCOME EQ 0.046MG BASE/INH N20692 001 SEP 19, 1997

SAMARIUM SM 153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION QUADRAMET CYTOGEN 50mCi/ML N20570 001 MAR 28, 1997

SAQUINAVIR

CAPSULE; ORAL FORTOVASE ROCHE EQ 200MG BASE N20828 001 NOV 07, 1997

SCOPOLAMINE

FILM, EXTENDED RELEASE; TRANSDERMAL TRANSDERM SCOP  
+ CIBA 0.5MG/24HR N17873 001  
NOVARTIS 1MG/72HR N17874 001

SECOBARBITAL SODIUM

CAPSULE; ORAL SECOBARBITAL SODIUM @ ZENITH GOLDLINE N85869 001	100MG	N85869 001
@ ZENITH LABS SODIUM SECOBARBITAL HALSEY @	100MG	N84676 001
	100MG	N84676 001

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL ELDEPRYL AB SOMERSET	5MG	N20647 001
+ +	5MG	MAY 15, 1996
		N20647 001
		MAY 15, 1996

TABLET; ORAL  
SELEGILINE HCL

AB ALPHAPHARM	5MG	N74866 001
AB APOTEX	5MG	N74871 001
AB APOTHECON	5MG	JUN 06, 1997
AB ENDO LABS	5MG	N74672 001
AB ENDO PHARMS	5MG	APR 01, 1997
AB TEVA	5MG	N74565 001
		AUG 02, 1996
		N74565 001
		AUG 02, 1996
		N74744 001
		JAN 27, 1997

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL SELENIUM SULFIDE > ADD > AT MORTON GROVE > ADD > 2.5%	N88228 001
> DLT > @ 2.5%	SEP 01, 1983
> DLT >	N88228 001
	SEP 01, 1983

SERMORELIN ACETATEINJECTABLE; INJECTION  
GEREF

+ SERONO

EQ 0.5MG BASE/VIAL

N20443 001

SEP 26, 1997

+

EQ 1MG BASE/VIAL

N20443 002

SEP 26, 1997

SODIUM IODIDE, I-131CAPSULE; ORAL  
IODOTOPE

BRACCO

8-100 uCi

1-130mCi

N10929 001

N10929 003

N10929 001

N10929 003

SIBUTRAMINE HYDROCHLORIDECAPSULE; ORAL  
MERIDIA

KNOLL PHARM

5MG

N20632 001

NOV 22, 1997

10MG

N20632 002

NOV 22, 1997

+

15MG

N20632 003

NOV 22, 1997

SODIUM NITROPRUSSIDEINJECTABLE; INJECTION  
NITROPRESS

AP ABBOTT

50MG/VIAL

N71555 001

NOV 16, 1987

N71555 001

NOV 16, 1987

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP ABBOTT

9MG/ML

N19465 002

JUL 15, 1985

SOMATROPIN, BIOSYNTHETICINJECTABLE; INJECTION  
NORDITROPIN

BX + NOVO NORDISK

4MG/VIAL

N19721 001

MAY 08, 1995

BX SEROSTIM

4MG/VIAL

N20604 003

JUL 25, 1997

SODIUM IODIDE, I-123

CAPSULE; ORAL

SODIUM IODIDE I-123

AA GOLDEN PHARMS

100 uCi

N18671 001

MAY 27, 1982

&gt; DLT &gt;

&gt; DLT &gt;

&gt; DLT &gt;

&gt; ADD &gt;

&gt; ADD &gt;

SOYBEAN OILINJECTABLE; INJECTION  
EMULSION 10%

AP \* BAXTER HEALTHCARE

10%

N18660 001

FEB 26, 1982

N18660 001

FEB 26, 1982

AA

200 uCi

N18671 002

MAY 27, 1982

&gt; DLT &gt;

&gt; DLT &gt;

&gt; ADD &gt;

&gt; ADD &gt;

@

400 uCi

N18671 003

MAY 27, 1982

SPIRONOLACTONETABLET; ORAL  
SPIRONOLACTONE

AB @ ZENITH GOLDLINE

25MG

N87108 001

N87108 001

AA

100 uCi

N17630 001

AA

NYCOMED AMERSHAM

N18671 001

AA

SYNCOR PHARMS

MAY 27, 1982

AA

200 uCi

N18671 002

@

400 uCi

MAY 27, 1982

AB ZENITH LABS

25MG

STRONTIUM CHLORIDE, SR-89

INJECTABLE; INJECTION

METASTRON

MEDI PHYSICS

1mCi/ML

N20134 001

JUN 18, 1993

NYCOMED AMERSHAM

1mCi/ML

N20134 001

JUN 18, 1993

SULFAMETHOXAZOLE

SUSPENSION; ORAL

GANTRIMIC

\* ROCHE

@

500MG/5ML

500MG/5ML

N13664 002

N13664 002

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP

ABBOTT

80MG/ML; 16MG/ML

N73199 001

SEP 11, 1992

AP

STERLING WINSTROP

80MG/ML; 16MG/ML

N73199 001

SEP 11, 1992

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

&gt; ADD &gt;

AB

HI TECH PHARMA

200MG/5ML; 40MG/5ML

N74650 001

DEC 29, 1997

SULFASALAZINE

TABLET; ORAL

SULFASALAZINE

&gt; DLT &gt;

AB

LEADER

500MG

N80197 001

500MG

SULFINPYRAZONE

CAPSULE; ORAL

SULFINPYRAZONE

AB

ZENITH GOLDLINE

200MG

N87770 001

NOV 19, 1992

ZENITH LABS

200MG

N87770 001

NOV 19, 1992

SULFINPYRAZONE

TABLET; ORAL

SULFINPYRAZONE

@ ZENITH GOLDLINE

100MG

N87769 001

JUN 01, 1992

N87769 001

JUN 01, 1992

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

AB PUREPAC PHARM

500MG

N80087 001

N80087 001

500MG

N80142 001

500MG

N80142 001

AB \* ZENITH LABS

500MG

SULFISOXAZOLE DIOLAMINE

SOLUTION/DROPS; OPHTHALMIC

GANTRISIN

\* ROCHE

EQ 4% BASE

N07757 002

N07757 002

@

EQ 4% BASE

SUMATRIPTAN

SPRAY; NASAL

IMITREX

+ GLAXO WELLCOME

5MG/SPRAY

N20626 001

AUG 26, 1997

+

10MG/SPRAY

N20626 002

AUG 26, 1997

+

20MG/SPRAY

N20626 003

AUG 26, 1997

+

&gt; ADD &gt;

TALC

&gt; ADD &gt; AEROSOL; INTRAPLEURAL

SCLERSOL

+ BRYAN

400MG/SPRAY

N20587 001

DEC 24, 1997

TAMOXIFEN CITRATE

TABLET; ORAL  
NOLVADEX  
\* ZENIGETIC  
EQ 10MG BASE  
EQ 10MG BASE

N17970 001  
N17970 001

TECHNETIUM TC-99M EXAMETAZIME KIT

INJECTABLE; INJECTION  
CERETEC  
NYCOMED AMERSHAM N/A

N19829 001  
DEC 30, 1988

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL  
FLOMAX  
+ BOEHRINGER INGELHEIM 0.4MG

N20579 001  
APR 15, 1997

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION  
AN-MDP  
CIS  
CIS-MDP  
CIS  
MDP-BRACCO  
BRACCO  
MDP-SQUIBB  
BRACCO  
TECHNETIUM TC 99M MPI MDP  
MEDI PHYSICS N/A  
NYCOMED AMERSHAM N/A

N18124 001  
N18124 001  
N18107 001  
N18107 001  
N18141 001  
N18141 001

TAZAROTENE

GEL; TOPICAL  
TAZORAC  
ALLERGAN  
0.05%  
+ 0.1%

N20600 001  
JUN 13, 1997  
N20600 002  
JUN 13, 1997

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION  
MPI DTPA KIT - CHELATE  
AP MEDI PHYSICS N/A  
AP NYCOMED AMERSHAM N/A  
TECHNETIUM TC-99M PENTETATE KIT  
AP MEDI PHYSICS N/A  
AP NYCOMED AMERSHAM N/A

N17255 001  
N17255 001  
N17264 002  
N17264 002

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION  
AN-MAX  
@ CIS N/A  
BS SORIN N/A

N17792 001  
N17792 001

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION  
AN-PYROTEC  
\* CIS N/A  
TECHNETIUM TC-99M PYROPHOSPHATE KIT  
AP CIS PYRO N/A  
AP CIS PYRO N/A

N19039 001  
JUN 30, 1987  
N19039 001  
JUN 30, 1987

TECHNETIUM TC-99M ALBUMIN KIT

INJECTABLE; INJECTION  
TECHNETIUM TC 99M HSA  
MEDI PHYSICS N/A  
NYCOMED AMERSHAM N/A

N17775 001  
N17775 001

TECHNETIUM TC-99M EXAMETAZIME KIT

INJECTABLE; INJECTION  
CERETEC  
AMERSHAM N/A

N19829 001  
DEC 30, 1988

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION  
MIRALUMA

DUPONT

N/A

N19785 003  
MAY 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL  
TECHNETIUM TC 99M GENERATOR

MEDII PHYSICS 830-16,600mCi/GENERATOR N17693 001  
NYCOMED AMERSHAM 830-16,600mCi/GENERATOR N17693 001

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE; INJECTION  
MPI DMSA KIDNEY REAGENT

MEDI PHYSICS N/A

N17944 001

MAY 18, 1982

NYCOMED AMERSHAM N/A

N17944 001

MAY 18, 1982

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION  
MYOVIEW

MEDI PHYSICS N/A

N20372 001

FEB 09, 1996

NYCOMED AMERSHAM N/A

N20372 001

FEB 09, 1996

TERBINAFINE HYDROCHLORIDE

SOLUTION; TOPICAL  
LAMISIL

+ NOVARTIS 1%

N20749 001

OCT 17, 1997

TERFENADINE

TABLET; ORAL  
SELDANE

AB + HOECHST MARION RSSL 60MG

N18949 001

MAY 08, 1985

TERFENADINE

TABLET; ORAL  
TERFENADINE

AB BAKER NORTON

60MG

N74475 001

JAN 03, 1997

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL  
ANDRODERM

BX + THERATECH 5MG/24HR

N20489 002

MAY 02, 1997

TESTODERM

BX + ALZA 5MG/24HR

N20791 001

DEC 18, 1997

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL  
TETRACYCLINE HCL

AB WARNER CHILCOTT 250MG

AB 500MG

@ 250MG

@ 500MG

N62300 001

N62300 002

N62300 001

N62300 002

INJECTABLE; INJECTION

ACHROMYCIN

AB LEDERLE 250MG/VIAL

AB 500MG/VIAL

N50273 002

N50273 003

TETRACYCIN

AB PELIZET 250MG/VIAL

AB 500MG/VIAL

N60091 001

N60096 002

@ 250MG/VIAL

@ 500MG/VIAL

N60096 001

N60096 002

SUSPENSION; ORAL

TETRACYCLINE HCL

AB ALPHARAC 125MG/5ML

AB 125MG/5ML

N60633 001

N60633 001

AB PUREPAC PHARM 125MG/5ML

AB 125MG/5ML

N60391 001

N60291 001

TETRACYCIN

AB PRIPHARMACECS 125MG/5ML

AB 125MG/5ML

N60393 001

N60095 001

TETRACYCLINE HYDROCHLORIDE

SUSPENSION; ORAL  
**TETRANED**  
 @ ZENITH GOLDLINE 125MG/5ML  
 AB ZENITH LABS 125MG/5ML

N61468 001  
 N61468 002

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION  
**THALLOUS CHLORIDE TL 201**  
 AP DUPONT 1mCi/ML  
 AP + 1mCi/ML  
 AP MALLEINCKRODT 1mCi/ML  
 AP + 1mCi/ML  
 AP \* MEDII PHYSICS 1mCi/ML  
 AP + NYCOMED AMERSHAM 1mCi/ML

N17806 001  
 N17806 001  
 N18150 001  
 N18150 001  
 FEB 27, 1996  
 N18110 002  
 FEB 27, 1996

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL  
**SOMOPHYLLIN-CRT**  
 @ GRAHAM DM 200MG  
 @ 250MG  
 @ 300MG

N88382 001  
 FEB 27, 1985  
 N87193 001  
 N88383 001  
 FEB 27, 1985

THEO-24

> ADD >	BC	UCB	100MG
> ADD >	BC		200MG
> ADD >	BC		300MG
> ADD >	BC		400MG
> ADD >	BC	WHITEY	100MG
> DLT >	BC		200MG
> DLT >	BC		300MG
> DLT >	BC		400MG
> DLT >	BC		400MG
> DLT >	BC		400MG

N87942 001  
 AUG 22, 1983  
 N87943 001  
 AUG 22, 1983  
 N87944 001  
 AUG 22, 1983  
 N81034 001  
 FEB 28, 1992  
 N87942 001  
 AUG 22, 1983  
 N87943 001  
 AUG 22, 1983  
 N87944 001  
 AUG 22, 1983  
 N81034 001  
 FEB 28, 1992

THEOPHYLLINE

CAPSULE, ORAL  
**BRONKODYL**  
 BP STERLING WINSTROP 100MG  
 BP 200MG  
 @ 100MG  
 @ 200MG  
**THEOPHYLLINE**  
 BP KV PHARM 100MG  
 BP 200MG  
 @ 100MG  
 @ 200MG  
 CAPSULE, EXTENDED RELEASE; ORAL  
**SOMOPHYLLIN-CRT**  
 BC GRAHAM DM 50MG  
 BC 100MG  
 BC 200MG  
 BC 250MG  
 BC 300MG  
 @ 50MG  
 @ 100MG

N85264 001  
 N85264 002  
 N85264 001  
 N85264 002  
 N85263 001  
 N85263 002  
 N85263 001  
 N85263 002  
 N87763 001  
 FEB 27, 1985  
 N87194 001  
 N88382 001  
 FEB 27, 1985  
 N87193 001  
 N88383 001  
 FEB 27, 1985  
 N87763 001  
 FEB 27, 1985  
 N87194 001

@ SCHERRING

@	50MG
@	75MG
@	125MG
@	200MG

N88022 001  
 SEP 10, 1985  
 N88015 001  
 SEP 10, 1985  
 N88016 001  
 SEP 10, 1985  
 N87995 001  
 SEP 10, 1985  
 N88022 001  
 SEP 10, 1985  
 N88015 001  
 SEP 10, 1985  
 N88016 001  
 SEP 10, 1985  
 N87995 001  
 SEP 10, 1985

THIAMINE HYDROCHLORIDEINJECTABLE; INJECTION  
THIAMINE HCL

<u>AP</u>	ABBOTT	<u>100MG/ML</u>	N40079 001 MAY 03, 1996
<u>AP</u>	SANOFI WINTHROP	<u>100MG/ML</u>	N40079 001 MAY 03, 1996
<u>AP</u>	STERIS	<u>100MG/ML</u> <u>200MG/ML</u>	N83534 001 N83534 002
@		<u>100MG/ML</u>	N83534 001
@		<u>200MG/ML</u>	N83534 002

THIORIDAZINE HYDROCHLORIDECONCENTRATE; ORAL  
THIORIDAZINE HCL

<u>AA</u>	PHARM ASSOC	<u>30MG/ML</u>	N40187 001 AUG 28, 1997
-----------	-------------	----------------	----------------------------

THIOTHIXENE HYDROCHLORIDEINJECTABLE; INJECTION  
NAVANE

> DLT >	* ROERIG	<u>EQ 2MG BASE/ML</u>	N16904 001
> DLT >		<u>EQ 10MG BASE/VIAL</u>	N16904 002
> ADD >	@	<u>EQ 2MG BASE/ML</u>	N16904 001
> ADD >	+	<u>EQ 10MG BASE/VIAL</u>	N16904 002

THYROTROPININJECTABLE; INJECTION  
THYTOPAR

*	ARMOUR PHARM	<u>10 IU/VIAL</u>	N08682 001
@	RHONE POULENC	<u>10 IU/VIAL</u>	N08682 001

TIAGABINE HYDROCHLORIDETABLET; ORAL  
GABITRIL  
ABBOTT

4MG	N20646 001 SEP 30, 1997
12MG	N20646 002 SEP 30, 1997

TIAGABINE HYDROCHLORIDETABLET; ORAL  
GABITRIL  
ABBOTT

16MG
20MG

N20646 003  
SEP 30, 1997  
N20646 004  
SEP 30, 1997TILUDRONATE DISODIUMTABLET; ORAL  
SKELID  
+ SANOFI

EQ 200MG BASE
N20707 001 MAR 07, 1997

TIMOLOLSOLUTION/DROPS; OPHTHALMIC  
BETIMOL

* MIRAS	<u>EQ 0.25% BASE</u>	N20439 001 MAR 31, 1995
	<u>EQ 0.5% BASE</u>	N20439 002 MAR 31, 1995
+ OY STAR	<u>EQ 0.25% BASE</u>	N20439 001 MAR 31, 1995
+	<u>EQ 0.5% BASE</u>	N20439 002 MAR 31, 1995

TIMOLOL MALEATESOLUTION/DROPS; OPHTHALMIC  
TIMOLOL MALEATE

AT	ADV REMEDIES	<u>EQ 0.25% BASE</u>	N74465 001 MAR 25, 1997
AT		<u>EQ 0.5% BASE</u>	N74466 001 MAR 25, 1997
AT	AKORN	<u>EQ 0.25% BASE</u>	N74515 001 MAR 25, 1997
AT		<u>EQ 0.5% BASE</u>	N74516 001 MAR 25, 1997
AT	BAUSCH AND LOMB	<u>EQ 0.25% BASE</u>	N74778 001 MAR 25, 1997
AT		<u>EQ 0.5% BASE</u>	N74776 001 MAR 25, 1997

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

<u>AT</u>	FOUGERA	<u>EQ 0.25% BASE</u>	N74667 001 MAR 25, 1997
<u>AT</u>		<u>EQ 0.5% BASE</u>	N74668 001 MAR 25, 1997
<u>AT</u>	PACIFIC PHARMA	<u>EQ 0.25% BASE</u>	N74746 001 MAR 25, 1997
<u>AT</u>		<u>EQ 0.5% BASE</u>	N74747 001 MAR 25, 1997

TOLMETIN SODIUM

TABLET; ORAL

TOLMETIN SODIUM

<u>AB</u>	BAKER NORTON	<u>EQ 600MG BASE</u>	N74399 001 MAR 28, 1996
<u>AB</u>	LEMON	<u>EQ 600MG BASE</u>	N74729 001 FEB 27, 1997
@	TEVA	EQ 600MG BASE	N74729 001 FEB 27, 1997
<u>AB</u>	ZENITH GOLDLINE	<u>EQ 600MG BASE</u>	N74399 001 MAR 28, 1996

TIOCONAZOLECINTMENT; VAGINAL  
VAGISTAT-1

\* BRISTOL MYERS

6.5%

N19355 001  
DEC 30, 1996TOPIRAMATE

TABLET; ORAL

TOPAMAX

@ JOHNSON RW

400MG

N20505 006  
DEC 24, 1996TIOPRONINTABLET; ORAL  
TIOPRONIN

+ MISSION PHARMA

100MG

N19569 001

AUG 11, 1988

\* UNIV TX

100MG

N19569 001

AUG 11, 1988

TOREMIFENE CITRATE

TABLET; ORAL

FARESTON

+ ORION

EQ 60MG BASE

N20497 001  
MAY 29, 1997TOBRAMYCIN> ADD > SOLUTION; INHALATION> ADD > TOBI> ADD > + PATHOGENESIS

300MG/5ML

N50753 001

DEC 22, 1997

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HCLAB TEVA

150MG

N74357 001  
APR 30, 1997TOLETAMIDE

TABLET; ORAL

TOLETAMIDE

AB PURIFAC PHARM

500MG

N88950 001

JUN 17, 1985

@

500MG

N88950 001

JUN 17, 1985

TRETINOIN

CREAM; TOPICAL

AVITA

> <u>DLT</u> >	<u>AB</u>	<u>PENEDEX</u>	<u>0.025%</u>
> <u>DLT</u> >			
> <u>ADD</u> >	<u>AB</u>	+	<u>0.025%</u>
> <u>ADD</u> >			
> <u>ADD</u> >			
> <u>DLT</u> >			
> <u>DLT</u> >			
> <u>DLT</u> >			

N20404 003  
JAN 14, 1997N20404 003  
JAN 14, 1997N19963 001  
DEC 29, 1995

TRETINOIN

CREAM; TOPICAL  
RENOVA  
> ADD > + J AND J 0.05%  
> ADD >  
RETIN-A  
AB + J AND J 0.025%  
GEL; TOPICAL  
RETIN-A MICRO  
+ ADV POLYMER 0.1%

N19963 001  
DEC 29, 1995  
N19049 001  
SEP 16, 1988  
N20475 001  
FEB 07, 1997

TRIAMCINOLONE

TABLET; ORAL  
TRIAMCINOLONE  
BP PUREPAC PHARM 2MG  
BP 4MG  
@ 2MG  
@ 4MG  
@ ZENITH GOLDLINE 4MG  
BP ZENITH LABS 4MG

N84020 002  
N84020 003  
N84020 002  
N84020 003  
N83750 001  
N83750 001

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL  
TRIAMCINOLONE ACETONIDE  
AT TARO 0.1%  
LOTION; TOPICAL  
TRIAMCINOLONE ACETONIDE  
AT ALZPHARMA 0.1%  
@ 0.1%

N40039 001  
NOV 26, 1997  
N87192 001  
SEP 08, 1982  
N87192 001  
SEP 08, 1982

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION  
TRIAMCINOLONE DIACETATE  
BP STERIS 40MG/ML  
@ 40MG/ML

N85529 001  
N85529 001

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL  
TRIFLUOPERAZINE HCL  
AB MYLAN EQ 1MG BASE  
AB EQ 2MG BASE  
AB EQ 5MG BASE  
AB EQ 10MG BASE

N40209 001  
JUL 07, 1997  
N40209 002  
JUL 07, 1997  
N40209 003  
JUL 07, 1997  
N40209 004  
JUL 07, 1997

TRIHEXYPHENIDYL HYDROCHLORIDE

CAPSULE; EXTENDED RELEASE; ORAL  
ARTANE  
\* LEDERLE 5MG  
@ 5MG  
ELIXIR; ORAL  
TRIHEXYPHENIDYL HCL  
AA PHARM ASSOC 2MG/5ML

N12947 001  
N12947 001  
N40177 001  
APR 17, 1997

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION  
TRIMETHOBENZAMIDE HCL  
AP ABBOTT 100MG/ML  
> DLT > AB SOLOPAK 100MG/ML  
> DLT > @ 100MG/ML  
> ADD > @ 100MG/ML  
> ADD > AB STERLING WINTHROP 100MG/ML

N88804 001  
APR 03, 1987  
N88804 001  
APR 14, 1986  
N89094 001  
APR 04, 1986  
N88804 001  
APR 01, 1987

TRIMETHOPRIM

TABLET; ORAL  
PROLOPRIM  
AB GLAXO WELLCOME 200MG  
AB + 200MG

N17943 003  
JUL 14, 1982  
N17943 003  
JUL 14, 1982

## **TRIMETHOPRIM**

**TABLET; ORAL  
TRIMEPER 200**

## **TROGLITTAZONE**

TABLET; ORAL		
<u>PRELAY</u>		
<u>AB</u>	SANKYO	<u>200MG</u>
<u>AB</u>		<u>300MG</u>
<u>AB</u>		<u>400MG</u>
<u>REZULIN</u>		
<u>AB</u>	PARKE DAVIS	<u>200MG</u>
<u>AB</u>		<u>300MG</u>
<u>AB</u>		<u>400MG</u>

> ADD > TROVAFLOXACIN MESYLATE

> ADD > TABLET; ORAL  
> ADD > TROVAN  
> ADD > PFIZER EQ 100MG TAB  
> ADD >  
> ADD > + EQ 200MG TAB  
> ADD >

UREA, C-14

CAPSULE; ORAL  
PYTEST  
+ TRI MED SPECLTS 1 uCi  
  
PYTEST KIT  
+ TRI MED SPECLTS 1 uCi

## **URSODIOL**

> ADD > TABLET; ORAL  
> ADD > URSO  
N17952 002 > ADD > + AXCAN 250MG  
NOV 09 1982 > ADD >  
N17952 002 NOV 09 1982

## VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION			
<u>LYPROCIN</u>			
<u>AP</u>	<u>FUJISAWA</u>	<u>EQ 500MG BASE/VIAL</u>	N62663 001 MAR 17, 1987
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	N62663 002 JUL 31, 1987
<u>AP</u>		<u>EQ 5GM BASE/VIAL</u>	N62663 003 JUN 03, 1988
VANCOCIN HCL IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE		<u>EQ 500MG BASE/100ML</u>	N50671 001 APR 29, 1993
*	<u>ELI LILLY</u>	<u>EQ 500MG BASE/100ML</u>	N50671 001 APR 29, 1993
<u>VANCOLED</u>			
<u>AP</u>	<u>FEDERICK</u>	<u>EQ 500MG BASE/VIAL</u>	N62682 001 JUL 22, 1986
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	N62682 001 JUL 22, 1986
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	N62682 002 MAR 30, 1988
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	N62682 002 MAR 30, 1988
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	N62682 005 MAY 11, 1988
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	N62682 005 MAY 11, 1988
<u>VANCOMYCIN HCL</u>			
<u>AP</u>	<u>FUJISAWA</u>	<u>EQ 500MG BASE/VIAL</u>	N62663 001 MAR 17, 1987
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	N62663 002 JUL 31, 1987
<u>AP</u>		<u>EQ 5GM BASE/VIAL</u>	N62663 003 JUN 03, 1988
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	N62663 004 NOV 28, 1997

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
EFFEXOR XR  
+ WYETH AYERST EQ 37.5MG BASE  
+ EQ 75MG BASE  
@ EQ 100MG BASE  
+ EQ 150MG BASE

N20699 001  
OCT 20, 1997  
N20699 002  
OCT 20, 1997  
N20699 003  
OCT 20, 1997  
N20699 004  
OCT 20, 1997

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCRINE

AP # BRISTOL MYERS 5MG/VIAL  
@ BRISTOL MYERS SQUIBB 5MG/VIAL  
AP VINCRISTINE SULFATE  
FAURNDING 5MG/VIAL  
+ 5MG/VIAL

N70867 001  
JUL 12, 1988  
N70867 001  
JUL 12, 1988  
N71561 001  
APR 11, 1988  
N71561 001  
APR 11, 1988

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HCL  
AP ABBOTT 2.5MG/ML  
> DLT > AB SOLOPAK 2.5MG/ML  
> DLT > @ 2.5MG/ML  
> ADD > @ 2.5MG/ML  
AB STERLING WINTHROP 2.5MG/ML

N70577 001  
FEB 02, 1987  
N70695 001  
JUL 31, 1987  
N70695 001  
JUL 31, 1987  
N70577 001  
FEB 02, 1987

VITAMIN A PALMITATE

CAPSULE; ORAL  
VITAMIN A  
@ ZENITH GOLDLINE  
@ ZENITH LABS

EQ 50,000 UNITS BASE  
EQ 50,000 UNITS BASE  
EQ 50,000 UNITS BASE  
EQ 50,000 UNITS BASE

N83035 001  
N83190 001  
N83035 001  
N83190 001

TABLET, EXTENDED RELEASE; ORAL

ISOPTIN SR  
AB + KNOLL PHARM 120MG  
VERAPAMIL HCL  
AB BAKER NORTON 180MG  
AB 240MG  
AB MYLAN 120MG  
AB 180MG  
AB ZENITH GOLDLINE 120MG  
AB 180MG  
AB 240MG

N19152 003  
MAR 06, 1991  
N74330 001  
JAN 31, 1994  
N73568 001  
JUL 31, 1992  
N74587 002  
FEB 21, 1997  
N74587 003  
SEP 09, 1997  
N73568 002  
OCT 10, 1997  
N74330 001  
JAN 31, 1994  
N73568 001  
JUL 31, 1992

WARFARIN SODIUMTABLET; ORAL  
COUMADIN

AB DUPONT MERCK 1MG  
AB + 2MG  
AB 2.5MG  
AB 4MG  
AB 5MG  
AB 7.5MG  
AB + 10MG  
AB WARFARIN SODIUM  
BARR 1MG  
AB 2MG  
AB 2.5MG  
AB 4MG  
AB 5MG

N09218 022  
MAR 01, 1990  
N09218 013  
N09218 018  
N09218 023  
AUG 24, 1993  
N09218 007  
N09218 016  
N09218 005  
N40145 001  
MAR 26, 1997  
N40145 002  
MAR 26, 1997  
N40145 003  
MAR 26, 1997  
N40145 004  
MAR 26, 1997  
N40145 005  
MAR 26, 1997

WARFARIN SODIUMTABLET; ORAL  
WARFARIN SODIUM

<u>AB</u>	BARR	<u>7.5MG</u>	N40145 006 MAR 26, 1997
<u>AB</u>		<u>10MG</u>	N40145 007 MAR 26, 1997
<u>AB</u>	INVAMED	<u>1MG</u>	N40196 001 SEP 30, 1997
<u>AB</u>		<u>2MG</u>	N40196 002 SEP 30, 1997
<u>AB</u>		<u>2.5MG</u>	N40196 003 SEP 30, 1997
<u>AB</u>		<u>4MG</u>	N40196 004 SEP 30, 1997
<u>AB</u>		<u>5MG</u>	N40196 005 SEP 30, 1997
<u>AB</u>		<u>7.5MG</u>	N40196 006 SEP 30, 1997
<u>AB</u>		<u>10MG</u>	N40196 007 SEP 30, 1997

ZINC ACETATECAPSULE; ORAL  
GALZIN  
TEVA

	EQ 25MG ZINC	N20458 001 JAN 28, 1997
+	EQ 50MG ZINC	N20458 002 JAN 28, 1997

ZOLMITRIPTANTABLET; ORAL  
ZOMIG  
ZENECA

	2.5MG	N20768 001 NOV 25, 1997
+	5MG	N20768 002 NOV 25, 1997

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL DYNA-HEX XTTRIUM	0.75%	N20111 001 SEP 11, 1997
TINCTURE; TOPICAL HIBITANE @ ZENECA	0.5%	N18049 001

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL CHLORPHENIRAMINE MALEATE GENEVA PHARMS	12MG	N70797 001 AUG 12, 1988
+	12MG	N70797 001 AUG 12, 1988
TELDRIN SMITHKLINE	12MG	N17369 002
@	12MG	N17369 002

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL COLE CAPSULE IV + GRAHAM DM	12MG; 75MG	N18793 001 APR 25, 1985
@	12MG; 75MG	N18793 001 APR 25, 1985
COLE CAPSULE V GRAHAM DM	8MG; 75MG	N18794 001 APR 23, 1985
@	8MG; 75MG	N18794 001 APR 23, 1985

TABLET, EXTENDED RELEASE; ORAL CONTAC NOVARTIS	12MG; 75MG	N19613 001 JUN 13, 1986
PHENYLPROPANOLAMINE HCl / CHLORPHENIRAMINE SANDOZ	12MG; 75MG	N19613 001

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL CODEMA L.A. 12 * GENI PHARMS	12MG; 120MG	N19945 001 APR 15, 1985
@ SCHWARZ PHARMA	12MG; 120MG	N18935 001 APR 15, 1985
PSEUDOEPHEDRINE HCl AND CHLORPHENIRAMINE MALEATE KV PHARM	12MG; 120MG	N73455 001 MAR 01, 1989
@	12MG; 120MG	N71455 001 MAR 01, 1989

CIMETIDINE

TABLET; ORAL TAGAMET HB SMITHKLINE BECKMAN	100MG	N19238 001 JUN 19, 1995
@	100MG	N20238 001 JUN 19, 1995

CLEMASTINE FUMARATE

TABLET; ORAL CLEMASTINE FUMARATE LEMON	1.34MG	N73282 002 DEC 03, 1992
TEVA	1.34MG	N73282 002 DEC 03, 1992

CLOTRIMAZOLE

CREAM; TOPICAL LOTRIMIN AF * SCHERING PLough	1%	N17619 002 OCT 27, 1989
+	1%	N20888 001 OCT 27, 1989
CREAM SUPPOSITORY, TOPICAL VAGINAL CYNE-LOTRIMIN 1 COMBINATION PACK * SCHERING PLough	1.200MG	N20526 002 JUL 29, 1996

CLOTRIMAZOLE

CREAM, SUPPOSITORY, TOPICAL, VAGINAL GYNE-LOTRIMIN COMBINATION PACK		
* SCHERING PLOUGH	1%, 100MG	N20289 002
		APR 26, 1993
MYCELEX-7 COMBINATION PACK BAYER	1%, 100MG	N20189 002
		JUN 23, 1994
CREAM, TABLET; TOPICAL, VAGINAL GYNE-LOTRIMIN 3 COMBINATION PACK		
+ SCHERING PLOUGH	1%, 200MG	N20526 002
		JUL 29, 1996
GYNE-LOTRIMIN COMBINATION PACK		
+ SCHERING PLOUGH	1%, 100MG	N20289 002
		APR 26, 1993
MYCELEX-7 COMBINATION PACK BAYER	1%, 100MG	N20389 002
		JUN 23, 1994
LOTION; TOPICAL LOTRIMIN AF		
* SCHERING	1%	N18813 002
		OCT 27, 1989
+ SCHERING PLOUGH	1%	N20889 001
		OCT 27, 1989
SOLUTION; TOPICAL LOTRIMIN AF		
* SCHERING PLOUGH	1%	N17613 002
		OCT 27, 1989
+	1%	N20890 001
		OCT 27, 1989
SUPPOSITORY; VAGINAL GYNE-LOTRIMIN		
* SCHERING PLOUGH	100MG	N17717 002
		NOV 30, 1990
GYNE-LOTRIMIN 3		
* SCHERING PLOUGH	200MG	N20525 002
		JUL 29, 1996
MYCELEX-7 BAYER	100MG	N18182 002
		DEC 26, 1993
TABLET; VAGINAL GYNE-LOTRIMIN		
+ SCHERING PLOUGH	100MG	N17717 002
		NOV 30, 1990

CLOTRIMAZOLE

TABLET; VAGINAL GYNE-LOTRIMIN 3			
+ SCHERING PLOUGH	200MG	N20525 001	
		JUL 29, 1996	
MYCELEX-7			
BAYER	100MG	N18182 002	
		DEC 26, 1991	

CROMOLYN SODIUM

SPRAY, METERED; NASAL NASALCROM			
+ PHARMACIA AND UPJOHN	5.2MG/SPRAY	N20463 001	
		JAN 03, 1997	

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL BENYLIN			
* PARKE DAVIS	12.5MG/5ML; 30MG/5ML	N19014 001	
@	12.5MG/5ML; 30MG/5ML	JUN 11, 1985	
		N19014 001	
		JUN 11, 1985	

IBUPROFEN

CAPSULE; ORAL PROVEL			
* SANDOZ	200MG	N20402 001	
		APR 24, 1995	

SUSPENSION; ORAL CHILDREN'S ADVIL-FLAVORED			
+ WHITEHALL ROBINS	100MG/5ML	N20589 002	
		NOV 07, 1997	

TABLET; ORAL IBUPROFEN			
* PUREPAC PHARM	200MG	N71122 001	
		OCT 03, 1986	
		N71122 001	
		FEB 03, 1987	
		N71122 001	
		OCT 03, 1986	

@	200MG	
---	-------	--

## OTC DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'97 - DEC'97

87

IBUPROFEN

TABLET; ORAL  
 IBUPROFEN  
 @ PUREPAC PHARM 200MG N71664 001  
 FEB 03, 1987  
 @ ZENITH GOLDLINE 200MG N71154 001  
 OCT 27, 1987  
 @ 200MG N72040 001  
 APR 29, 1988  
 @ ~~ZENITH LABS~~ 200MG N71154 001  
 OCT 27, 1987  
 @ 200MG N72040 001  
 APR 29, 1988  
 JUNIOR STRENGTH MOTRIN  
~~MCNEIL~~ 100MG N20602 001  
 JUN 10, 1996  
 + 100MG N20602 001  
 JUN 10, 1996  
 NUPRIN  
 @ MCNEIL 200MG N19012 001  
 MAY 18, 1984  
 @ 200MG N19012 003  
 JUL 29, 1987  
 @ PHARMACIA AND UPJOHN 200MG N19012 001  
 MAY 18, 1984  
 @ 200MG N19012 003  
 JUL 29, 1987

IBUPROFEN POTASSIUM

CAPSULE; ORAL  
 PROVEL  
 @ NOVARTIS 200MG N20402 001  
 APR 20, 1995

INSULIN SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION  
 VELOSULIN BR HUMAN  
 + NOVO NORDISK 100 UNITS/ML N19450 001  
 MAY 30, 1986  
~~VELOSULIN HUMAN~~  
~~+ NOVO NORDISK~~ 100 UNITS/ML N19450 001  
 MAY 30, 1986

KETOCONAZOLE

SHAMPOO; TOPICAL  
 NIZORAL A-D  
 J AND J 1%  
 N20310 001  
 OCT 10, 1997

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL  
 LOPERAMIDE HCL  
 DURAMED 1MG/5ML  
 MORTON GROVE 1MG/5ML  
 > ADD >  
 > ADD >

TABLET, CHEWABLE; ORAL  
 IMODIUM A-D  
 + MCNEIL 2MG  
 N20448 001  
 JUL 24, 1997

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE; ORAL  
 IMODIUM ADVANCED  
 + MCNEIL 2MG;125MG  
 N20606 001  
 JUN 26, 1996

MICONAZOLE NITRATE

CREAM; VAGINAL  
 MICONAZOLE NITRATE  
 PERRIGO 2%  
 TARO 2%  
 N74760 001  
 MAY 15, 1997  
 N74444 001  
 JAN 13, 1997

CREAM, SUPPOSITORY; TOPICAL, VAGINAL  
 M-ZOLE 7 DUAL PACK  
 ALPHARMA 2%,100MG  
 N74586 001  
 JUL 17, 1997

SUPPOSITORY; VAGINAL  
 MICONAZOLE NITRATE  
 G AND W LABS 100MG  
 N74414 001  
 APR 30, 1997

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL  
MICONAZOLE NITRATE  
+ PERRIGO 100MG  
N74395 001  
MAR 20, 1997

MINOXIDIL

SOLUTION; TOPICAL  
MINOXIDIL (FOR MEN)  
MORTON GROVE 2%  
N74767 001  
FEB 28, 1997

ROGAINE EXTRA STRENGTH (FOR MEN)  
+ PHARMACIA AND UPJOHN 5%  
N20834 001  
NOV 14, 1997

NAPROXEN SODIUM

TABLET; ORAL  
NAPROXEN SODIUM  
GRANUTEC EQ 200MG BASE  
INVAMED EQ 200MG BASE  
NOVOPHARM EQ 200MG BASE  
PERRIGO EQ 200MG BASE  
PVT FORM EQ 200MG BASE  
N74635 001  
JAN 13, 1997  
N74646 001  
JAN 13, 1997  
N74635 001  
JAN 13, 1997  
N74661 001  
JAN 13, 1997  
N74789 001  
FEB 27, 1997

PERMETHRIN

LOTION; TOPICAL  
NIX  
+ WARNER LAMBERT 1%  
N19918 001  
MAY 02, 1990  
N19918 001  
MAY 02, 1990

PSEUDOEPHENDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE; EXTENDED RELEASE; ORAL  
TRIPROLIDINE AND PSEUDOEPHENDRINE HYDROCHLORIDES  
KV PHARM 120MG;5MG  
N71798 001  
MAR 16, 1989  
@ 120MG;5MG  
N71798 001  
MAR 16, 1989

SODIUM FLUORIDE; TRICLOSAN

PASTE; DENTAL  
COLGATE TOTAL  
+ COLGATE PALMOLIVE 0.24%;0.3%  
N20231 001  
JUL 11, 1997

TIOCONAZOLE

OINTMENT; VAGINAL  
VAGISTAT-1  
+ BRISTOL MYERS SQUIBB 6.5%  
N20676 001  
FEB 11, 1997

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE  
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 12/ DECEMBER '97**

**NO DECEMBER 1997 APPROVALS**

**This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.**

**Orphan Product Designations and Approvals List  
January 1997 through December 1997**

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
15AU81 TN=	Treatment of primary pulmonary hypertension.	Lung Rx, Inc. 2 Davis Drive P.O. Box 13169 Research Triangle Park, NC 27709 DD=06/04/1997
8 Cyclopentyl 1,3-dipropylxanthine TN=	Treatment of cystic fibrosis.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Boulevard Suite 315 San Mateo, CA 94404 DD=03/24/1997
9-cis-retinoic acid TN=	Prevention of retinal detachment due to proliferative vitreoretinopathy.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine, CA 92623 DD=01/02/1997
Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture TN= CYTOIMPLANT	Treatment of pancreatic cancer.	Applied Immunotherapeutics, LLC 14132 E. Firestone Boulevard Santa Fe Springs, CA 90670 DD=06/13/1997
Alpha-melanocyte stimulating hormone TN=	Prevention and treatment of intrinsic acute renal failure due to ischemia.	Star, Robert A., M.D. UT-Southwestern Medical School 5323 Harry Hines Dallas, TX 75235 DD=08/19/1997

**Orphan Product Designations and Approvals List**  
**January 1997 through December 1997**

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Anagrelide TN= Agrylin	Treatment of essential thrombocythemia.	Roberts Pharmaceutical Corp. Meridian Center III 6 Industrial Way West Eatontown, NJ 07724 DD=01/27/1988 MA=03/14/1997
Ancrod TN=	To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.	Knoll Pharmaceuticals 30 North Jefferson Road Whippany, NJ 07981 DD=11/12/1997
Apomorphine TN= Zydis	For use as rescue treatment for early morning motor dysfunction in late-stage Parkinson's disease.	Scherer DDS Frankland Road Swindon SN5 8RU Wiltshire UK DD=10/20/1997
B2036-PEG TN= Trovert	Treatment of acromegaly.	Sensus Corporation Suite 430, 98 San Jacinto Boulevard Austin, TX 78701 DD=06/24/1997
Basiliximab TN= Simulect	Prophylaxis of solid organ rejection.	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=12/12/1997
Beta alethine TN= Betathine	Treatment of multiple myeloma.	Dovetail Technologies, Inc. Bldg. 337, Paint Branch Drive College Park, MD 20742 DD=03/24/1997

**Orphan Product Designations and Approvals List**  
**January 1997 through December 1997**

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Beta alethine TN= Betathine	Treatment of metastatic melanoma.	Dovetail Technologies, Inc. Bldg. 337, Paint Branch Drive College Park, MD 20742 DD=03/24/1997
Busulfan TN= Spartaject	Treatment of primary brain malignancies.	Sparta Pharmaceuticals, Inc. 111 Rock Road Horsham, PA 19044 DD=07/07/1997
CAMPATH-1H TN=	Treatment of chronic lymphocytic leukemia.	L&I Partners, LP 11550 IH 10 West, Suite 300 San Antonio, TX 78230 DD=10/20/1997
CDP571 TN=	Treatment of Crohn's disease.	Celltech Therapeutics Ltd. 216 Bath Road Slough SL1 4EN Berkshire UK DD=12/11/1997
CY-1503 TN= Cylexin	Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.	Cytel Corporation 3525 John Hopkins Court San Diego, CA 92121 DD=07/18/1997
Calcium gluconate TN= Calgonate	For use as a wash for hydrofluoric acid spills on human skin.	Calgonate Corp. 190 Commerce Drive Warwick, RI 02886 DD=11/20/1997
Chondrocyte-algi nate gel suspension TN=	For use in correcting vesicoureteral reflux in the pediatric population.	Reprogenesis, Inc. 800 Huntington Ave. Boston, MA 02115 DD=12/01/1997

**Orphan Product Designations and Approvals List**  
**January 1997 through December 1997**

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Coagulation Factor IX (recombinant) TN= BeneFix	Treatment of hemophilia B.	Genetics Institute, Inc. 87 Cambridge Park Drive Cambridge, MA 02140 DD=10/03/1994 MA=02/11/1997
Cysteamine hydrochloride TN=	Treatment of corneal cystine crystal accumulation in cystinosis patients.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue Gaithersburg, MD 20877 DD=08/19/1997
Daclizumab TN= Zenapax	Prevention of acute renal allograft rejection.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley, NJ 07110 DD=03/05/1993 MA=12/10/1997
Dehydroepiandrosterone sulfate sodium TN=	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City, UT 84109 DD=01/28/1997
Dehydroepiandrosterone sulfate sodium TN=	Treatment of serious burns requiring hospitalization.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City, UT 84109 DD=01/29/1997
Diazepam viscous solution for rectal administration TN=	For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity.	Athena Neurosciences, Inc. 800f Gateway Boulevard South San Francisco, CA 94080 DD=02/25/1992 MA=07/29/1997

**Orphan Product Designations and Approvals List**  
**January 1997 through December 1997**

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Dimethylsulfoxide e TN=	Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson, AZ 85710 DD=04/15/1997
Duramycin TN=	Treatment of cystic fibrosis.	MoliChem Medicines Inc. 2135 North Lakeshore Drive Chapel Hill, NC 27514 DD=12/11/1997
Enadoline hydrochloride TN=	Treatment of severe head injury.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor, MI 48105 DD=01/28/1997
Fampridine TN=	Treatment of chronic, incomplete spinal cord injury.	Acorda Therapeutics, Inc. 145 West 58th Street Suite 8J New York, NY 10019 DD=06/02/1997
Fomepizole TN= Antizole	Treatment of methanol or ethylene glycol poisoning.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka, MN 55305 DD=12/22/1988 MA=12/04/1997
Gp100 adenoviral gene therapy TN=	Treatment of metastatic melanoma.	Genzyme Corporation P.O. Box 9322 One Mountain Road Framingham, MA 01701 DD=03/25/1997

**Orphan Product Designations and Approvals List**  
**January 1997 through December 1997**

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Human retinal pigmented epithelial cells on collagen microcarriers TN= Spheramine	Treatment of Hoehn and Yahr stage 3 and 4 Parkinson's disease.	Theracell, Inc. 50 Division Street, Suite 503 Somerville, NJ 08876 DD=07/18/1997
Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution TN= Extraneal (with 7.5% Icodextrin) Peritoneal Dialysis Solutio	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Baxter Healthcare Corporation Renal Division 1620 Waukegan Road Waukegan, IL 60085 DD=07/18/1997
Lepirudin TN= Refluden	Treatment of heparin-associated thrombocytopenia Type II.	Behringwerke AG P.O. Box 1140 D-35001 Marburg Germany, DD=02/13/1997
Levocarnitine TN= Carnitor	Treatment of zidovudine-induced mitochondrial myopathy.	Sigma-Tau Pharmaceuticals, Inc. 800 S. Frederick Avenue, Suite 300 Gaithersburg, MD 20877 DD=04/07/1997
Liposomal amphotericin B TN= AmBisome	Treatment of cryptococcal meningitis.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield, IL 60015 DD=12/10/1996 MA=08/11/1997
Liposomal amphotericin B TN= AmBisome	Treatment of visceral leishmaniasis.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield, IL 60015 DD=12/06/1996 MA=08/11/1997

**Orphan Product Designations and Approvals List**  
**January 1997 through December 1997**

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Liposomal amphotericin B TN= AmBisome	Treatment of histoplasmosis.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield, IL 60015 DD=12/10/1996
MART-1 adenoviral gene therapy for malignant melanoma TN=	Treatment of metastatic melanoma.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=03/28/1997
Oprelvekin TN= Neumega	Prevention of severe chemotherapy-induced thrombocytopenia.	Genetics Institute, Inc. 87 Cambridge Park Drive Cambridge, MA 02140 DD=12/17/1996 MA=11/25/1997
Oxandrolone TN= Oxandrin	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Bio-Technology General Corp. 70 Wood Avenue South Iselin, NJ 08830 DD=04/22/1997
Paclitaxel TN= Taxol	Treatment of AIDS-related Kaposi's sarcoma.	Bristol-Myers Squibb Pharmaceutical Research Institute 5 Research Parkway P.O. Box 5100 Wallingford, CT 06492 DD=03/25/1997 MA=08/04/1997
Paclitaxel TN= Paxene	Treatment of AIDS-related Kaposi's sarcoma.	Baker Norton Pharmaceuticals, Inc. 4400 Biscayne Boulevard Miami, FL 33137 DD=04/15/1997

**Orphan Product Designations and Approvals List**  
**January 1997 through December 1997**

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Patul-end TN=	Treatment of patulous eustachian tube.	Ear Foundation 24209 Castillo Street, Suite 100 Santa Barbara, CA 93105 DD=02/18/1997
Pegylated recombinant human megakaryocyte growth and development factor TN= MEGAGEN	For reducing the period of thrombocytopenia in patients undergoing hematopoietic stem cell transplantation.	Amgen, Inc. 1840 DeHavilland Drive Thousand Oaks, CA 91320 DD=10/20/1997
Pergolide TN= Permax	Treatment of Tourette's syndrome.	Sallee, Floyd R. M.D., Ph.D. Medical University of South Carolina 171 Ashley Avenue, Room PH246 Charleston, SC 29425 DD=11/20/1997
Poloxamer 188 TN=	Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.	CytRx Corporation 154 Technology Parkway Norcross, GA 30092 DD=08/05/1997
Poly-ICLC TN=	Treatment of primary brain tumors.	Salazar, Andres M. M.D. and Levy, Hilton B. Ph.D. 3202 Cleveland Avenue N.W. Washington, DC 20008 DD=03/17/1997
Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural tissue TN= N-Graft	Treatment of Hoehn and Yahr stage four and five Parkinson's disease.	Theracell, Inc. 50 Division Street Suite 503 Somerville, NJ 08876 DD=06/24/1997

**Orphan Product Designations and Approvals List**  
**January 1997 through December 1997**

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Porfiromycin TN= Promycin	Treatment of cervical cancer.	Vion Pharmaceuticals, Inc. Four Science Park New Haven, CT 06511 DD=03/13/1997
Purified extract of Pseudomonas aeruginosa TN= ImmuDyn	Treatment of immune thrombocytopenia purpura where it is required to increase platelet counts.	DynaGen, Inc. 99 Erie Street Cambridge, MA 02139 DD=09/22/1997
RGG0853, E1A lipid complex TN=	Treatment of ovarian cancer.	Targeted Genetics Corporation 1100 Olive way, Suite 100 Seattle, WA 98101 DD=10/27/1997
Recombinant human acid alpha-glucosidas e TN=	Treatment of glycogen storage disease type II.	Chen, Y.T., M.D., Ph.D. Department of Pediatrics Duke University Medical Center Durham, NC 27710 DD=08/19/1997
Recombinant human alpha-L-iduronid ase TN=	Treatment of patients with mucopolysaccharidosis-I.	BioMarin Pharmaceuticals, Inc. 11 Pimental Court Novato, CA 94949 DD=09/24/1997
Recombinant human interleukin-12 TN=	Treatment of renal cell carcinoma.	Genetics Institute 87 CambridgePark Drive Cambridge, MA 02140 DD=10/20/1997
Recombinant human thrombopoietin TN=	For use in accelerating platelet recovery in patients undergoing hematopoietic stem cell transplantation.	Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 DD=09/29/1997

**Orphan Product Designations and Approvals List**  
**January 1997 through December 1997**

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Retroviral vector, R-GC and GC gene 1750 TN=	Treatment of Gaucher disease.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=05/06/1997
Rituximab TN= Rituxan	Treatment of non-Hodgkin's B-cell lymphoma.	IDEC Pharmaceuticals Corporation 3030 Callan Road San Diego, CA 92121 DD=06/13/1994 MA=11/26/1997
Sermorelin acetate TN= Geref	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	Serono Laboratories, Inc. 100 Longwater Circle Norwell, MA 02061 DD=09/14/1988 MA=09/26/1997
Short chain fatty acid enema proctitis. TN= Colomed	Treatment of chronic radiation	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka, MN 55305 DD=08/19/1997
Sodium dichloroacetate TN=	Treatment of congenital lactic acidosis.	Cypros Pharmaceutical Corporation 2714 Loker Avenue West Carlsbad, CA 92008 DD=12/31/1997
Somatropin TN= Genotropin	Treatment of adults with growth hormone deficiency.	Pharmacia & Upjohn 7000 Portage Road Kalamazoo, MI 49001 DD=09/06/1994 MA=10/31/1997
Somatropin for injection TN= Nutropin	As replacement therapy for growth hormone deficiency in adults after epiphyseal closure.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco, CA 94080 DD=11/18/1996 MA=12/15/1997

**Orphan Product Designations and Approvals List**  
**January 1997 through December 1997**

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Sterile aerosol talc TN=	Treatment of malignant pleural effusion.	Bryan Corporation 4 Plympton Street Woburn, MA 01801 DD=09/18/1995 MA=12/24/1997
Sterile talc TN= Steritalc	Treatment of malignant pleural effusion.	Novatech SA Avenue du Vent des Dames - Z.l. les Paluds 13685 Aubagne France, DD=12/08/1997
Sterile talc TN= Steritalc	Treatment of pneumothorax.	Novatech SA Avenue du Vent des Dames - Z.l. les Paluds 13685 Aubagne France, DD=12/08/1997
Suramin TN=	Treatment of hormone-refractory prostate cancer.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor, MI 48105 DD=05/06/1997
Testosterone TN= TheraDerm Testosterone Transdermal System	For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.	TheraTech, Inc. 417 Wakara Way Salt Lake City, UT 84108 DD=09/22/1997
Tetrabenazine TN=	Treatment of Huntington's disease.	Lifehealth Limited Richmond House, Old Brewery Court, Sandyford Road Newcastle upon Tyne NE2 1XG England, UK DD=12/11/1997

**Orphan Product Designations and Approvals List**  
**January 1997 through December 1997**

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Tobramycin for inhalation TN= TOBI	Treatment of bronchopulmonary infections of <i>Pseudomonas</i> <i>aeruginosa</i> in cystic fibrosis patients.	Pathogenesis Corporation 201 Elliott Avenue West, Suite 150 Seattle, WA 98119 DD=10/13/1994 MA=12/22/1997
Toremifene TN= Fareston	Hormonal therapy of metastatic carcinoma of the breast.	Orion Corporation P.O. Box 65 02101 ESPOO Finland, DD=09/19/1991 MA=05/29/1997
Urofollitropin TN= Fertinex	For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism.	Serono Laboratories, Inc. 100 Longwater Circle Norwell, MA 02061 DD=12/05/1997
Ursodiol TN= URSO	Treatment of patients with primary biliary cirrhosis.	Axcan Pharma Inc. 3881, Industriel boulevard Laval, Quebec H7L 4S3 Canada, DD=06/20/1991 MA=12/10/1997
Zinc acetate TN= Galzin	Treatment of Wilson's disease.	Lemmon Company 1510 Delp Drive Kulpsville, PA 19443 DD=11/06/1985 MA=01/28/1997

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY  
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

---

**NO DECEMBER 1997 ADDITIONS**

## PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 17TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

### REFERENCES *NEW DOSING SCHEDULE*

- D-33      ONCE DAILY DOSING FOR PLAQUE PSORIASIS**
- D-34      EVERY FOUR MONTHS DOSAGE REGIMEN**
- D-35      FOR A ONE WEEK DOSING PERIOD FOR INTERDIGITAL TINEA PEDIS**
- D-36      FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVE TWICE DAILY**
- D-37      DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)**

### *NEW INDICATION*

- I-177      TREATMENT OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15 YEARS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS**
- I-178      TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN**
- I-179      NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE**
- I-180      TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)**
- I-181      TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION**
- I-182      TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME**
- I-183      MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11**
- I-184      TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2 MG/DAY (MAXIMUM OF 4MG)**
- I-185      PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN**
- I-186      TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)**
- I-187      PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS**
- I-188      TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS**
- I-189      TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS**
- I-190      PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS**
- I-191      ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING**
- I-192      THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION**
- I-193      TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY**
- I-194      CONGESTIVE HEART FAILURE**
- I-195      USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER**

**PATENT AND EXCLUSIVITY TERMS**  
*NEW INDICATION*

- I-196 ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
- I-197 MAINTENANCE OF HEALING OF DUODENAL ULCER
- I-198 USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OF A ONE-YEAR HISTORY OF A DUODENAL ULCER
- I-199 MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
- I-200 TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
- I-201 EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
- I-202 SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
- I-203 MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
- I-204 USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
- I-205 INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS
- I-206 TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
- I-207 FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
- I-208 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION
- I-209 PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)
- I-210 TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS
- I-211 FOR USE IN THE PEDIATRIC POPULATION

*PATENT USE CODE*

- U-161 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
- U-162 METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
- U-163 METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
- U-164 METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
- U-165 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
- U-166 TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER
- U-167 METHOD FOR TREATING HIV-1 INFECTION
- U-168 METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA
- U-169 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING
- U-170 METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT
- U-171 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT
- U-172 TREATMENT OF GENITAL WARTS
- U-173 ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
- U-174 USE AS AN ANTIHISTAMINE AGENT
- U-175 METHOD OF TREATING MALIGNANT TUMORS
- U-176 METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSIS
- U-177 FUNGICIDE

**PATENT AND EXCLUSIVITY TERMS**  
**PATENT USE CODE**

- U-178 FACILITATED ADHERENCE OF AGENTS TO SKIN
- U-179 ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
- U-180 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
- U-181 PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
- U-182 USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
- U-183 TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION
- U-184 TREATING ALLERGIC EYE DISEASES IN HUMANS
- U-185 METHOD OF TREATING HYPERTENSION
- U-186 METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISSES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
- U-187 THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
- U-188 TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER
- U-189 ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
- U-190 USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
- U-191 METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
- U-192 USE IN TREATING ALLERGIC REACTIONS
- U-193 PSORIASIS
- U-194 TREATING AGINA PECTORIS AND HIGH BLOOD PRESSURE
- U-195 METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON
- U-196 TREATMENT OF METASTIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
- U-197 USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
- U-198 TREATMENT METASTATIC CARCINOMA OF OVARY AFTER FIRST-LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
- U-199 METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT
- U-200 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
- U-201 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
- U-202 METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS
- U-203 TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
- U-204 USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
- U-205 METHOD OF TREATING HEARTBURN
- U-206 METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENOUS LH, IN IN VITRO FERTILIZATION
- U-207 USE AS NASAL SPRAY
- U-208 VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION
- U-209 VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION

**PATENT AND EXCLUSIVITY TERMS**  
*PATENT USE CODE*

- U-210      METHOD OF TREATING CONGESTIVE HEART FAILURE**
- U-211      USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION**
- U-212      METHOD OF TREATMENT OF PARKINSON'S DISEASE**
- U-213      METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA  
AND METHOD FOR TREATING HYPERLIPIDEMIA**
- U-214      USE AS A BLOOD GLUCOSE-LOWERING AGENT**

**PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA**

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>						
020059 001	ADENOSINE;ADENOSCAN	5070877	MAY 18, 2009	U-116		
020760 001	ALATROFLOXACIN MESYLATE;TROVAN			NCE	DEC 18, 2002	
020899 001	ALBUMIN HUMAN;OPTISON	5603918	JUN 09, 2015	NP	DEC 31, 2000	
020291 001	ALBUTEROL SULFATE;COMBIVENT	5225183	JUL 06, 2010	NC	OCT 24, 1999	
020503 001	ALBUTEROL SULFATE;PROVENTIL-HFA	5439670	JUL 06, 2010	NP	AUG 15, 1999	
		5605674	FEB 25, 2014			
020560 001	ALENDRONATE SODIUM;FOSAMAX	4621077	AUG 06, 2007	U-114	I-185	APR 25, 2000
		5681590	DEC 02, 2012		I-187	APR 25, 2000
020560 002	ALENDRONATE SODIUM;FOSAMAX	4621077	AUG 06, 2007	U-114	I-185	APR 25, 2000
		5681590	DEC 02, 2012		I-187	APR 25, 2000
020560 003	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012	NS	APR 25, 2000	
		4621077	AUG 06, 2007	U-114	I-185	APR 25, 2000
		5681590	DEC 02, 2012		I-187	APR 25, 2000
				NCE	SEP 29, 2000	
020649 001	ALPROSTADIL;EDEX			NP	JUL 06, 1998	
020649 002	ALPROSTADIL;EDEX			NP	JUL 06, 1988	
020649 003	ALPROSTADIL;EDEX			NP	JUL 06, 1998	
020649 004	ALPROSTADIL;EDEX			NP	JUL 06, 1998	
020221 001	AMIFOSTINE;ETHYOL	5424471	JUL 31, 2012			
		5591731	JUL 31, 2012			
020333 001	ANAGRELIDE HYDROCHLORIDE;AGRYLIN			ODE	MAR 14, 2004	
020333 002	ANAGRELIDE HYDROCHLORIDE;AGRYLIN			NCE	MAR 14, 2002	
020541 001	ANASTROZOLE;ARIMIDEX	4935437	DEC 27, 2009		ODE	MAR 14, 2004
020420 001	ARBUTAMINE HYDROCHLORIDE;GENESA			NCE	SEP 12, 2002	
020227 002	ARDEPARIN SODIUM;NORMIFLO			NCE	MAY 23, 2002	
020702 001	ATORVASTATIN CALCIUM;LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
		5273995	DEC 28, 2010	U-162		
		5385929	MAY 04, 2014	U-59		
		5686104	NOV 11, 2014	U-213		
020702 002	ATORVASTATIN CALCIUM;LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
		5273995	DEC 28, 2010	U-162		
		5385929	MAY 04, 2014	U-59		
		5686104	NOV 11, 2014	U-213		
020702 003	ATORVASTATIN CALCIUM;LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
		5273995	DEC 28, 2010	U-162		
		5385929	MAY 04, 2014	U-59		
		5686104	NOV 11, 2014	U-213		
020114 001	AZELASTINE HYDROCHLORIDE;ASTELIN	5164194	NOV 17, 2009	U-207	NP	DEC 24, 1999
020486 001	BECLOMETHASONE DIPROPIONATE;VANCERIL DOUBLE STRENGTH					
020032 001	BERACTANT;SURVANTA	4397839	JUL 01, 2005			
020619 001	BETAXOLOL HYDROCHLORIDE;BETOPTIC PILO	5635172	JUN 03, 2014	U-191	NC	APR 17, 2000
020498 001	BICALUTAMIDE;CASODEX	4636505	OCT 01, 2008			
		4472382	SEP 18, 2001	U-197		
		5389613	SEP 18, 2001	U-197		
020490 001	BRIMONIDINE TARTRATE;ALPHAGAN			NP	MAR 13, 2000	
				NCE	SEP 06, 2001	

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020535 002	BROMFENAC SODIUM;DURACT					
	020441 002	BUDESONIDE;PULMICORT	4907583	MAR 13, 2007		NCE	JUL 15, 2002
			4524769	JUN 25, 2002		NCE	FEB 14, 1999
>ADD>	020441 003	BUDESONIDE;PULMICORT	4668218	APR 11, 2006			
			4907583	MAR 13, 2007			
			4524769	JUN 25, 2002		NCE	FEB 14, 1999
			4668218	APR 11, 2006			
	018644 001	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5358970	AUG 12, 2013			
	018644 002	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5358970	AUG 12, 2013			
	018644 003	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5358970	AUG 12, 2013			
	020711 002	BUPROPION HYDROCHLORIDE;ZYBAN	5358970	AUG 12, 2013		NP	MAY 14, 2000
			5427798	AUG 12, 2013			
			RE33994	AUG 18, 2004			
	020711 003	BUPROPION HYDROCHLORIDE;ZYBAN	5358970	AUG 12, 2013		NP	MAY 14, 2000
			5427798	AUG 12, 2013			
			RE33994	AUG 18, 2004			
	018731 003	BUSPIRONE HYDROCHLORIDE;BUSPAR	4215104	MAR 26, 1999			
	018731 004	BUSPIRONE HYDROCHLORIDE;BUSPAR	4258027	MAR 26, 1999			
			4215104	MAR 26, 1999			
			4258027	MAR 26, 1999			
	020524 001	BUTENAFINE HYDROCHLORIDE;MENTAX	5021458	JUN 04, 2008	U-177	D-35	NOV 25, 2000
	019881 001	BUTOCONAZOLE NITRATE;FENSTAT ONE	4078071	MAR 07, 1997		NP	FEB 07, 2000
	020664 001	CABERGOLINE;DOSTINEX	4526892	JUL 02, 2002		NCE	DEC 23, 2001
	020273 001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007		D-33	MAR 20, 2000
	020554 001	CALCIPOTRIENE;DOVONEX				NCE	DEC 29, 1998
	020611 001	CALCIPOTRIENE;DOVONEX	4866048	SEP 12, 2006		NCE	DEC 29, 1998
						NDF	MAR 03, 2000
	019880 001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
	019880 002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
	019880 003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
	020297 001	CARVEDILOL;COREG				I-194	MAY 29, 2000
	020297 002	CARVEDILOL;COREG				I-194	MAY 29, 2000
	020297 003	CARVEDILOL;COREG				I-194	MAY 29, 2000
	020297 004	CARVEDILOL;COREG				I-194	MAY 29, 2000
			4503067	MAR 05, 2002	U-3	NCE	SEP 14, 2000
	020740 001	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		NCE	JUN 26, 2002
			5177080	NOV 26, 2011			
	020740 002	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		NCE	JUN 26, 2002
			5177080	NOV 26, 2011			
	020740 003	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		NCE	JUN 26, 2002
			5177080	NOV 26, 2011			
	020740 004	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		NCE	JUN 26, 2002
			5177080	NOV 26, 2011			
	019835 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
	019835 002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
	020346 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
>ADD>	020111 001	CHLORHEXIDINE GLUCONATE;DYNA-HEX					
	020519 001	CICLOPIROX;LOPROX					
	019537 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	5286754	FEB 15, 2011		NP	SEP 11, 2000
			4670444	DEC 09, 2003	U-36	NDF	JUL 21, 2000
						I-188	JUN 03, 2000

**PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA**

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019537 002	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-188	JUN 03, 2000
019537 003	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-188	JUN 03, 2000
019537 004	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-188	JUN 03, 2000
019847 001	CIPROFLOXACIN;CIPRO	4705789	NOV 10, 2004		I-179	OCT 21, 1999
					I-201	AUG 07, 2000
020780 001	CIPROFLOXACIN;CIPRO	5695784	DEC 09, 2014			
020780 002	CIPROFLOXACIN;CIPRO	5695784	DEC 09, 2014			
019857 001	CIPROFLOXACIN;CIPRO IN DEXTROSE 5%	4808583	FEB 28, 2006		I-179	OCT 21, 1999
					I-201	AUG 07, 2000
019858 001	CIPROFLOXACIN;CIPRO IN SODIUM CHLORIDE 0.9%	4705789	NOV 10, 2004		I-179	OCT 21, 1999
					I-201	AUG 07, 2000
020767 001	CISAPRIDE MONOHYDRATE;PROPULSID QUICKSOLV	4962115	OCT 09, 2007	U-79	NCE	JUL 29, 1998
017533 001	CLONAZEPAM;KLONOPI				I-184	APR 09, 2000
017533 002	CLONAZEPAM;KLONOPI				I-184	APR 09, 2000
017533 003	CLONAZEPAM;KLONOPI				I-184	APR 09, 2000
017533 005	CLONAZEPAM;KLONOPI				I-184	APR 09, 2000
017533 006	CLONAZEPAM;KLONOPI				I-184	APR 09, 2000
020813 001	CLONAZEPAM;KLONOPI	4305502	DEC 15, 1998			
		4371516	FEB 01, 2000			
		4758598	DEC 15, 1998			
020813 002	CLONAZEPAM;KLONOPI	4305502	DEC 15, 1998			
		4371516	FEB 01, 2000			
		4758598	DEC 15, 1998			
020813 003	CLONAZEPAM;KLONOPI	4305502	DEC 15, 1998			
		4371516	FEB 01, 2000			
		4758598	DEC 15, 1998			
020813 004	CLONAZEPAM;KLONOPI	4305502	DEC 15, 1998			
		4371516	FEB 01, 2000			
		4758598	DEC 15, 1998			
020813 005	CLONAZEPAM;KLONOPI	4758598	DEC 15, 1998			
		4305502	DEC 15, 1998			
		4371516	FEB 01, 2000			
020839 001	CLOPIDOGREL BISULFATE;PLAVIX				NCE	NOV 17, 2002
020463 001	CROMOLYN SODIUM;NASALCROM				NP	JAN 03, 2000
020430 001	DANAPAROID SODIUM;ORGARAN	5164377	OCT 03, 2010			
020705 001	DELAVIRDINE MESYLATE;RESCRIPTOR	5563142	OCT 08, 2013			
017922 001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013		NCE	APR 04, 2002
		5482931	JUN 29, 2013			
		5674850	DEC 23, 2013			
		5498598	JUN 29, 2013			
017922 002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5482931	JUN 29, 2013			
		5674850	DEC 23, 2013			
		5498598	JUN 29, 2013			
017922 003	DESMOPRESSIN ACETATE;DDAVP	5674850	DEC 23, 2013			
		5498598	JUN 29, 2013			
		5500413	JUN 29, 2013			
		5482931	JUN 29, 2013			
018938 001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			

**PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA**

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
018938 002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
019955 001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
019955 002	DESMOPRESSIN ACETATE;DDAVP	5674850	DEC 23, 2013			
		5500413	JUN 29, 2013			
		5674850	DEC 23, 2013			
020648 001	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012	NDF	JUL 29, 2000	
020648 002	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012	NDF	JUL 29, 2000	
020648 003	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012	NDF	JUL 29, 2000	
020648 004	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012	NDF	JUL 29, 2000	
020648 005	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012	NDF	JUL 29, 2000	
>ADD>	020607 001 DICLOFENAC SODIUM;ARTHROTEC	4301146	JUL 29, 2000			
>ADD>		5601843	FEB 11, 2014			
>ADD>	020607 002 DICLOFENAC SODIUM;ARTHROTEC	4301146	JUL 29, 2000			
>ADD>		5601843	FEB 11, 2014			
>ADD>	020037 001 DICLOFENAC SODIUM;VOLTAREN	4960799	OCT 03, 2007			
		4829088	APR 14, 2007			
020154 002	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
020154 003	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
020154 004	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
020154 005	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
020155 003	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
020155 004	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
020155 005	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
020156 001	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
>ADD>	020405 001 DIGOXIN;LANOXIN			I-194	SEP 30, 2000	
>ADD>	020405 002 DIGOXIN;LANOXIN			I-194	SEP 30, 2000	
>ADD>	020405 003 DIGOXIN;LANOXIN			I-194	SEP 30, 2000	
>ADD>	020405 004 DIGOXIN;LANOXIN			I-194	SEP 30, 2000	
>ADD>	020405 005 DIGOXIN;LANOXIN			I-194	SEP 30, 2000	
>ADD>	020405 006 DIGOXIN;LANOXIN			I-194	SEP 30, 2000	
020148 001	DIHYDROERGOTAMINE MESYLATE;MIGRALAN			NDF	DEC 08, 2000	
018723 001	DIVALPROEX SODIUM;DEPAKOTE			I-181	JUN 20, 1999	
018723 002	DIVALPROEX SODIUM;DEPAKOTE			I-181	JUN 20, 1999	
018723 003	DIVALPROEX SODIUM;DEPAKOTE			I-181	JUN 20, 1999	
019680 001	DIVALPROEX SODIUM;DEPAKOTE	4988731	JAN 29, 2008	I-181	JUN 20, 1999	
020623 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET			NCE	SEP 11, 2002	
020623 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET			NCE	SEP 11, 2002	
020624 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET			NCE	SEP 11, 2002	
020624 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET			NCE	SEP 11, 2002	
020706 001	EMEDASTINE DIFUMARATE;EMADINE			NCE	DEC 29, 2002	
020668 001	ENALAPRIL MALEATE;LEXCEL	4472380	SEP 18, 2001			
		4374829	DEC 30, 2001	U-3		
		4703038	OCT 07, 2005	U-3		
020164 001	ENOXAPARIN SODIUM;LOVENOX			I-192	MAY 06, 2000	

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES	
020444 001	EPOPROSTENOL SODIUM;FLOLAN	4335139 4539333 4883812 4338325	JUN 15, 1999 SEP 03, 2002 MAY 12, 2006 JUL 06, 1999				
020444 002	EPOPROSTENOL SODIUM;FLOLAN	4539333 4338325 4883812 4335139	SEP 03, 2002 JUL 06, 1999 MAY 12, 2006 JUN 15, 1999	U-185			
>ADD>	020738 004	EPROSARTAN MESYLATE;TEVETEN	5656650	AUG 12, 2014	U-3	NCE	DEC 22, 2002
>ADD>	020738 005	EPROSARTAN MESYLATE;TEVETEN	5656650	AUG 12, 2014	U-3	NCE	DEC 22, 2002
>ADD>	020417 001	ESTRADIOL;FEMPATCH	4906463 5006342	MAR 06, 2007 APR 09, 2008	NP	NP	DEC 03, 1999
020683 001	ETHINYL ESTRADIOL;ALESSE				NP	MAR 27, 2000	
020683 002	ETHINYL ESTRADIOL;ALESSE				NP	MAR 27, 2000	
019697 001	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66	I-177	DEC 31, 1999	
019697 002	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66	I-177	DEC 31, 1999	
018922 005	ETODOLAC;LODINE				I-24	JUN 28, 1999	
020457 001	ETOPOSIDE PHOSPHATE;ETOPOPHOS	RE35524	AUG 04, 2007				
020363 001	FAMCICLOVIR;FAMVIR				I-207	SEP 16, 2000	
020363 002	FAMCICLOVIR;FAMVIR				I-207	SEP 16, 2000	
020363 003	FAMCICLOVIR;FAMVIR				I-207	SEP 16, 2000	
020325 001	FAMOTIDIINE;PEPCID AC	4283408 5667794	OCT 15, 2000 MAY 02, 2015	U-205			
019922 001	FENOLDOPAM MESYLATE;CORLOPAM				NCE	SEP 23, 2002	
020292 001	FERRIC AMMONIUM CITRATE;FERRISELTZ				NP	OCT 14, 2000	
020410 001	FERUMOXSIL;GASTROMARK	5069216 5219554 4827945 4951675 5055288 4695392 4695393 4770183 5578610	MAY 09, 2006 JUN 15, 2010 MAY 09, 2006 SEP 13, 2005 OCT 08, 2008 SEP 22, 2004 SEP 22, 2004 SEP 13, 2005 NOV 26, 2013	U-171 U-170 U-169	U-171 U-170 U-169	NCE NP NCE	DEC 06, 2001
020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA						
020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D						
>ADD>	020788 001	FINASTERIDE;PROPECIA	4377584 4760071 5571817 4357324	MAR 22, 2000 JUN 19, 2006 NOV 05, 2013 FEB 24, 2003	U-169 U-192	NC NP	DEC 24, 2000 DEC 19, 2000
>ADD>	020038 001	FLUDARABINE PHOSPHATE;FLUDARA					
>ADD>	020549 001	FLUTICASONE PROPIONATE;FLOVENT					
>ADD>	020549 002	FLUTICASONE PROPIONATE;FLOVENT					
>ADD>	020549 003	FLUTICASONE PROPIONATE;FLOVENT					
>ADD>	020261 001	FLUVASTATIN SODIUM;LESCOL					
>ADD>	020261 002	FLUVASTATIN SODIUM;LESCOL					
020582 001	FOLLITROPIN ALFA/BETA;FOLLISTIM	5270057 4589402	MAR 20, 2011 JUL 26, 2004	U-206	NP	SEP 29, 2000	
020582 002	FOLLITROPIN ALFA/BETA;FOLLISTIM	5270057 4589402	MAR 20, 2011 JUL 26, 2004	U-206	NP	SEP 29, 2000	
020378 001	FOLLITROPIN ALFA/BETA;GONAL-F				NP	SEP 29, 2000	

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020378	002	FOLLITROPIN ALFA/BETA;GONAL-F				NP	SEP 29, 2000
020696	001	FOMEPIZOLE;ANTIZOL				NCE	DEC 04, 2002
						ODE	DEC 04, 2004
020235	001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-86		
020235	002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-86		
020235	003	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008			
			4087544	JAN 16, 2000	U-86		
020622	001	GLATIRAMER ACETATE;COPAXONE					
020329	001	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
020329	002	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U-150	ODE	DEC 20, 2003
>ADD>	001	GLYBURIDE;GLYBURIDE (MICRONIZED)				PC	JUN 01, 1998
>ADD>	002	GLYBURIDE;GLYBURIDE (MICRONIZED)				PC	JUN 01, 1998
>ADD>	003	GLYBURIDE;GLYBURIDE (MICRONIZED)				PC	JUN 01, 1998
>ADD>	004	GLYBURIDE;GLYBURIDE (MICRONIZED)				PC	JUN 01, 1998
074591	001	GOSERELIN ACETATE;ZOLADEX				I-191	JUN 27, 2000
020305	001	GRANISETRON HYDROCHLORIDE;KYTRIL				D-36	OCT 06, 2000
020695	001	GREPAFLOXACIN HYDROCHLORIDE;RAXAR				NCE	NOV 06, 2002
020758	001	HYDROCHLOROTHIAZIDE;IRBESARTAN-HYDROCHLOROTHIAZIDE	5270317	MAR 20, 2011		NCE	SEP 30, 2002
020758	002	HYDROCHLOROTHIAZIDE;IRBESARTAN-HYDROCHLOROTHIAZIDE	5270317	MAR 20, 2011		NCE	SEP 30, 2002
020504	001	HYDROCHLOROTHIAZIDE;MICROZIDE				NS	DEC 27, 1999
020729	001	HYDROCHLOROTHIAZIDE;UNIRETIC	4344949	OCT 03, 2000		NC	JUN 27, 2000
	002	HYDROCHLOROTHIAZIDE;UNIRETIC	4743450	FEB 24, 2007			
			4344949	OCT 03, 2000			
			4743450	FEB 24, 2007			
020729	002	HYDROCHLOROTHIAZIDE;UNIRETIC				NC	JUN 27, 2000
020716	001	HYDROCODONE BITARTRATE;VICOPROFEN				NC	SEP 23, 2000
020601	001	IBUPROFEN;CHILDREN'S MOTRIN				NP	NOV 15, 1999
>DLT>	001	IBUPROFEN;CHILDREN'S MOTRIN				NP	JUN 16, 1998
020267	002	IBUPROFEN;JUNIOR STRENGTH ADVIL				NP	JUN 16, 1998
>ADD>	003	IBUPROFEN;JUNIOR STRENGTH MOTRIN				NP	NOV 15, 1999
>DLT>	003	IBUPROFEN;JUNIOR STRENGTH MOTRIN				NP	JUN 16, 1998
020723	001	IMIQUIMOD;ALDARA	4689338	AUG 25, 2004	U-172	NCE	FEB 27, 2002
			5238944	AUG 24, 2010			
>ADD>	001	IODIXANOL;VISIPAQUE 270				I-211	OCT 10, 2000
020808	001	IODIXANOL;VISIPAQUE 270	5349085	SEP 20, 2011			
			4278654	JUL 03, 1999			
			4396597	JUL 03, 1999			
>ADD>	002	IODIXANOL;VISIPAQUE 320	5349085	SEP 20, 2011		I-211	OCT 10, 2000
020351	002	IODIXANOL;VISIPAQUE 320	4278654	JUL 03, 1999			
			4396597	JUL 03, 1999			
020757	001	IRBESARTAN;AVAPRO	5270317	MAR 20, 2011		NCE	SEP 30, 2002
020757	002	IRBESARTAN;AVAPRO	5270317	MAR 20, 2011		NCE	SEP 30, 2002
020757	003	IRBESARTAN;AVAPRO	5270317	MAR 20, 2011		NCE	SEP 30, 2002
040024	001	IRON DEXTRAN;DEXFERRUM	5624668	SEP 29, 2015			
020083	001	ITRACONAZOLE;SPORANOX				I-178	DEC 06, 1999
020657	001	ITRACONAZOLE;SPORANOX				NDF	FEB 21, 2000
019927	001	KETOCONAZOLE;NIZORAL				I-186	MAY 30, 2000
020310	001	KETOCONAZOLE;NIZORAL A-D				NP	OCT 10, 2000
020811	001	KETOROLAC TROMETHAMINE;ACULAR PRESERVATIVE FREE				NP	NOV 03, 2000

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020857 001	LAMIVUDINE;COMBIVIR	4828838 4833130 4837208 5047407 4724232 4818538	SEP 17, 2005 SEP 17, 2005 SEP 17, 2005 FEB 08, 2009 SEP 17, 2005 SEP 17, 2005		NCE	NOV 17, 2000
020406 001	LANSOPRAZOLE;PREVACID			I-195 I-196 I-197 I-198	JUN 17, 2000 MAY 08, 2000 APR 17, 2000 JUN 17, 2000	
020406 002	LANSOPRAZOLE;PREVACID			I-195 I-196 I-197 I-198	JUN 17, 2000 MAY 08, 2000 APR 17, 2000 JUN 17, 2000	
020726 001 019732 001	LETROZOLE;FEMARA LEUPROLIDE ACETATE;LUPRON DEPOT	4978672 5631020 5631021 4954298 5480656 5643607 5631020 5631021 4954298 5480656 5643607 5631020 5631021 5643607 4677191 4728721 4849228 5631020 5631021 4652411 5476663 5480656 5575987 4917893 4954298 5330767 5643607 5480656 5631020 5631021 4954298 5643607 5480656 5631020 5631021 4954298 5643607	DEC 18, 2007 MAY 20, 2014 MAY 20, 2014 NOV 01, 2004 JAN 02, 2013 JUL 01, 2014 MAY 20, 2014 MAY 20, 2014 NOV 01, 2004 JAN 02, 2013 JUL 01, 2014 MAY 20, 2014 MAY 20, 2014 JUL 01, 2014 JUL 03, 2005 MAY 01, 2006 JUL 18, 2006 MAY 20, 2014 MAY 20, 2014 NOV 01, 2004 APR 17, 2007 JAN 02, 2013 NOV 19, 2013 NOV 01, 2004 NOV 01, 2004 NOV 01, 2004 JUL 01, 2014 JAN 02, 2013 MAY 20, 2014 MAY 20, 2014 NOV 01, 2004 JUL 01, 2014 JAN 02, 2013 MAY 20, 2014 MAY 20, 2014 NOV 01, 2004 JUL 01, 2014	U-203	NCE	JUL 25, 2002
020011 001	LEUPROLIDE ACETATE;LUPRON DEPOT					
020517 001	LEUPROLIDE ACETATE;LUPRON DEPOT					
020517 002	LEUPROLIDE ACETATE;LUPRON DEPOT-4			NS D-34	MAY 30, 2000 MAY 30, 2000	
020263 002	LEUPROLIDE ACETATE;LUPRON DEPOT-PED					
020263 003	LEUPROLIDE ACETATE;LUPRON DEPOT-PED					

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020263 004	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5480656 5631020 5631021 4954298 5643607	JAN 02, 2013 MAY 20, 2014 MAY 20, 2014 NOV 01, 2004 JUL 01, 2014			
020263 005	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5480656 5631020 5631021 4954298 5643607	JAN 02, 2013 MAY 20, 2014 MAY 20, 2014 NOV 01, 2004 JUL 01, 2014			
020263 006	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5480656 5631020 5631021 4954298 5643607	JAN 02, 2013 MAY 20, 2014 MAY 20, 2014 NOV 01, 2004 JUL 01, 2014			
020708 001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	4652411 4677191 4728721 4849228 4917893 4954298 5330767 5476663 5480656 5575987 5631020 5631021 4652441 5643607	NOV 01, 2004 JUL 03, 2005 MAY 01, 2006 JUL 18, 2006 NOV 01, 2004 NOV 01, 2004 NOV 01, 2004 APR 17, 2007 JAN 02, 2013 NOV 19, 2013 MAY 20, 2014 MAY 20, 2014 NOV 01, 2004 JUL 01, 2014	NP	MAR 07, 2000	
020580 001	LIPASE;COTAZYM			NP	DEC 09, 1999	
020448 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM A-D	5489436	FEB 06, 2013			
020606 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5248505 5612054 5489436	JUL 28, 2010 SEP 28, 2010 FEB 06, 2013	NC	JUN 26, 2000	
>ADD>	019658 001	LORATADINE;CLARITIN	5679376	OCT 21, 2014		
>ADD>	020641 001	LORATADINE;CLARITIN	4863931 4863931 4659716	SEP 15, 2008 SEP 15, 2008 APR 21, 2004	U-142	
	020704 001	LORATADINE;CLARITIN REDITABS	4282233 4659716 4863931	JUN 19, 2002 APR 21, 2004 SEP 15, 2008	U-77 U-142	NCE
						APR 12, 1998
>ADD>	019670 001	LORATADINE;CLARITIN-D	4863931	SEP 15, 2008		
>ADD>	020470 001	LORATADINE;CLARITIN-D 24 HOUR	4863931	SEP 15, 2008		
	018140 001	LORAZEPAM;ATIVAN			I-205	SEP 05, 2000
	018140 002	LORAZEPAM;ATIVAN			I-205	SEP 05, 2000
	020652 001	MANGAFODIPIR TRISODIUM;TESLASCAN			NCE	NOV 26, 2002
>ADD>	020686 001	MANGANESE CHLORIDE TETRAHYDRATE;LUMENHANCE			NP	DEC 19, 2000
	020264 001	MEGESTROL ACETATE;MEGACE	5338732	AUG 16, 2011		
	019651 001	MESALAMINE;ASACOL			I-203	AUG 18, 2000

**PREScription AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA**

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES	
020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE			NCE	MAR 03,	2000	
020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE			NCE	MAR 03,	2000	
020868 001	METRONIDAZOLE;FLAGYL ER			NDF	NOV 26,	2000	
020743 001	METRONIDAZOLE;NORITATE			NP	SEP 26,	2000	
020689 001	MIBEFRADIL DIHYDROCHLORIDE;POSICOR	4808605	NOV 10, 2007	U-194	NCE	JUN 20,	2002
020689 002	MIBEFRADIL DIHYDROCHLORIDE;POSICOR	4808605	NOV 10, 2007	U-194	NCE	JUN 20,	2002
020834 001	MINOXIDIL;ROGAINE EXTRA STRENGTH (FOR MEN)			NP	NOV 14,	2000	
020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX			NDF	OCT 01,	2000	
020353 001	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014				
020353 002	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014				
020353 003	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014				
019660 001	NEDOCROMIL SODIUM;TILADE			I-183	MAR 06,	2000	
020750 001	NEDOCROMIL SODIUM;TILADE			NDF	OCT 01,	2000	
020778 001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013				
020779 001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013				
020636 001	NEVIRAPINE;VIRAMUNE	5366972	NOV 22, 2011	U-167	NCE	JUN 21,	2001
020381 001	NIACIN;NIASPAN			NDF	JUL 28,	2000	
020381 002	NIACIN;NIASPAN			NDF	JUL 28,	2000	
020381 003	NIACIN;NIASPAN			NDF	JUL 28,	2000	
020381 004	NIACIN;NIASPAN			NDF	JUL 28,	2000	
020381 005	NIACIN;NIASPAN TITRATION STARTER PACK			NDF	JUL 28,	2000	
020714 001	NICOTINE;NICOTROL			NP	MAY 02,	2000	
020592 001	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176			
020592 002	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176			
020592 003	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176			
020592 004	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176			
020688 001	OLOPATADINE HYDROCHLORIDE;PATANOL	4871865	OCT 03, 2006				
		4923892	MAY 08, 2007	U-174			
		5116863	MAY 26, 2009				
		5641805	JUN 24, 2014	U-184			
019810 001	OMEPRAZOLE;PRILOSEC	4636499	MAY 30, 2005				
		5093342	FEB 02, 2010	U-166			
		5599794	FEB 04, 2014	U-166			
019810 003	OMEPRAZOLE;PRILOSEC	5629305	FEB 04, 2014	U-188			
		4636499	MAY 30, 2005				
		5093342	FEB 02, 2010	U-166			
		5599794	FEB 04, 2014	U-166			
020605 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5629305	FEB 04, 2014	U-188			
		4753789	JUN 24, 2006	U-44			
		4695578	JUN 25, 2005	U-183			
019828 001	OXICONAZOLE NITRATE;OXISTAT	5578628	JUN 24, 2006	U-44			
020262 001	PACLITAXEL;TAXOL			I-200	AUG 18,	2000	
		5641803	AUG 03, 2012	U-198	ODE	AUG 04,	2004
		5670537	AUG 03, 2012	U-198	I-202	AUG 04,	2000
		5496804	MAR 09, 2013	U-204			
020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07,	1999
020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07,	1999
020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07,	1999
020031 004	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07,	1999

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020031 005		PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
020710 001		PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-150	MAY 07, 1999
					NCE		DEC 29, 1997
019385 001		PERGOLIDE MESYLATE;PERMAX	5114948	OCT 19, 2009			
			4180582	FEB 08, 1998	U-20		
019385 002		PERGOLIDE MESYLATE;PERMAX	5114948	OCT 19, 2009			
			4180582	FEB 08, 1998	U-20		
019385 003		PERGOLIDE MESYLATE;PERMAX	5114948	OCT 19, 2009			
			4180582	FEB 08, 1998	U-20		
018796 001		PILOCARPINE HYDROCHLORIDE;PILOPINE HS	4271143	MAY 09, 1999			
020529 001		PODOFILOX;CONDYLOX	4680399	JUL 14, 2004		NDF	MAR 13, 2000
			5057616	OCT 15, 2008			
020667 001		PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
020667 002		PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
020667 003		PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
020667 004		PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
020667 005		PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
019568 001		PREDNICARBATE;DERMATOP	4242334	AUG 02, 2000	U-50		
020279 001		PREDNICARBATE;DERMATOP	4242334	AUG 02, 2000	U-50		
020545 001		PROCAINAMIDE HYDROCHLORIDE;PROCANBID	5656296	AUG 12, 2014			
020545 002		PROCAINAMIDE HYDROCHLORIDE;PROCANBID	5656296	AUG 12, 2014			
020701 001		PROGESTERONE;CRINONE	4615697	OCT 07, 2003	U-208	NP	JUL 31, 2000
			5543150	SEP 15, 2013	U-209		
020701 002		PROGESTERONE;CRINONE	4615697	OCT 07, 2003	U-208	NP	JUL 31, 2000
			5543150	SEP 15, 2013	U-209		
020756 001		PROGESTERONE;CRINONE				NP	MAY 13, 2000
019151 001		PROPafenone HYDROCHLORIDE;RYTHMOL				I-209	DEC 23, 2000
019151 002		PROPafenone HYDROCHLORIDE;RYTHMOL				I-209	DEC 23, 2000
019151 003		PROPafenone HYDROCHLORIDE;RYTHMOL				I-209	DEC 23, 2000
<u>&gt;ADD&gt;</u>							
019627 002		PROPOFOL;DIPRIVAN	5714520	MAR 22, 2015		NP	JUN 11, 1999
020639 001		QUETIAPINE FUMARATE;SEROQUEL	4879288	MAR 20, 2007		NCE	SEP 26, 2002
020639 002		QUETIAPINE FUMARATE;SEROQUEL	4879288	MAR 20, 2007		NCE	SEP 26, 2002
020639 003		QUETIAPINE FUMARATE;SEROQUEL	4879288	MAR 20, 2007		NCE	SEP 26, 2002
019885 001		QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5684016	NOV 04, 2014	U-210		
019885 002		QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5684016	NOV 04, 2014	U-210		
019885 003		QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5684016	NOV 04, 2014	U-210		
019885 004		QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5684016	NOV 04, 2014	U-210		
<u>&gt;ADD&gt;</u>							
020815 001		RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2003		NCE	DEC 09, 2002
			5393763	JUL 28, 2012			
			5457117	JUL 28, 2012			
			5478847	MAR 02, 2014			
			5641790	JUN 24, 2014			
<u>&gt;ADD&gt;</u>							
<u>&gt;ADD&gt;</u>							
<u>&gt;ADD&gt;</u>							
<u>&gt;ADD&gt;</u>							
<u>&gt;ADD&gt;</u>							
<u>&gt;ADD&gt;</u>							
020559 001		RANITIDINE BISMUTH CITRATE;TRITEC	5456925	OCT 10, 2012			
			5629297	MAY 13, 2014	U-186		
			5256684	OCT 26, 2010	U-199		
			5403830	APR 04, 2012	U-200		
			5407688	APR 04, 2012	U-201		
			5601848	FEB 11, 2014	U-202		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME		PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020741 001	REPAGLINIDE;PRANDIN	5216167	OCT 10, 2006		NCE	DEC 22, 2002
>ADD>			5312924	OCT 10, 2006			
>ADD>			4873080	OCT 10, 2006			
>ADD>	020741 002	REPAGLINIDE;PRANDIN	5216167	OCT 10, 2006		NCE	DEC 22, 2002
>ADD>			5312924	OCT 10, 2006	U-214		
>ADD>			4873080	OCT 10, 2006			
>ADD>	020741 003	REPAGLINIDE;PRANDIN	5216167	OCT 10, 2006		NCE	DEC 22, 2002
>ADD>			5312924	OCT 10, 2006	U-214		
>ADD>			4873080	OCT 10, 2006			
>ADD>	020474 001	RIMEXOLONE;VEXOL	4686214	JUL 22, 2008	U-100		
>DLT>	020474 001	RIMEXOLONE;VEXOL	4686214	JUL 23, 2008	U-100		
>ADD>	020272 001	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90	D-37	OCT 17, 2000
>ADD>	020272 002	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90	D-37	OCT 17, 2000
>ADD>	020272 003	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90	D-37	OCT 17, 2000
>ADD>	020272 004	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90	D-37	OCT 17, 2000
>ADD>	020588 001	RISPERIDONE;RISPERDAL	5453425	JUN 11, 2014		D-37	OCT 17, 2000
			5616587	JUN 11, 2014			
			5635523	JUN 03, 2014	U-190		
	020659 001	RITONAVIR;NORVIR	5648497	JUL 15, 2014			
	020680 001	RITONAVIR;NORVIR	5635523	JUN 03, 2014	U-190		
			5648497	JUL 15, 2014			
	020658 001	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002		NCE	SEP 19, 2002
			4824860	MAY 19, 2008	U-212		
	020658 002	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002		NCE	SEP 19, 2002
			4824860	MAY 19, 2008	U-212		
	020658 003	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002		NCE	SEP 19, 2002
			4824860	MAY 19, 2008	U-212		
	020658 004	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002		NCE	SEP 19, 2002
			4824860	MAY 19, 2008	U-212		
	020658 005	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002		NCE	SEP 19, 2002
			4824860	MAY 19, 2008	U-212		
	020236 001	SALMETEROL XINAFOATE;SEREVENT	5380922	JAN 10, 2012			
			5225445	FEB 12, 2008	U-182		
	020692 001	SALMETEROL XINAFOATE;SEREVENT	4992474	FEB 12, 2008			
			5225445	FEB 19, 2012	U-211		
			5380922	MAY 14, 2013			
>ADD>	020570 001	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM;QUADRAMET	4898724	FEB 06, 2007	U-187	NCE	MAR 28, 2002
	020570 002	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM;QUADRAMET	4898724	FEB 06, 2007	U-187	NCE	MAR 28, 2002
	020828 001	SAQUINAVIR;FORTOVASE				NP	NOV 07, 2000
	020443 001	SERMORELIN ACETATE;GEREF				NP	SEP 26, 2000
						ODE	SEP 26, 2004
	020443 002	SERMORELIN ACETATE;GEREF				NP	SEP 26, 2000
						ODE	SEP 26, 2004
	019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-193	JUL 08, 2000
	019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-208	OCT 10, 2000
	019839 003	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-193	JUL 08, 2000
						I-208	OCT 10, 2000

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019839 004	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-193	JUL 08, 2000
019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-208	OCT 10, 2000
020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2002		I-193	JUL 08, 2000
020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2002		I-208	OCT 10, 2000
020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2002		NCE	NOV 22, 2002
020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4929629	MAY 29, 2007			
020231 001	SODIUM FLUORIDE;COLGATE TOTAL				NC	JUL 11, 2000
020280 006	SOMATROPIN, BIOSYNTHETIC;GENOTROPIN				ODE	OCT 31, 2004
020280 004	SOMATROPIN, BIOSYNTHETIC;GENOTROPIN PRESERVATIVE FREE				ODE	OCT 31, 2004
019640 001	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				I-182	DEC 30, 1999
019640 004	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				ODE	DEC 30, 2003
020168 001	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				I-182	DEC 30, 1999
020168 002	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	DEC 30, 2003
020604 003	SOMATROPIN, BIOSYNTHETIC;SEROSTIM				I-182	DEC 30, 1999
020626 001	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U-72	NDF	AUG 26, 2000
020626 002	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U-72	NDF	AUG 26, 2000
020626 003	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U-72	NDF	AUG 26, 2000
020070 001	TACRINE HYDROCHLORIDE;COGNEX	4816456	SEP 09, 2007	U-82		
020070 002	TACRINE HYDROCHLORIDE;COGNEX	4816456	SEP 09, 2007	U-82		
020070 003	TACRINE HYDROCHLORIDE;COGNEX	4816456	SEP 09, 2007	U-82		
020070 004	TACRINE HYDROCHLORIDE;COGNEX	4816456	SEP 09, 2007	U-82		
020587 001	TALC;SCLEROSOL				NCE	DEC 24, 2002
>ADD>					ODE	DEC 24, 2004
020579 001	TAMSULOSIN HYDROCHLORIDE;FLOMAX	4868216	SEP 19, 2006	U-181	NCE	APR 15, 2002
		4731478	OCT 27, 2004			
		4703063	OCT 27, 2004			
		4772475	FEB 27, 2006			
020600 001	TAZAROTENE;TAZORAC	5089509	FEB 18, 2009	U-193	NCE	JUN 13, 2002
020600 002	TAZAROTENE;TAZORAC	5089509	FEB 18, 2009	U-193	NCE	JUN 13, 2002
019785 003	TECHNETIUM TC-99M SESTAMIBI KIT;MIRALUMA				I-190	MAY 23, 2000
020372 001	TECHNETIUM TC-99M TETROFOSMIN KIT;MYOVIEW	5045302	AUG 14, 2008			
019057 001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
		5294615	APR 29, 2013			
019057 002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013	U-165		
		5294615	APR 29, 2013	U-3		
019057 003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013	U-165		
		5294615	APR 29, 2013	U-3		
019057 004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013	U-165		
		5294615	APR 29, 2013	U-3		


**PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA**

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020347 001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-165 U-3		
020347 002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-165 U-3		
020347 003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-165 U-3		
020347 004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-165 U-3		
020192 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534	DEC 30, 2006	U-73	I-180	JAN 21, 2000
020539 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534	DEC 30, 2006	U-73		
020749 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534	DEC 30, 2006		NDF	OCT 17, 2000
020646 001	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			
020646 002	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			
020646 003	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			
020646 004	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			
020707 001	TILDENONATE DISODIUM;SKELID	4876248	OCT 24, 2006		NCE	MAR 07, 2002
		4980171	APR 06, 2009			
020676 001	TIOCONAZOLE;VAGISTAT-1				NP	FEB 11, 2000
050753 001	TOBRAMYCIN;TOBI				ODE	DEC 22, 2004
020497 001	TOREMIFENE CITRATE;FARESTON	4696949	SEP 29, 2004	U-196	NCE	MAY 29, 2002
					ODE	MAY 29, 2004
					I-206	SEP 09, 2000
020136 001	TORSEMIDE;DEMADEX				I-206	SEP 09, 2000
020136 002	TORSEMIDE;DEMADEX				I-206	SEP 09, 2000
020136 003	TORSEMIDE;DEMADEX				I-206	SEP 09, 2000
020136 004	TORSEMIDE;DEMADEX				I-206	SEP 09, 2000
020137 002	TORSEMIDE;DEMADEX				I-206	SEP 09, 2000
020404 003	TRETINOIN;AVITA	4971800	NOV 20, 2007	U-178		
		5045317	SEP 03, 2008	U-179		
020475 001	TRETINOIN;RETIN-A MICRO	4690825	OCT 04, 2005	U-134	NP	FEB 07, 2000
020468 001	TRIACINOLONE ACETONIDE;NASACORT AQ				I-204	SEP 26, 2000
074374 001	TRIMETHOPRIM HYDROCHLORIDE;PRIMSOL				I-189	JUN 17, 2000
020326 001	TRIMETREXATE GLUCURONATE;NEUTREXIN	4376858	MAY 09, 2004			
020719 001	TROGLITAZONE;PRELAY	4572912	AUG 28, 2004		NCE	JAN 29, 2002
		5104888	AUG 28, 2004		I-199	AUG 04, 2000
		5478852	SEP 15, 2013	U-163		
		5457109	SEP 15, 2013	U-164		
		5602133	SEP 15, 2013	U-173		
020719 002	TROGLITAZONE;PRELAY	4572912	AUG 28, 2004		NCE	JAN 29, 2002
		5104888	AUG 28, 2004		I-199	AUG 04, 2000
		5478852	SEP 15, 2013	U-163		
		5457109	SEP 15, 2013	U-164		
		5602133	SEP 15, 2013	U-173		
020719 003	TROGLITAZONE;PRELAY	5457109	SEP 15, 2013	U-164	I-199	AUG 04, 2000
		5602133	SEP 15, 2013	U-173	NCE	JAN 29, 2002
		5478852	SEP 15, 2013	U-163		
		4572912	AUG 28, 2004			
		5104888	AUG 28, 2004			

**PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA**

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020720 001	TROGLITAZONE;REZULIN	5457109 5602133 5478852 4572912 5104888	SEP 15, 2013 SEP 15, 2013 SEP 15, 2013 AUG 28, 2004 AUG 28, 2004	U-164 U-173 U-163	NCE I-199	JAN 29, 2002 AUG 04, 2000
020720 002	TROGLITAZONE;REZULIN	5602133 4572912 5104888 5478852 5457109	SEP 15, 2013 AUG 28, 2004 AUG 28, 2004 SEP 15, 2013 SEP 15, 2013	U-173	NCE I-199	JAN 29, 2002 AUG 04, 2000
020720 003	TROGLITAZONE;REZULIN	5602133 5478852 4572912 5104888 5478852 5457109 5457109 5602133 5478852 4572912 5104888	SEP 15, 2013 SEP 15, 2013 AUG 28, 2004 AUG 28, 2004 SEP 15, 2013 SEP 15, 2013 SEP 15, 2013 U-163 U-164 U-164 U-173 NCE I-199 AUG 04, 2000 JAN 29, 2002	U-164 U-163 U-163 U-163 U-163 U-164 U-164 U-173 U-163 AUG 28, 2004 AUG 28, 2004	I-199 NCE	AUG 04, 2000 JAN 29, 2002
020759 001	TROVAFLOXACIN MESYLATE;TROVAN				NCE	DEC 18, 2002
020759 002	TROVAFLOXACIN MESYLATE;TROVAN				NCE	DEC 18, 2002
020617 001	UREA, C-14;PYTEST	4830010	MAY 15, 2006	U-195	NCE	MAY 09, 2002
020617 002	UREA, C-14;PYTEST KIT	4830010	MAY 15, 2006	U-195	NCE	MAY 09, 2002
020675 001	URSODIOL;URSO				NP ODE	DEC 10, 2000 DEC 10, 2004
020487 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX				I-207	SEP 26, 2000
020487 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX				I-207	SEP 26, 2000
020665 001	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U-3	NCE	DEC 28, 1998
020665 002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U-3	ND F	OCT 20, 2000
020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2002		NCE	DEC 28, 1998
020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2002		ND F	OCT 20, 2000
020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2002		NCE	DEC 28, 1998
020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2002		ND F	OCT 20, 2000
020547 001	ZAFIRLUKAST;ACCOLATE	5612367 5583152	MAR 18, 2014 AUG 22, 2006	U-189	NP ODE	JAN 28, 2000 JAN 28, 2004
020471 001	ZILEUTON;ZYFLO	4873259	FEB 10, 2007	U-168	NP	JAN 28, 2000
020471 003	ZILEUTON;ZYFLO	4873259	FEB 10, 2007	U-168	ODE	JAN 28, 2004
020458 001	ZINC ACETATE;GALZIN				NP	JAN 28, 2000
020458 002	ZINC ACETATE;GALZIN				ODE	JAN 28, 2004
020768 001	ZOLMITRIPTAN;ZOMIG	5466699	NOV 14, 2012		NCE	NOV 25, 2002
020768 002	ZOLMITRIPTAN;ZOMIG	5466699	NOV 14, 2012		NCE	NOV 25, 2002

## *New 18th Edition*



# **APPROVED DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

18<sup>TH</sup> EDITION

## **Superintendent of Documents Subscription Order Form**

# **Order Processing Code**

**\* 80128**

*Charge your order.  
It's easy!*



Yes, enter my subscription as follows:

— subscriptions of APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, ADP, and the monthly Cumulative Supplements, for \$77.00 per year.

The total cost of my order is \$\_\_\_\_\_. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

**For privacy protection, check the box below:**

- Do not make my name available to other mailers.

**Please choose method of payment:**

- |                          |   |  |  |  |  |  |  |  |
|--------------------------|---|--|--|--|--|--|--|--|
| <input type="checkbox"/> | Check payable to Superintendent of Documents  |  |  |  |  |  |  |  |
| <input type="checkbox"/> | GPO Deposit Account <table border="1" style="display: inline-table; vertical-align: middle;"><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr></table> - <table border="1" style="display: inline-table; vertical-align: middle;"><tr><td> </td></tr></table> |  |  |  |  |  |  |  |
|                          |   |  |  |  |  |  |  |  |
|                          |   |  |  |  |  |  |  |  |
| <input type="checkbox"/> | VISA or MasterCard  |  |  |  |  |  |  |  |

*Thank you for your order!*

(Credit card expiration date)

---

Purchase Order No. (optional)

(11/97)

**Mail To:** Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954  
**To FAX** your charge order, call (202) 512-2250.  
**To charge** your subscription call (202) 512-1800.

